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Meier-Gorlin syndrome (MGS) is a rare autosomal recessive disorder characterised by 
short stature, microtia and patella aplasia/hypoplasia. Genetic variants, which cause MGS, 
have previously been found in genes involved in the initiation of DNA replication. This 
study examined the cellular consequences of novel variants in MGS genes; ORC1, CDC45 
and DONSON.  
The ORC1 gene encodes an essential component of the pre-replication complex and 
functions during late mitosis/early G1 phase to initiate DNA replication. MGS individuals 
previously reported to have variants in ORC1 have had at least one variant in the bromo-
adjacent homology (BAH) domain at the N-terminus of the protein, a region suggested to 
be important for protein-protein interactions. In this study we report a patient with a 
novel homozygous variant (c.1865T>C, p.L622P) in the ATPase Associated with a wide 
range of cellular Activities (AAA) domain at the C-terminus of ORC1, and attempted to 
investigate how variants in this region of the protein lead to a MGS phenotype using 
CRISPR-Cas9 genome editing and a minigene splicing assay. Due to time constraints, 
results were inconclusive and more work is required to better understand variants in this 
area of ORC1.  
CDC45 encodes an essential component of the pre-initiation and CDC45-MCM-GINS (CMG) 
complex, required during G1 and S-phase. The novel homozygous CDC45 variant (c. 1441-
2 A>G) under investigation in this study was found in two siblings presenting with a 
severe MGS phenotype alongside a range of secondary phenotypes some of which are not 
typically associated with MGS. It was hypothesised that this novel variant may represent 
the extreme end of the CDC45 phenotypic spectrum. A splicing assay showed that the 
variant, located within the canonical splice acceptor site for CDC45 exon 16, caused 
aberrant splicing and use of an alternative 5′ splice acceptor within exon 16. This resulted 
in a two amino acid deletion (p.Thr481_Lys482del) and a 72.9% reduction in CDC45 
mRNA levels, which was confirmed by RT-qPCR analysis using patient fibroblasts. 
DONSON is required for stabilising replication forks during S-phase when replication 
stress is encountered. Biallelic variants in this gene have previously been described in 
patients presenting with Microcephaly-Micromelia syndrome (MIMIS) and Microcephaly 
Short Stature, and Limb Abnormalities (MISSLA), both of which are characterized by 
severe microcephaly and a slight reduction in height. In this study we discovered a novel 
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DONSON variant (c.631C>T, p.R211C), for the first time in clinically diagnosed MGS 
patients, presenting with a global reduction in size. This project used CRISPR-Cas9 
genome editing as well as a range of cellular techniques including subcellular localisation, 
immunocytochemistry and DNA fibre combing to better understand the cellular 
consequences of this novel MGS gene. Taken together, results confirmed DONSON as a 
novel MGS gene and showed that MGS variants led to more subtle changes in subcellular 
localisation, DNA damage, and replication events than variants seen in non-MGS DONSON 
patients, reflecting the difference in phenotype. 
This project aimed to study the cellular consequences of novel MGS variants using 
CRISPR-Cas9 and a variety of cellular techniques to understand the effect these novel 
variants had on initiation of DNA replication. 
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This project aimed to investigate three novel Meier-Gorlin syndrome (MGS) variants 
using CRISPR-Cas9 and a variety of cellular assays. MGS is a type of primordial dwarfism 
caused by variants in genes important in the initiation of DNA replication, a highly 
regulated process. This project describes an investigation of three novel variants in three 
MGS genes (ORC1, CDC45 and DONSON) whose protein products work at different stages 
of DNA replication. The ORC1 gene encodes an essential subunit of the origin recognition 
complex (ORC), a component of the pre-replication complex (preRC), required for the 
initiation of DNA replication during the late M/early G1 phase of the cell cycle. CDC45 is 
required for firing of the pre-initiation complex (preIC) during the G1/S interphase of the 
cell cycle and DONSON is a novel MGS gene known to be involved in replication fork 
stability during S-phase. 
 
 DNA replication and cell cycle progression  
The cell cycle is an important, highly regulated process. During the cell cycle, a cell must 
copy its genetic material and grow in size before dividing into two identical daughter cells. 
DNA replication is tightly regulated in eukaryotes and is only undertaken once per cell 
cycle in healthy cells (Benmerzouga et al., 2012; Kara et al., 2015). There are four phases 
in the cell cycle, the first is gap 1 (G1) phase. This is the longest phase where the cell grows 
and DNA replication is initiated, next is S phase where the DNA is copied; this is followed 
by gap 2 (G2) phase where the cell grows in size in preparation for the final phase mitosis 
(M-phase); where the cell divides. The process by which DNA is copied during the S phase 
is complex. DNA replication starts at origins of replication; in larger genomes there are 
many of these sites across the genome in order to copy the DNA quickly (Remus et al., 
2009). Licencing proteins such as those that make up the preRC are recruited to the 
origins of replication in the late M phase/early G1 phase, before the initiation of 
replication in the S phase by the preIC (Klein and Gilbert, 2016). The process of DNA 
replication licencing is conserved in Eukaryotes, Bacteria and Archaea (Dueber et al., 
2011, 2007; O’Donnell et al., 2013; de la Paz Sanchez and Gutierrez, 2009). In prokaryotes, 
there are few origins of replication due to the small genome size. The human genome has 
over 6,000,000,000 base pairs (bp) which must be copied correctly in a relatively short 
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amount of time in order for the cell to progress through the cell cycle and divide, therefore 
many origin of replication sites (~50,000) are required (Gambus, 2017).  
 
1.1.1 Pre-replication complex 
The eukaryotic preRC is required for the initiation of DNA replication and is highly 
conserved from humans through to Saccharomyces cerevisiae (Bell, 2002; Bleichert et al., 
2013; Dueber et al., 2011; Stillman, 2001). The preRC contains origin recognition complex 
(ORC) subunits 1-6, cell division control protein 6 (CDC6), chromatin licensing and DNA 
replication factor 1 (CDT1) and minichromosome maintenance DNA helicase (MCM) 
subunits 2-7. ORC1-6 subunits encircle the chromatin at origin of replication start sites to 
form the hexameric ORC complex. After the ORC has been loaded onto the chromatin, 
CDC6 is recruited to the complex and loaded with the help of ORC1 (Wang et al., 1999). 
One MCM2-7 complex is loaded with CDT1 and bound by the ORC and CDC6 complex. The 
second MCM2-7 complex is then loaded along with the help of CDC6 and CDT1 (Ticau et 





Figure 1.1 Pre-replication complex assembly. The six ORC subunits encircle and bind to chromatin 
at origin of replication sites. CDC6 is loaded to the ORC complex with the help of ORC1; 
CDT1 is loaded next to the complex with the help of ORC6. CDT1 associates with the C-
terminal of CDC6 to load the two MCM 2-7 helicases, creating the pre-replication 
complex. Figure from (Bicknell et al., 2011b), copyright obtained from Springer Nature - 
4850520608800.  
 
1.1.1.1 ORC complex 
The ORC complex is the first to be recruited to the origin of replication sites, at the 
initiation of DNA replication. Six subunits make up the ORC complex (Figure 1.1). ORC1 is 
the biggest subunit and ORC6 is the smallest subunit. In yeast ORC is permanently 
associated with the chromatin (Kolesnikova, 2013), while in other eukaryotes the ORC 
complex is recruited to the origin of replication sites in late mitosis/early G1 phase 
(Mendoza-Maldonado et al., 2010). This is the start of DNA replication (Bell and Stillman, 
1992; Bicknell et al., 2011a). The ORC complex uses ATPase activity to bind to the DNA 
independently of other proteins (Bell, 2002; Bell and Stillman, 1992; Méchali, 2010). The 
six ORC subunits assemble around the DNA encircling it and binding to each other.  
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1.1.1.2 Origins of Replication 
Origins of replication in metazoan are not chosen based on sequence but on epigenetic 
feature and sequence content (Aladjem, 2007). Previous studies have found that origins 
are enriched at transcription start sites, CpG islands and G-rich motifs (Cayrou et al., 2011; 
Delgado et al., 1998). It is thought that G-rich motifs may be enriched for as the asymmetry 
in the G/C, A/T content causes distortion in the double helix leading to the formation of 
non-B DNA. Non-B DNA is more likely to unwind than B-form DNA, allowing the DNA to 
unwind during S-phase (Arnott et al., 1983; Bartholdy et al., 2015). Kuo et al., 2012 found 
a direct link between chromatin modifications and replication licensing. It was found that 
the bromo-adjacent homology (BAH) domain of human ORC1 binds to H4K20me2 
modifications and therefore may act as a selector of origin sites in humans. This complex 
is extremely important in DNA replication as any problems or delay with the first step of 
DNA replication will likely lead to a delay in DNA replication and cell cycle progression 
(discussed further in section 1.2.3). 
 
1.1.1.3 CDC6, CDT1 and GMNN interactions 
CDC6 is an essential pre-replication complex protein, which is only active in G1 phase. It 
is rapidly degraded during S-phase in budding and fission yeast, but in metazoan it’s 
activity is down-regulated by being exported from the nucleus (Kim and Kipreos, 2007; 
Kim et al., 2007; Musiałek and Rybaczek, 2015; Piatti et al., 1995). CDC6 is loaded with the 
help of ORC1 and is important in maintaining pre-replication complex formation (Chen et 
al., 2008; Saha et al., 1998; Wang et al., 1999). Like ORC1, CDC6 is an (ATPase Associated 
with a wide range of cellular Activities) AAA+ ATPase.  
CDT1 plays an important role in replication; it is loaded to the pre-replication complex 
with the help of ORC6. CDT1 then associates with the C-terminus of CDC6 to load the 
MCM2-7 helicase (Fernández-Cid et al., 2013; Khayrutdinov et al., 2009; Liu et al., 2012; 
Takara and Bell, 2011). CDT1 also plays a role in mitosis localizing to kinetochores 
through interaction with Hec1, although its exact function is not known (Pozo and Cook, 
2016; Varma et al., 2012). CDT1’s vital role in origin licencing makes it a target for DNA 
replication regulation, as without regulation CDT1 can load the MCM2-7 complex in G2-
phase leading to inappropriate replication licensing and DNA damage (Blow and Dutta, 
2005; Truong and Wu, 2011). CDT1 is regulated by both degradation and inactivation. 
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CDT1 levels are high in G1 phase where it is involved in MCM loading, significantly lower 
during S phase where it is actively degraded to prevent re-replication and increased again 
in G2 and M phase to prepare for DNA replication initiation in G1 phase. In humans CDT1 
is degraded in S phase by two ubiquitin-mediated E3 ligases, CUL4-DDB1CDT2 and SCFSkp2. 
(Kim and Kipreos, 2007; Lin et al., 2010; Machida et al., 2005; Sansam et al., 2006).  
The second mechanism by which CDT1 is regulated is inactivation by Geminin (GMNN). 
GMNN is an inhibitor of DNA replication, active during S, G2 and M phase to prevent the 
incorporation of MCM to the pre-replication complex (Burrage et al., 2015; Yoshida et al., 
2004). GMNN is quickly degraded during G1 phase to allow CDT1 to load MCM2-7 onto 
the chromatin (Figure 1.2). It is thought that the majority of CDT1 is degraded during S-
phase and any low levels remaining are inactivated by GMNN. However CDT1 must 
accumulate in G2 phase in order to be at the high level required for DNA replication 
initiation in the G1 phase. Therefore GMNN is thought to play a role in increasing and 





Figure 1.2 Cdt1, Cdc6 and GMNN role and interaction during cell cycle in yeast. Cdt1 and Cdc6 are 
required during G1 phase to load MCM2-7 complex. GMNN binds any Cdt1, which had not 
been degraded during S phase to prevent re-replication. Cdc6 is exported to the 
cytoplasm until the next G1 phase. GMNN levels increases during G2/M phase to bind 
Cdt1 in order for it to act quickly in G1 phase. GMNN is degraded at the end of M phase 
to allow Cdt1 to work quickly in G1 phase. Figure from (Montanari et al., 2006), copyright 
obtained from Springer Nature 4850520916840. 
 
1.1.1.4 Minichromosome maintenance (MCM) 2-7 complex 
The MCM complex comprises six subunits (MCM2-7), all of which are part of the AAA+ 
superfamily (Bell and Labib, 2016). These six subunits are important for ATP hydrolysis, 
which is required for conformational changes leading to the unwinding of the DNA duplex 
(Costa et al., 2011; Ilves et al., 2010). The MCM complex functions in S-phase as a DNA 
helicase, where it plays two important roles. First, it works in the initiation of DNA 
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replication and second it works to elongate DNA during S-phase. MCM2-7 acts by 
unwinding DNA ahead of the replication fork (Musiałek and Rybaczek, 2015). DNA 
helicase activity in vitro only requires three out of the six subunits (MCM4, 6 and 7), but 
all six are required for DNA replication (You et al., 1999). MCM2-7 exists as a single 
hexamer in solution but forms a double hexamer when loaded onto DNA (Evrin et al., 
2009; Gambus et al., 2011). The double hexamer formation is important as this allows the 
MCM complex to move and unwind DNA in both directions from the origin of replication. 
MCM2-7 is loaded by ORC-CDC6 and chaperoned by CDT1 in an inactive state (Hua and 
Orr-Weaver, 2017; Parker et al., 2017). The MCM complex does not have the required 
helicase activity to initiate DNA replication alone and requires other proteins and kinases, 
which form the pre-initiation complex (Parker et al., 2017). This helps to regulate DNA 




Figure 1.3 Composition of the pre-initiation complex in humans. The ORC complex is loaded onto 
the chromatin at the origins of replication, CDC6, CDT1 and MCM 2-7 are recruited to the 
complex. The pre-replication complex becomes the pre-initiation complex when CDC45 
along with the GINS complex and many other proteins are recruited. All known MGS genes 
play a role in the initiation of DNA replication. Published MGS genes are written in orange. 
Figure from (Fenwick et al., 2016), copyright obtained from Elsevier - 4850521104495.  
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1.1.2 Pre-Initiation complex 
The pre-initiation complex forms at the G1/S phase transition. CDC45 and the GINS 
complex (GINS subunits 1-4) are among the many proteins which bind to the pre-
replication complex to form the pre-initiation complex (Miyazawa-Onami et al., 2017). 
This is regulated by S-phase Cyclin-Dependent Kinase (S-CDK) and Dbf4-Dependent 
Kinase (DDK) during the transition from G1 to S-phase (Musiałek and Rybaczek, 2015; 
Uzcanga et al., 2017). The addition of CDC45 and the GINS complex leads to the assembly 
of the CDC45-MCM2–7-GINS (CMG) complex, an inactive functional replicative helicase 
(Bleichert et al., 2017; Hua and Orr-Weaver, 2017; Parker et al., 2017). MCM10 is required 
for activation of this complex (Ricke and Bielinsky, 2004). The MCM2-7 double hexamer 
becomes separated into single hexamers, where both MCM2-7 complexes form an active 
CMG helicase complex, which unwind DNA in opposite directions initiating at the origin 
of replication (Figure 1.3).  
 
1.1.2.1 Replication fork initiation 
DDK phosphorylates the N-terminus of several MCM2-7 subunits (specifically MCM2, 
MCM4 and MCM6) (Francis et al., 2009; Sheu and Stillman, 2006), thereby creating a 
binding site for Treslin allowing the subsequent recruitment of CDC45 (Bell and Labib, 
2016) (Figure 1.4). Next, the S-CDK phosphorylates Treslin and RecQL4, allowing the 
recruitment of TopBP1 to the phosphorylated RecQL4 protein (Tanaka et al., 2007; Yeeles 
et al., 2015; Zegerman and Diffley, 2007). This phosphorylation event also leads to the 
recruitment of Pol ε and the GINS complex (Figure 1.4). RecQL4-TopBP1-GINS-Pol ε 
complex is call the pre-loading complex (preLC) (Muramatsu et al., 2010). The pre-loading 
complex is recruited to the MCM helicase by interaction with TopBP1 and Treslin (Tanaka 
et al., 2007; Zegerman and Diffley, 2007).  
RecQL4, Treslin and TopBP1 disassociate from the complex leaving just the CMG complex 
remaining (CDC45/MCM2-7/GINS). Although the CMG is ultimately the active helicase it 
does not have DNA unwinding abilities until it is activated by MCM10 (Figure 1.4) (van 




Figure 1.4 Detailed assembly of the preIC and an active replication fork. A) Depicts order and 
method by which each protein is acquired to preIC complex. Proteins in the figure 
represent the yeast system, human orthologues are in brackets. Sld2 (RecQL4), Sld3 
(Treslin) and Dpb11 (TopBP1) are not part of the final replisome; however when they are 
released is unknown. B) Model mechanism for origin DNA melting and MCM2-7 non-
translocating strand exportation. Figure from (Bell and Labib, 2016) reuse allowed under 
the Creative Commons Attribution 4.0 International License. 
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Once the CMG complex has been activated by MCM10, RPA proteins bind the single-
stranded DNA to prevent re annealing (Figure 1.4A), the origin DNA is melted away to 
allow access by replisome components (Figure 1.4B) (Bell and Labib, 2016). As the MCM 
complexes originally bind double-stranded DNA the non-translocating strand must be 
exported from the MCM complex, via a conformational change of the CMG complex, as 
each of the MCM2-7 hexamers initiates DNA replication on single-stranded DNA in 
opposite directions (bidirectional replication fork) (Bell and Labib, 2016; Riera and Speck, 
2015). 
Next, Polymerase (Pol) α and primase are recruited by interactions with Ctf4 and the GINS 
complex (Gambus et al., 2009; Tanaka et al., 2009; Zhu et al., 2007). The primase 
synthesizes the first RNA primers to support initiation of elongation by Pol α (Bell and 
Labib, 2016). Pol δ or Pol ε undertake the majority of DNA replication, depending on 
whether DNA synthesis is occurring on the leading or lagging strand (Kunkel and Burgers, 
2014; Pellegrini, 2012). Once a primer is placed on the leading strand, extension is 
continuous in the 5′ to 3′ direction by Pol ε (Kunkel and Burgers, 2014). Multiple primers 
must be placed on the lagging strand and small Okazaki fragments are elongated by pol δ 
(Kunkel and Burgers, 2014; Ogawa and Okazaki, 1980). When Pol δ reaches the 5′ end of 
the preceding Okazaki fragment it can continue synthesis by displacing part of the primer 




CDC45 is an essential DNA replication gene as it is required for formation of the CMG 
complex along with the GINS complex when it binds to the origin bound MCM2-7 complex 
(Fenwick et al., 2016; Hardy, 1997; Zou and Stillman, 2000; Zou et al., 1997). CDC45 is 
required for elongation during S-phase and during replication fork stalling events 
(Karnani and Dutta, 2011; Moyer et al., 2006; Pacek and Walter, 2004). CDC45 binds the 
leading strand of DNA at the replication fork, facilitating strand displacement (Fenwick et 
al., 2016; Parker et al., 2017). CDC45 is a limiting factor in origin firing based on low 
abundance, thus determining the number of origins of replication that can be active at any 
one time (Köhler et al., 2016). Compared to other proteins in the preRC there is only ~0.35 
total molecules of CDC45, based on a preRC containing one ORC1-6 hexamer, four-five 
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MCM2-7 hexamers and two CDC6 proteins spaced every 100 kb (Wong et al., 2011). Due 
to the very low levels of CDC45, later origins cannot initiate until early replicons terminate 
and release CDC45 to be recycled (Musiałek and Rybaczek, 2015). 
 
1.1.3 Replication Stress 
During DNA replication a proportion of active replication forks may stall; this is called 
replication stress, and can lead to single or double-stranded breaks and chromosomal 
instability (Fragkos and Naim, 2017). As the replication fork moves along unwinding and 
copying DNA, there are many endogenous and exogenous stressors, which may cause the 
replication fork to slow down or stall. These stressors can include hard to copy areas of 
DNA such as highly repetitive regions, DNA lesions including nicks, gaps or long stretches 
of single-stranded DNA, DNA secondary structures, limited nucleotides or highly compact 
chromatin (Zeman and Cimprich, 2014). 
When a replication fork stalls, there are different stress pathways and checkpoints 
activated depending on the level of stress. Normally during fork arrest the ATM and Rad3 
related (ATR)-interacting protein (ATR–ATRIP) complex would be activated, and would 
subsequently phosphorylate and activate proteins required to inhibit cell cycle 
progression and promote DNA repair (Fragkos and Naim, 2017; Kemp et al., 2010; Sancar 
et al., 2004). Stalled replication forks must be stabilised to prevent collapse and recently 




Downstream neighbour of SON (DONSON) was first described in 2000 by Wynn et al., but 
only had its role in replication fork stability described in 2017 first by Reynolds et al., 
2017 in Nature Genetics, then confirmed by Evrony et al., 2017 in Genome Research. 
DONSON is a highly conserved gene with orthologues conserved as distantly as 
Caenorhabditis elegans (Bandura et al., 2005; Richardson, 2006). Genetic knockouts of the 
DONSON gene have been found to be embryonic lethal in both mouse and fly (Drosophila 
melanogaster) model systems tested (Dickinson et al., 2016; Lesly et al., 2017; Reynolds 
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et al., 2017), thus suggesting that DONSON is an essential DNA replication gene. The 
Drosophila orthologue of DONSON (humpty dumpty) has been shown to be involved in 
both DNA replication and cell cycle proliferation during development (Bandura et al., 
2005). Both humpty dumpty and DONSON expression peaks during G1/S phase, suggesting 
they are involved in DNA replication and S-phase progression (Bandura et al., 2005; 
Evrony et al., 2017; Fuchs et al., 2010). DONSON responds to replication stress through 
ATR signalling and is thought to help stabilise the replication fork during replication 
(Reynolds et al., 2017). In the absence of DONSON, stalled replication forks are cleaved 
resulting in double-stranded breaks, chromosome instability and cell death (Reynolds et 
al., 2017) (Figure 1.5). While Reynolds et al., 2017 also proposed that DONSON may be 
involved in activating the ATR–CHK1 replication stress response, how DONSON ensures 
fork stability and promotes checkpoint activation is not known yet and more research is 




Figure 1.5 Proposed model depicting how loss of DONSON may lead to genome instability. 
DONSON is thought to help stabilise replication forks during replication (left) which leads 
to normal replication and genome stability. In the absence (or reduced function) of 
DONSON, stalled replication forks are not stabilised long enough for replication forks to 
reactivate, leading to double-stranded breaks, genome instability and cell death Figure 
from (Reynolds et al., 2017), copyright obtained from Springer Nature - 4850530174277.  
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 DNA replication disorders  
The inability to replicate DNA appropriately leads to disease. Complications in replicating 
DNA cause replication stress, DNA damage and double-stranded breaks. DNA replication 
is a tightly regulated process, but issues can occur at many points; the initiation of 
replication, during replication, restarting stalled replication forks and cell cycle 
checkpoints. It is essential that cells replicate their DNA and progress through the cell 
cycle at the correct rate. Cells which divide too quickly can cause overgrowth and lead to 
tumours or cancers (Jackson et al., 2014; O’Driscoll, 2017). Cells which do not divide fast 
enough can lead to delayed growth of part or all of an organism (Mazouzi et al., 2014). 
There are many disorders associated with the proteins involved in DNA replication 
(O’Driscoll, 2017). Many of these lead to reduced organism size as the cells fail to progress 
through the cell cycle at the expected rate (Klingseisen and Jackson, 2011). 
DNA replication disorders cause a range of phenotypes with some genes causing multiple 
disorders (Harley et al., 2015; Karaca et al., 2019; Knapp et al., 2019; Mo et al., 2018) while 
some single gene disorders can be caused by variants in multiple different genes (Bicknell 
et al., 2011b; de Munnik et al., 2015). While there are many DNA replication disorders, the 
focus of this study is on Meier-Gorlin syndrome and related Primordial Dwarfism 
disorders (see: Sections 1.1.2-1.3), and only a selection of other replication disorders 
relevant to this study. 
DNA replication disorders resulting from variants within essential components of the pre-
RC and pre-IC include: Immunodeficiency 54 and Immunodeficiency 55 (Gennery et al., 
2000). Immunodeficiency 54 (IMD54) is caused by biallelic variants in the MCM4 gene, 
and patients present with delayed growth, adrenal insufficiency and natural killer cell 
deficiency (Casey et al., 2012; Eidenschenk et al., 2006; Gineau et al., 2012; Hughes et al., 
2012). Increased genomic instability, double-stranded breaks and impaired proliferation 
has been observed in patient cells (Casey et al., 2012; Eidenschenk et al., 2006; Gineau et 
al., 2012; Hughes et al., 2012). Immunodeficiency 55 (IMD55) is caused by biallelic 
variants in genes encoding the GINS complex, specifically GINS1, and again patients 
present with delayed growth and natural killer cell deficiency but have additional chronic 
neutropenia (Cottineau et al., 2017). Unsurprisingly, patient cells showed impaired GINS 
complex assembly leading to replication stress, genome instability, impaired checkpoint 
signalling and cell cycle control (Cottineau et al., 2017).  
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Additional published DNA replication disorders result from variants within the PCNA, 
POLε and RECQL4 genes. Ataxia-telangiectasia-like disorder-2 (ATLD2) is caused by 
biallelic variants in the PCNA gene. PCNA forms a sliding clamp around DNA and interacts 
with many proteins (Baple et al., 2014; O’Driscoll, 2017). ATLD2 patients present with a 
wide range of phenotypes including, telangiectasia, sensorineural hearing loss, cerebellar 
atrophy, short stature, neurodegeneration, photosensitivity and ataxia, due to the role of 
PCNA in many genomic stability pathways (Baple et al., 2014; O’Driscoll, 2017). Variants 
in DNA Polymerase Epsilon (POLε) are associated with a range of disorders including 
increased susceptibility to colorectal cancer (Bellido et al., 2016; Elsayed et al., 2015; 
Palles et al., 2013), facial dysmorphism-immunodeficiency-livedo-short stature (FILS) 
syndrome (Pachlopnik Schmid et al., 2012; Thiffault et al., 2015) and intrauterine growth 
retardation, metaphyseal dysplasia, adrenal hypoplasia congenita, genital anomalies, and 
immunodeficiency (IMAGEI) syndrome (Logan et al., 2018). Lastly variants in RECQL4 
also causes a range of syndromes (Siitonen et al., 2009), including Rothmund-Thomson 
syndrome (Kitao et al., 1999), Ballier–Gerold syndrome (Van Maldergem et al., 2006) and 
radial hypoplasia, patella hypoplasia and cleft or arched palate, diarrhoea and dislocated 
joints, little size and limb malformation, slender nose and normal intelligence 
(RAPADILINO) syndrome (Siitonen et al., 2003, 2009). RECQL4 is a DNA helicase required 
for genomic stability (Capp et al., 2010; Khakhar et al., 2003; Kitao et al., 1998; Matsuno 
et al., 2006; Sangrithi et al., 2005; Siitonen et al., 2009). 
Rothmund-Thomson syndrome patients present with short stature, congenital bone 
defects, skin rash (poikiloderma), premature ageing and increased risk of skin cancer 
later in life (Beghini et al., 2003; Kitao et al., 1999; Larizza et al., 2010; Lindor et al., 2000; 
Wang et al., 2003). As suggested by the name RAPADILINO syndrome is associated with a 
range of phenotypes (Kääriäinen et al., 1989; Siitonen et al., 2003, 2009; Vargas et al., 
1992). Ballier–Gerold syndrome is characterised by craniosynostosis and radial aplasia 
(Galea and Tolmie, 1990). RECQL4 is an example of a single replication gene which causes 
a wide range and severity of phenotypes and syndromes (Siitonen et al., 2009). 
 
1.1.4 Primordial Dwarfism 
Primordial dwarfism is a group of rare genetic disorders characterised by severe pre- and 
post-natal growth restriction affecting both males and females equally (Codd et al., 2009; 
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Khetarpal et al., 2016). Primordial dwarfism is largely caused by variants in genes 
encoding proteins involved in DNA replication, cell cycle progression, proliferation, 
differentiation and apoptosis (Khetarpal et al., 2016; Müller et al., 2012). 
Microcephalic primordial dwarfisms are a group of single gene disorders, in which 
causative gene variants discovered to date, are involved in DNA replication and cell cycle 
progression. A common phenotype of these disorders is prenatal and postnatal growth 
delay, as well as microcephaly and skeletal abnormalities (Klingseisen and Jackson, 2011). 
Disorders include microcephalic osteodysplastic primordial dwarfism (MOPD) types I, II 
and III, microcephaly‐micromelia syndrome (MIMIS), microcephaly, short stature and 
limb abnormalities (MISSLA), ATR–Seckel syndrome (SCKL1), and Meier-Gorlin 
syndrome (MGS) (Evrony et al., 2017; Karaca et al., 2019; Reynolds et al., 2017). These 
disorders are all caused by variants in important DNA replication/ cell cycle progression 
genes (Figure 1.6).  
MOPD type I and III are caused by variants in the RNU4ATAC gene, which encodes a 
component of the minor spliceosome that is responsible for splicing mRNA transcripts 
including those from DNA replication genes (Edery et al., 2011; He et al., 2011). MOPD 
type II is caused by variants in the PCNT gene, which encodes a key centrosomal protein 
essential for the formation of mitotic spindle and chromosome segregation (Kantaputra 
et al., 2011; Petry, 2016; Rauch et al., 2008).  
Seckel syndrome is caused by variants in TRAIP, CEP63, ATR, NSMCE2, DNA2, CENPJ, NIN, 
CEP152, and RBBP8, the encoded proteins have crucial roles in DNA damage response 
signalling, DNA repair, chromosome segregation and genome stability (Harley et al., 2015; 
Karaca et al., 2019). MGS (see section 1.2.3 and 1.3) is caused by genes involved in the 
initiation of DNA replication – specifically the pre-replication and pre-initiation complex, 
ORC1, ORC4, ORC6, CDT1, CDC6, CDC45, MCM5, GMNN (Bicknell et al., 2011a, 2011b; 
Burrage et al., 2015; Fenwick et al., 2016; Vetro et al., 2017). These proteins are essential 
for licencing replication origins, mediating loading and function of the replication fork. 
Lastly MISSLA and MIMIS are both caused by variants in DONSON (Evrony et al., 2017; 




Figure 1.6 Schematic visualising where different genes causing microcephalic primordial dwarfism 
act in the cell cycle. Genes are colour coded based on primary associated disease; Meier-
Gorlin syndrome (MGS) green, microcephalic osteodysplastic primordial dwarfism type 1 
(MOPDI) purple, microcephalic osteodysplastic primordial dwarfism type 2 (MOPDII) navy 
blue, Seckel Syndrome (SS) orange, Microcephaly, short stature, and limb abnormalities 
(MISSLA) brown, Microcephaly Micromelia syndrome (MIMIS) red, microcephalic 
primordial dwarfisms light blue. Note genes involved in MGS are present in three out of 
four cell cycle phases. Phenotypic overlap of diseases is depicted in Venn diagram. Figure 
adapted from (Karaca et al., 2019), copyright obtained from John Wiley and Sons - 
4850530640988.  
 
1.1.5 DONSON disorders 
DONSON is a gene, which has recently been implicated in a range of microcephalic 
primordial dwarfism disorders. Pathogenic variants in DONSON were found in 29 patients 
presenting with MIcrocephaly and Short Stature, with Limb Anomalies (MISSLA, OMIM 
#617604) (Reynolds et al., 2017). These patients all had severe microcephaly and a mild 
reduction in height as well as assorted other anomalies including a number of skeletal 
defects. A more recent publication reported a pair of German siblings presenting with 
MISSLA (Schulz et al., 2018). These siblings had previously been diagnosed with Fanconi 
anaemia-like syndrome, a disorder which Reynolds et al., 2017 also noted in three 
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affected siblings from one family in their cohort. Evrony et al., 2017 identified a splicing 
variant in DONSON (c.1047-9A>G) underlying microcephaly-micromelia syndrome 
(MIMIS) segregating in a First Nations community in Canada. Homozygosity for this 
variant caused a more severe phenotype with severe intrauterine growth restriction, 
severe microcephaly, craniofacial dysmorphism, and marked limb malformations. The 
majority of the patients are stillborn or die within 24 hours of birth but all die within 7 
days. The same variant has been found to cause MIMIS in two Saudi Arabian and two 
Emirati patients (Abdelrahman et al., 2019; Reynolds et al., 2017). More recently, Karaca 
et al., 2019 reported five affected individuals across four families with variants in 
DONSON. Two individuals presented with MGS, and two siblings with Seckel‐like 
phenotype. The remaining individual presenting with Femoral‐Facial syndrome was 
found to have a de novo DONSON variant, but as all other syndromes associated with 
DONSON are recessive it is possible this last patient has an undetected variant on the 
other allele. 
 
1.1.6 Meier-Gorlin Syndrome  
Meier-Gorlin syndrome (MGS, OMIM 224690) is a disorder caused by variants in genes 
encoding proteins with essential roles in DNA replication. It is a monogenetic autosomal 
recessive disorder that presents with an equal occurrence in males and females (Bongers 
et al., 2001; Hossain and Stillman, 2016; de Munnik et al., 2012a). MGS was originally 
named ear-patella-short stature syndrome after the diagnostic features (Cohen et al., 
1991), but was later renamed by Boles et al., 1994 after the first two authors to describe 
the syndrome, Meier et al., 1959 and Gorlin et al., 1975. Unlike other forms of dwarfism 
(such as achondroplasia), patients are proportionally small, with delayed growth, both 
prenatally and postnatally in the first year of life (Bicknell et al., 2011b; Klingseisen and 
Jackson, 2011; de Munnik et al., 2012b, 2015). MGS patients do not tend to respond to 
growth hormone treatments, except for a small number of cases where the patients also 
presented with low levels of IGF1 (de Munnik et al., 2012b). Ninety-seven percent of 
patients have two of the following; short stature, microtia (small malformed ears) and 
patellar aplasia/hypoplasia (small or absent kneecaps) (de Munnik et al., 2015). 
Associated features of the disease include feeding problems (de Munnik et al., 2015), 
mammary hypoplasia in females (de Munnik et al., 2012b), urogenital anomalies (Kora et 
al., 2016) and proportional microcephaly (de Munnik et al., 2012a). Characteristic facial 
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features such as a small mouth with full lips, micrognathia (undersized jaw) and beaked 
nose are often present in infants, this changes in adults to a high forehead with a 
prominent and narrow nose with a broad nasal bridge (Bongers et al., 2003, 2005; de 
Munnik et al., 2012b). Despite an often small head size, the majority of patients have 
normal intellect (Bicknell et al., 2011b; Shawky et al., 2014).  
Variants underlying MGS have been found in genes involved in DNA replication. 
Specifically genes in the pre-replication complex, ORC1, ORC4, ORC6, CDT1, CDC6, MCM5, 
GMNN and genes in the pre-initiation complex CDC45. Variants in any of these genes lead 
to disruptions in initiation of DNA replication, therefore variants are hypomorphic as null 
homozygous null alleles would be lethal (Bicknell et al., 2011a, 2011b; Burrage et al., 
2015; Fenwick et al., 2016; Guernsey et al., 2011; Kerzendorfer et al., 2013; Vetro et al., 
2017). GMNN is the only gene known to harbour de novo gain of function variants causing 
the disorder. GMNN normally functions as a negative regulator for CDT1. MGS variants in 
GMNN are found in the destruction box motif within the N-terminus of GMNN, a motif is 
recognised by anaphase-promoting complex (APC) which degrades GMNN during the 
metaphase-anaphase transition (Burrage et al., 2015). MGS-related variants prevent the 
degradation of GMNN, effectively reducing available CDT1 for DNA replication licensing, 
and therefore acting in a similar fashion to MGS variants in other preRC and preIC 
encoding genes.  
All of the previously mentioned MGS genes are essential for the initiation of DNA 
replication. There are two main hypotheses as to how the variants cause disease. The first 
is that reduced protein function is likely to lead to slower initiation of DNA replication, 
leading to slower cell cycle progression and division, therefore resulting in delayed 
growth, leading to the severe short stature phenotype (Klingseisen and Jackson, 2011). 
The other hypothesis is that normally during replication there are many more licenced 
origins than required, giving rise to ‘dormant origins’ (Ge et al., 2007). The majority of the 
time these won’t be required to fire, but they are able to fire in times of replication stress 
leading to replication being completed as efficiently as possible (Blow and Ge, 2009; Blow 
et al., 2011; Ge et al., 2007; Woodward et al., 2006). It is thought that MGS patients may 
not have the same reservoir of dormant origins and so during critical points in 
development when rapid proliferation is required, delays can occur which slow cell 
division, ultimately reducing the number of cells and reducing the size of an organism. 
The critical point(s) in development have not yet been identified. 
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 Meier-Gorlin syndrome individuals participating in this study 
Whole genome sequencing of our MGS patient cohort revealed two patients to have novel 
homozygous variants in either the known MGS gene, ORC1 or a new MGS gene DONSON 
(Dr Karen Knapp, Department of Pathology, University of Otago). The two MGS patients 
we are focusing on in this study are LB005 (ORC1 c. 1865T>C, p.Leu622Pro) and LB008 
(DONSON c.631C>T, p.Arg211Cys). Both come from consanguineous families, and have a 
reduction in head size, measured as occipitofrontal circumference (OFC) of -4.1 and -4.0 
standard deviations (SD) below the mean and also have a reduction in height of -4.2 and 
-3.5 SD for LB005 and LB008 respectively. They also have small hypoplastic/dysplastic 
ears, micrognathia (small jaw) and absent patella which is characteristic of MGS. LB005 
has no apparent intellectual disability. LB008 has mild hearing loss and a high arched 
palate. 
Two additional patients LB191 and LB192 with a predicted homozygous splicing variant 
in CDC45 (c.1441-2A>G) were also studied. These two siblings were referred after both 
pregnancies were terminated ~ 20-week’s gestation due to severe growth restriction and 
malformations. The parents were healthy and consanguineous (mother’s mother and 
father’s father were siblings); they had no family history of inherited conditions, 
congenital abnormalities, recurrent miscarriages or mental retardation. An ultrasound at 
17 weeks gestation showed the first sibling’s growth was lagging 3 weeks behind 
expected. A follow up ultrasound at 21.5 weeks showed continued growth retardation and 
a variety of other malformations. The pregnancy was terminated and an autopsy 
confirmed observations. The second pregnancy was monitored from the beginning and 
an ultrasound at 16.5 weeks showed growth was lagging two weeks behind, the next 
ultrasound at 20.1 weeks confirmed growth was lagging 2.9 weeks behind along with 
other malformations similar to the first pregnancy. Both siblings presented with many 
complications including absent eyelids, intrauterine growth approximately three weeks 
behind, cardiac abnormalities, oligohydramnios, dolichocephaly, cerebral 
ventriculomegaly, kyphotic lumbar spine, lordotic thoracic spine, thin ribs, absent 
clavicles and absent genitalia. 
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1.1.7 Novel variants found in ORC1 
MGS patients have previously been reported to have variants in ORC1 (Bicknell et al., 
2011a, 2011b; Guernsey et al., 2011). All of these patients have at least one deleterious 
allele in the BAH domain at the N-terminal domain of the protein (Figure 1.7). ORC1 is the 
only ORC subunit that contains a BAH domain (Noguchi et al., 2006), which is involved in 
protein-protein interaction, as well as other roles such as chromatin binding (Callebaut et 
al., 1999; Kuo et al., 2012; Noguchi et al., 2006; Zhang et al., 2015). Variants in the BAH 
domain were previously thought to be causing the severe MGS phenotype (Kuo et al., 
2012). The novel homozygous ORC1 variant (c. 1865T>C) is however found at the 3′ end 
of the ORC1 gene, distant from the BAH domain. Two other MGS patients have previously 
been found to have compound heterozygous variants involving a null allele and a 
missense variant (c.1996C>T, p.Arg666Trp) located within the same area of ORC1. The 
first of these two patients was published in Guernsey et al., 2011 with the phenotype 
previously described in Shalev and Hall, 2003, and comes from a non-consanguineous 
family. At 25 years old she presents with a reduction in head size (-4.8 SD), a reduction in 
height (-5.5 SD), absent kneecaps, small but not misshapen ears (-7 SD) and breast 
hypoplasia. She presented with dislocation of her hips and knees at birth, had feeding 
problems, normal intellect and has completed three years of college (Guernsey et al., 
2011; Shalev and Hall, 2003). The second patient is unpublished with no data available 
except a clinical diagnosis of MGS (Dr Louise Bicknell, personal communication). 
The two missense variants (p.Leu622Pro and p.Arg666Trp) are located in the AAA 
domain toward the C-terminal end of the protein (Bicknell et al., 2011a). The AAA domain 
is important for chromatin binding, partner protein recruitment, ATP hydrolysis, 
oligomerization and double-stranded DNA binding (Bleichert et al., 2017). ORC1 plays an 
essential role and mouse model ORC1 knockouts have been found to be lethal (Cooper, 
2016; Meehan et al., 2017). MGS patient cells also show a reduced amount of both 
chromatin-bound and unbound ORC1, suggesting variants in the BAH domain impact 
protein stability (Bicknell et al., 2011a). This suggests that variants in this gene cause a 




Figure 1.7 Important ORC1 domains and previous MGS variants. ORC1 MGS variants are indicated 
by arrowheads. Missense in red, splicing in yellow, truncation in black. The two variants 
studied in this thesis, p.L622P and p.R666W are indicated with a red asterisk. Other 
important features of ORC1 include the BAH domain (grey), AAA domain (purple), walker 
motifs (pink) and sensor motifs (blue).  
 
Previous research found that ORC1 depletion in zebrafish leads to a MGS-like phenotype 
which can be rescued by the addition of wild type (WT) human ORC1 (Bicknell et al., 
2011a; Kuo et al., 2012). ORC1 has also been reported to have roles in cilia formation (Stiff 
et al., 2013) and regulation of centriole and centrosome reduplication (Hemerly et al., 
2009; Kuo et al., 2012), suggesting ORC1 could be involved in more than just the initiation 
of DNA replication. The BAH domain of ORC1 has also been found to be an H4K20me2 
binding molecule, suggesting a role in chromatin modifications (Kuo et al., 2012; Zhang et 
al., 2015). Kuo et al., 2012 suggested that this H4K20me2-BAH domain interaction is the 
underlying cause of the MGS phenotype. This interaction was hypothesized to be causing 
the MGS phenotype, as all reported patients with ORC1 variants had at least one allele with 
a BAH domain variant (Kuo et al., 2012). However, the novel ORC1 p.L622P missense 
variant is homozygous and is located in the AAA domain, not in the BAH domain of the 
protein. This previous theory of the BAH domain being the cause of the MGS phenotype 
therefore does not explain why the same phenotype is observed in patients who do not 
have variants in the BAH domain. 
 
1.1.8 Novel CDC45 variants  
Biallelic CDC45 variants have previously been reported in patients presenting with 
craniosynostosis and MGS (Fenwick et al., 2016). The majority (80%) of CDC45-MGS 
patients presented with craniosynostosis compared to just 4% of MGS patients with 
variants in other genes (Fenwick et al., 2016; de Munnik et al., 2012a; Ting et al., 2019). 
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Although there is a slight difference in phenotype with these patients, besides the addition 
of craniosynostosis the secondary phenotypes are not considered more severe. In this 
study two severely affected foetuses presenting with a range of severe secondary 
phenotypes, including absent eyelids, cardiac abnormalities and craniosynostosis are 
presented. Both siblings were terminated at approximately 20 weeks gestation due to 
severe growth restrictions and secondary phenotypes. These siblings harbour a 
homozygous variant (c.1441-2A>G) within an essential splice site in CDC45. We suspected 
this variant may cause a more severe reduction in CDC45 protein levels compared to 
previously described patients with compound heterozygous splicing variants in CDC45. 
 
1.1.9 Novel MGS variants in DONSON 
DONSON’s role in replication fork stability and the S-phase checkpoint has previously 
been described by Reynolds et al., 2017. DONSON has been found to be involved in a range 
of MPD disorders, with patients with variants in DONSON tending to present with 
moderate to severe microcephaly and a slight reduction in height (Evrony et al., 2017; 
Reynolds et al., 2017). While MGS patients tend to be proportionally small, MISSLA and 
MIMIS patients tend to have a greater reduction in head size (Figure 1.8). It was thought 
that the brain is more severely affected as it undergoes a period of rapid proliferation with 
a very short G1 phase (Kalogeropoulou et al., 2019), and is therefore disproportionally 
affected by chromosomal instability and cell death. MGS patients tend to be proportionally 
small as all other MGS genes play a role early on in DNA replication effecting all cells 
evenly. It is hypothesised that DONSON may play another role earlier in DNA replication, 
which would be consistent with other MGS genes. Reynolds et al., 2017 showed that 
patient cell lines have reduced DONSON protein levels and mislocalisation of protein in 
the cytoplasm. DONSON is highly conserved between species and a homozygous mouse 
model is lethal (Evrony et al., 2017; Reynolds et al., 2017). This suggests that DONSON 
plays an important role in the cells and patient variants are likely to be knockdown rather 




Figure 1.8 Differences in phenotype between MISSLA patients and MGS-DONSON patients. 
Phenotypic data for MGS patients (green) and MISSLA patients (grey) show differences in 
phenotype between the two groups. MGS patients are proportionally small or have a 
larger reduction in height than head size whereas DONSON patients have a larger 
reduction in head size than height. Figure adapted from (Knapp et al., 2019) (figure 
created by Dr Louise Bicknell for Bicknell Marsden grant).  
 
1.1.9.1 DONSON in MGS patients  
Through whole genome sequencing a novel homozygous (c.631C>T, p.R211C) variant was 
found in a patient (LB008) presenting with MGS. A total of four patients with five missense 
and one splicing variant were found in the cohort (24%), making DONSON a relatively 
common MGS gene (Knapp et al., 2019). At the time of discovery, there were no published 
DONSON variants in MGS patients. The c.631C > T (p.Arg211Cys) DONSON variant has 
subsequently been published by Karaca et al., 2019 (Figure 1.9). Interestingly these 
authors also found a second MGS patient presenting with the same missense variant – 
both patients are from Turkey. LB008 was clinically diagnosed with MGS with an almost 
proportionate reduction in head size (-3.97 SD) and height (-3.48 SD), absent patella and 
small dysplastic ears, the three main markers of MGS. This phenotype is very clinically 
typical of MGS and different from the severe microcephaly seen with most other DONSON 
disorders (Figure 1.9). LB008 was chosen from the four MGS-DONSON patients, as this 
was the only patient with a homozygous missense variant, more suitable for CRISPR 
editing by homology directed repair (HDR) than a compound heterozygous variant. 
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Other functional studies on DONSON were carried out using fibroblasts derived from 
LB128, the only patient for which cells were available. LB128 is compound heterozygous 
for missense variants c.670C>T (p.Pro224Ser) and c.809A>G (p.Tyr270Cys). This patient 
also presented with the triad of MGS markers, microtia, absent patella and almost 
proportionate reduction in size, (-5.26 SD) head size and (-4.35 SD) height (Figure 1.9). 
 
Figure 1.9 MGS patients with variants in DONSON show the classical triad of MGS symptoms. Note 
the absent kneecaps in LB008, small-misshaped ears and bowed long bones (secondary 
phenotype) in both patients. A) LB008 comes from healthy consanguineous parents and 
presents with the classical triad of MGS phenotypes. B) LB128 comes from healthy 
unrelated parents and shows the classical triad of MGS phenotypes. C). Head to height 
ratio is plotted for MISSLA patients, MGS patients and MIMS patients. A proportionally 
small head to height ratio is seen in both MGS and MIMIS patients while MISSLA patients 
show a much more diverse spread of head to height ratios. Figure adapted from (Karaca 
et al., 2019 & Knapp et al., 2019), copyright obtained from John Wiley and Sons – 
4850530640988 and under the Creative Commons Attribution 4.0 International License.  
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  Aims and objectives 
This project aims to use CRISPR-Cas9 HDR to introduce Meier-Gorlin syndrome patient 
variants into hTERT-RPE-1 cell lines, a commonly used cell model for studying DNA 
replication and DNA damage. These cells will be used to investigate how these MGS 
variants affect the cells ability to load chromatin and progress through the cell cycle. The 
aims of this project changed slightly as it progressed, and instead focused on using 
transfected HeLa and HEK293FT cells and patient fibroblasts to investigate the cellular 
consequences of these variants. 
The overall aim of this project was to understand the cellular consequences of novel 
Meier-Gorlin syndrome variants using CRISPR-Cas9 and a variety of cellular assays.  
Aims: 
Explore whether CRISPR-Cas9 can be used to knock in patient MGS variants (essential 
genes) into hTERT-RPE-1 cells.  
Use a variety of cellular techniques to look at chromatin loading, DNA replication, and cell 
cycle progression. 
Investigate the novel consequences of a novel CDC45 splicing variant. 
Investigate the cellular effects of MGS-DONSON variants. 
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2 Methods  
Families were recruited to the study through Dr Louise Bicknell's international 
collaborations on Meier-Gorlin syndrome. Ethical approval for this study was provided by 
the New Zealand Health and Disability Ethics Committee (16/STH/3). 
A full list of chemicals/reagents (Appendix A.1) and buffers (Appendix A.2) used is this 
project is available in the appendix.  
 
 Molecular biology 
2.1.1 DNA extraction 
 Quick DNA extraction from cultured cells 
One μL Lucigen QuickExtract (Mediray) was added to 50-200 μL trypsinized cell culture 
in 8 well PCR strip tubes. Cells were vortexed for 15 seconds before being incubated at 65 
°C for 6 minutes. Samples were vortexed again for 15 seconds before being incubated at 
98 °C for 2 minutes to deactivate the enzymes. Samples were left in the fridge overnight 
for cell components to settle. DNA was then diluted 1:10 for use in PCR reactions (2.1.2) 
or an ethanol precipitation reaction (2.1.1.4) was performed to clean up the DNA. 
 
 Crude DNA extraction 
Fifty μL 1 M NaOH, 10 mM EDTA pH12 was added to ~150 μL trypsinized cells. Cells were 
incubated at 95 °C for 15 minutes before being cooled to 4 °C for 5 minutes and 
neutralised with 50 μL neutralising solution (2 M Tris-HCl, pH5 – Appendix A.2). DNA 
samples were stored at -20 °C and used diluted 1:10 in PCR reactions (2.1.2). 
 
 High quality DNA extraction 
Qiagen DNeasy Blood & Tissue Kit (Bio-Strategy) was used to extract high quality control 
DNA from cells cultured in a T25 or T75 flasks, following the manufacturer’s instructions. 
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 Ethanol precipitation of DNA 
Ten % sodium acetate (Thermo Scientific) was added to each tube. Two and a half 
volumes of absolute ethanol was added to each DNA sample. Samples were incubated at -
20 °C for 24 hours before being centrifuged at max speed (3220 g) for 40 minutes. 
Supernatant was removed and samples washed with 70% ethanol, centrifuged again at 
max speed for 15-20 minutes. Pellets were left to air dry for a few hours before being 
resuspended in 10-20 μL resuspension buffer or MilliQ water for at least 10 minutes at 37 
°C or a few hours at room temperature. Samples were stored long term at 4 °C. 
 
2.1.2 Polymerase chain reaction (PCR) 
Primers were designed using primer3 (Koressaar and Remm, 2007; Untergasser et al., 
2012) or primer BLAST (Ye et al., 2012). A full list of primers used is avalible in Appendix 
A.3. 
 
 Standard PCR 
Standard PCRs were set up using (2x) DreamTaq Green PCR Master Mix (Thermo 
Scientific). Five μL DreamTaq, 1 μL 20 nM primer mix or 2 μL 10 nM primer mix, 1-4 μL 
10 nM DNA made up to 10 μL with dH2O. 
PCRs were first optimised by altering the annealing temperature or changing to Phusion 
Flash High-Fidelity master mix (2.1.2.2). If these methods failed 1 μL 5x C.E.F. was added 
to improve amplification. In the case of long PCR products (>2.5 kb) the extension 
temperature was reduced from 72 °C to 68 °C. 
 
 Phusion flash high-fidelity PCR 
2x Phusion Flash High-Fidelity PCR Master mix (Thermo Scientific) was used for large 
fragments or optimisation. PCR was set up with 5 μL master mix, 1 μL F primer (10 nM), 
1 μL R primer ( 10 nM), 2 μL dH2O and 1 μL DNA (10 nM). 
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 PCR clean up 
PCR products were purified to remove unincorporated dNTPS before sequencing to 
reduce noise. One μL Exonuclease I (NEB) and 0.5 μL Shrimp Alkaline Phosphatase (rSAP) 
(NEB) were added to 5 μL of PCR product, and incubated at 37 °C for 15 minutes before 
being inactivated by incubating at 80 °C for 15 minutes. Appropriate concentration of 
samples were added to BigDye sequencing reaction (2.1.4.1) or stored at 4 °C. 
 
 PCR cycling conditions 
PCR reactions were carried out on a BIO-RAD DNA Engine Dyad Peltier Thermal Cycler. 
Cycling conditions are listed below. 
 
2.1.2.4.1 Standard PCR cycling conditions 
Initial denaturing: 95 °C for 10 minutes 
Denaturing:  95 °C for 30 seconds 
Annealing:  50-65 °C for 30 seconds 
Extension:  72 °C for 30 seconds 
Cycle:   40 times 
Final Extension: 72 °C for 10 minutes 
Hold   10 °C forever 
 
2.1.2.4.2 Touchdown PCR cycling conditions 
Initial denaturing: 95 °C for 10 minutes 
Denaturing:  95 °C for 30 seconds 
Annealing:  65 °C for 30 seconds 
Extension:  72 °C for 30 seconds 
Cycle:   3 times 
Denaturing:  95 °C for 30 seconds 
Annealing:  62 °C for 30 seconds 
Extension:  72 °C for 30 seconds 
Cycle:   3 times 
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Denaturing:  95 °C for 30 seconds 
Annealing:  59 °C for 30 seconds 
Extension:  72 °C for 30 seconds 
Cycle:   3 times 
Denaturing:  95 °C for 30 seconds 
Annealing:  56 °C for 30 seconds 
Extension:  72 °C for 30 seconds 
Cycle:   36 times 
Final Extension: 72 °C for 10 minutes 
Hold   10 °C forever 
 
2.1.2.4.3 Phusion flash PCR cycling conditions 
Initial denaturing: 98 °C for 10 seconds 
Denaturing:  98 °C for 1 Second 
Annealing:  55 °C or 60 °C for 5 seconds 
Extension:  72 °C for 30 seconds (15 second per kb) 
Cycle:   30 times 
Final Extension: 72 °C for 1 minute  
Hold   4 °C forever 
 
2.1.2.4.4 Mutagenesis cycling conditions 
Initial denaturing: 98 °C for 10 minutes 
Denaturing:  98 °C for 30 seconds 
Annealing:   55 °C for 30 seconds 
Extension:   68 °C for 8 minutes 
Cycle:    18 times 
Final Extension: 68 °C for 10 minutes 





Initial denaturing: 96 °C for 1 minute, 15 seconds 
Denaturing:  96 °C for 45 seconds 
Annealing:   50 °C for 45 seconds 
Extension:   60 °C for 8 minutes, 30 seconds 
Cycle:    25 times 
Hold:   10 °C forever 
 
2.1.2.4.6 Allele-Specific PCR 
Initial denaturing: 95 °C for 10 minutes 
Denaturing:  95 °C for 30 seconds 
Annealing:  70 °C for 30 seconds 
Extension:  72 °C for 30 seconds 
Cycle:   40 times 
Final Extension: 72 °C for 10 minutes 
Hold   10 °C forever 
 
2.1.3 Restriction endonuclease digests 
Restriction endonuclease digests were performed using restriction enzymes from NEB or 
Thermo Scientific. One μg or less DNA was incubated with 1 μL restriction enzyme, 1 μL 
buffer made up to 10 μL in dH2O. Restriction digests were performed following the 
manufacturer’s instructions. BbsI (Thermo Scientific) or BsrGI (NEB) were used to 
linearize PX458 for insertion of sgRNA sequence or Gibson assembly. Taq (α) 1 or SacI 
(NEB) were used to genotype CRISPR clones. DpnI (NEB) was used to degrade any 
remaining E.coli plasmid after mutagenesis. DpnI cleaves methylation sites present in 
E.coli amplified plasmid but not present in mutagenesis plasmids amplified by PCR. 
 
2.1.4 Agarose gel electrophoresis 
PCR products and restriction endonuclease digests were analysed by electrophoresis on 
1-2.5% agarose gels. Agarose power (MediRay) was added to a conical flask with 50 mL 
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0.5x TBE (Appendix A.2), and microwaved for 2 minutes or until dissolved. Molten 
agarose was left to cool for a minute before 5 μL SYBR™ Safe DNA Gel Stain (Invitrogen) 
was added and swirled to mix. The mixture was transferred to a 50 mL falcon tube and 
0.5x TBE was added to make up to 50 mL. The gel was poured into a minigel tank 
containing 1-2, 16 or 20 well combs, and left to set for half an hour. Once set combs were 
removed and the gel was covered with 0.5x TBE, samples and 100 bp or 1 kb ladder (NEB) 
were loaded. One μL of loading dye (NEB) was mixed with 3 μL of restriction digest 
samples or PCR samples run with Phusion flash master mix, before being loaded on the 
gel. Two-9 μL DreamTaq PCR reactions were loaded on the gel directly without the need 
to add loading dye. 
Electrophoresis was carried out at 80 V/cm for 25-50 minutes before being imaged on the 
UVITEC Cambridge gel doc or BioRad UV light transilluminator. 
 
 Purify DNA from agarose gel 
Bands were extracted from agarose gels using the GeneJET Gel Extraction Kit (Thermo 
Scientific) following the manufacturer’s instructions. 
 
2.1.5 Sanger sequencing 
 Big dye reaction 
BigDye sequencing reactions were set up using 1.75 µL 5x sequencing buffer (Genetic 
Analysis Services (GAS) Otago), 0.5 µL Big Dye Terminator (GAS Otago), 1 µL (3.2 μM) 
Primer and >200 ng plasmid DNA or 1 ng/100 bp cleaned up PCR product (2.1.2.3) and 
made up to total volume of 10 µL with distilled water. Sequencing reactions were 
performed using the BigDye program (2.1.2.4.5) in a thermocycler. 
 
 Sequencing clean up and calling 
Two μL 3 M Sodium acetate (Thermo Scientific), 10 MilliQ water and 50 μL absolute 
ethanol was added to each sample. Samples were incubated for 10 minutes at room 
temperature before being centrifuged at 3220 g for 20 minutes. Samples were then 
washed twice with 150 μL, 70% ethanol. Pellets were left to air dry before being 
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transported to Genetic Analysis Services Otago (Department of Anatomy) for analysis on 
their Applied Biosystems™ 3730xl DNA Analyzer.  
 
 Sanger sequencing analysis 
Sanger sequencing results were analysed using Sequencher® version 5.4.6 DNA sequence 
analysis software, Gene Codes Corporation, Ann Arbor, MI USA 
http://www.genecodes.com or Geneious 11.1.3 (https://www.geneious.com). 
 
2.1.6 Cloning  
 Plasmids 
Table 2.1 Table of plasmids used in this project. 
Plasmid Source 
p.EGFP-empty (Reynolds et al., 2017) 
p.EGFP-DONSON (Reynolds et al., 2017) 
pSpCas9(BB)-2A-GFP (PX458) empty, 
ORC1, DONSON 
Addgene (#48138) (Ran et al., 2013a) 
PCS2+Cas9-mSA Addgene (#103882) (Gu et al., 2018) 
Flag-tag-CDC45 (Dr Karen Knapp) 
pSpliceExpress Addgene (#32485) (Kishore et al., 
2008) 
 
 Chemically competent E.coli top 10 
Chemically competent E.coli Top10 were used for all transformations. Fifty mM CaCl2, 10 
mM Tris-HCL pH 7.4 solution was used to make chemically competent E.coli top10 
(protocol Appendix B.1). 
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 E.coli transformations 
Fifty μL aliquots of E.coli were thawed on ice ~20 minutes. Fifty μL E.coli was incubated 
with 1-5 μL plasmid or cloning reaction for 10 minutes on ice. Vials were heat shocked for 
30 seconds at 42 °C then incubated on ice for 2 minutes. The transformation reaction was 
either plated straight away or 300 μL LB medium (Appendix A.2) added and incubated 
shaking for 30-45 minutes before – centrifuging, removing 300 μL supernatant and 
resuspending in the remaining 50 μL. 
 
 Colony PCR 
Colony PCR (cPCR) was used to screen E.coli colonies for correct plasmids. These were set 
up as previously described (2.1.2.1) using one plasmid-specific and one insert-specific 
primer. E.coli colonies were picked using a P200 tip and suspended in 20 μL dH2O, 3 μL of 
the suspension was added to each PCR reaction and 2 μL was spotted on an agar plate 
containing appropriate antibiotic and incubated overnight 37 °C. A scraping of colonies 
containing the correct insert were taken for a mini plasmid prep followed by Sanger 
sequencing to confirm the correct sequence. 
 
 Plasmid purification and glycerol stock preperation 
Glycerol stocks were prepared for every plasmid by adding 250 μL overnight culture to 
250 μL 50% glycerol (Thermo Scientific) and storing in the -80 °C freezer. Small-scale 
plasmid preparations were performed using the GeneJET miniprep kit (Thermo 
Scientific) following the manufacturer’s instructions. Large-scale plasmid preparations 
were performed using the GeneJET midiprep kit (Thermo Scientific) following the 
manufacturer’s instructions. Plasmid concentrations were measured by NanoDrop 
(2.1.6.6) or Qubit (2.2.6.7). 
 
 Initial quantification of DNA, RNA and E.coli concentrations 
DNA, RNA or E.coli concentrations were measured using the NanoDrop™ OneC UV-Vis 
Spectrophotometer. The NanoDrop was set to zero using elution buffer, RNAase free 
water or LB medium. Two-3 μL of sample was added to the clean pedestal and 
measurements taken. DNA and RNA concentrations were measured by absorbance at 260 
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nm. Absorbance at 230 nm and 280 nm was used to calculate A260/A230 and A260/A280 
purity ratios, an A260/A280 ratio of ~1.8 (DNA) or ~2.0 (RNA) and an A260/A230 ratio 
between 1.8 and 2.2 was considered pure. E.coli concentrations were measured using 
OD600 (600 nm) reading. Two-three replicates were performed to confirm concentration.  
 
 Conformation of plasmid concentrations for transformations 
Qubit was used to confirm plasmid concentrations for transfections. Other members of 
the laboratory group had found plasmid concentrations had been overestimated by the 
NanoDrop in some circumstances. The plasmid concentrations were measured using the 
Qubit™ dsDNA BR Assay Kit (Thermo Scientific) following the manufacturer’s 
instructions.  
 
 sgRNA cloning 
sgRNA were designed using http://crispr.mit.edu/, however this tool is no longer 
functional. Guides were chosen based on proximity of cut site to desired knock-in variant, 
a high off-target score (few off-targets in exons and introns) and fewest variants required 
to disrupt the PAM site, add or remove a restriction enzyme site and insert a patient 
variant. 
DNA oligonucleotides representing the sgRNAs were phosphorylated using NEB T4 PNK 
and annealed. Double-stranded DNAs representing the sgRNA sequences were then 
ligated into the PX458 (Addgene #48138) vector at the BbsI restriction cut site using NEB 
T4 ligase as per the manufacturer’s instructions.  
Repair templates (ssODN) were designed with homology arms of at least 88 bp on each 
side of the variant site (Yang et al., 2013). 
 
 Site directed mutagenesis 
Primers were designed using the QuikChange® Primer Design tool. This tool allows 1-7 
bp to be deleted or substituted from the original plasmid sequence.  
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Site directed mutagenesis was used to introduce a patient c.631C>T missense variant into 
the pEGFP-DONSON vector. The pEGFP-DONSON and pEGFP-empty vectors were created 
and used by Reynolds et al., 2017. The forward and reverse mutagenesis primers 
contained the variant in the middle (in red) CTCTCCTCTGAGCTCTGTTGTACCTTCCAGC. 
The pEGFP-DONSON plasmid was amplified using the Phusion Flash high-fidelity PCR 
protocol as previously described (2.1.2.2) and Phusion flash PCR cycling conditions 
(2.1.2.4.3). 
As the pEGFP vector contained kanamycin resistance, transformed E.coli (2.1.6.3) was 
plated on kanamycin containing agar plates. Mini plasmid preps (2.1.6.5) were performed 
on two colonies, these were Sanger sequenced (2.1.4) to confirm variant. 
Mutagenesis was also used to delete 6 bp of cDNA from flag tagged CDC45 cDNA plasmid. 
This allowed over expression of the cDNA from a patient with a splicing variant in HeLa 
cells.  
 
 Gibson assembly  
Gibson assembly was performed following the manufacturer’s instructions. First a 
restriction digest was performed (2.1.5) using BsrGI to linearize the PX458 plasmid at the 






Figure 2.1 Gibson assembly master mix assembles two overlapping fragments. The Gibson 
assembly reaction takes place in a single tube at 50 °C and can be used to combine 
multiple fragments with overlapping ends. First, the mSA fragment was PCR amplified 
with primers containing overlapping PX458 sequence. Next, the endonuclease digests the 
5′ ends of the PCR product and plasmid. The two complimentary strands anneal before 




Next, the monomeric streptavidin (mSA) fragment was amplified by PCR from PCS2 + 
Cas9-mSA (2.1.2.2). The end of the Gibson assembly primers contain part of the PX458 
plasmid. The Gibson assembly reaction was then performed to incorporate this fragment 
into the PX458 plasmid. This created a plasmid containing the specific sgRNA encoding 
sequence under the U6 promotor and a Cas9-GFP-mSA complex under a CAG promoter 




















Figure 2.2 PX458 plasmid modified by Gibson assembly to include mSA fragment. Plasmid map 
shows insertion site of the mSA fragment (BsrGI), alongside the orientation of the Cas9-
GFP-mSA construct in the new PX458-mSA plasmid. Schematic shows how this new Cas9-
GFP-mSA complex should interact with the sgRNA, DNA and biotin tagged ssODN at the 
desired cut site (DNA adapted from https://smart.servier.com/ template). 
 
 Gateway cloning 
Gateway cloning was used to create a p.SpliceExpress vector containing a small part of the 
ORC1 gene. This allowed assessment of potential splicing variants between WT ORC1 and 
LB005 homozygous variant p.L622P. Ex12-14 and >200 bp of intron either side were 
amplified by Phusion PCR (2.1.2.2). Gateway cloning was performed following the 
manufacturer’s instructions and E.coli was transformed as previously described (2.1.6.3) 
and plated on ampicillin containing agar. Gateway cloning uses attB/attP sites for site-
specific recombination to insert the desired fragment (Figure 2.3). Intact plasmid is toxic 
to E.coli top10, which selects for any E.coli with the original plasmid. p.SpliceExpress also 





Figure 2.3 Gateway cloning uses attB/attP recombination sites to insert region of interest into 
p.SpliceExpress vector. 
 
2.1.7 Expression level analysis: 
 RNA extraction  
Cells lysates were homogenised by passing through a blunt 20-gauge (0.9 mm) needle 5-
10 times. RNA was then extracted using a Qiagen RNA mini kit (Bio-Strategy) following 
the manufacturer’s instructions. cDNA was synthesised (2.1.7.2) from the extracted RNA 
immediately. Any remaining RNA was stored at -80 °C. 
 
 cDNA synthesis 
cDNA was synthesised using SuperScript™ IV VILO™ Master Mix with ezDNase™ Enzyme 
(Thermo Scientific) following the manufacturer’s instructions. cDNA was stored at -20 °C. 
 
 RT-qPCR 
CDC45 expression levels were measured by relative quantification from RT-qPCR, using 
PowerUp™ SYBR™ Green Master Mix (Thermo Scientific) following the manufacturer’s 
instructions, using the Roche LightCycler® 480 Instrument II.  
UDG activation  50 °C for 2 minutes 
Dual-lock DNA polymerase 95 °C for 2 minutes 
Amplification   95 °C for 15 seconds, 
     55 °C for 15 seconds,  
     72 °C for 1 minute  
     x 40 cycles 
Dissociation curve  95 °C for 15 seconds, 60 °C for 15 seconds, 95 °C continuous 
Cooling   40 °C for 30 seconds 
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Standard curves were performed for all primer pairs (appendix C.1) and primer 
efficiencies were calculated to be between 92-109%. 
CDC45 expression was normalised to Hypoxanthine-guanine phosphoribosyltransferase 
(HPRT) and Ribosomal Protein S18 (RPS18) levels as housekeeping genes, although after 
investigation it was decided to only use RPS18 as HPRT expression in fibroblasts is 
variable (Nielsen et al., 2018). 
Expression was compared using the 2-ΔΔCT method (Livak and Schmittgen, 2001).  
 
 RT-PCR 
RT-PCR was set up using DreamTaq a described (2.1.2.1) using cDNA synthesised above 
(2.1.7.2) and a standard PCR cycle (2.1.2.4.1). 
 
2.1.8 Protein Analysis 
 Protein Extraction and quantification 
A western blot was performed on fibroblast cell lysate to measure protein levels. 
KDM14.9 (healthy control) and patient (LB192) fibroblasts, as well as transfected 
(Section 2.3.7) and untransfected HEK293FT cells were used for western blots (2.1.8.3). 
Protein was extracted using 1x cOmplete™ Mini, EDTA-free Protease Inhibitor Cocktail 
(Sigma-Aldrich) in RIPA buffer (Thermo Scientific) on ice for 10 minutes (100 uL per 5.0 
x 105 cells). Samples were then sonicated (20% Amp, 30 seconds) to disrupt the cell 
membranes and release the cells contents.  
Protein levels were measured using Pierce Rapid Gold BCA Protein Assay kit (Thermo 
Scientific) following the manufacturer’s instructions together with a BSA standard curve. 
 
 SDS-PAGE 
40-80 μg protein in RIPA buffer was added to Laemmli buffer (containing 5% β-
mercaptoethanol), and incubated at 95 °C for 5 minutes to denature protein. Samples 
were stored at -20 °C until needed. A 10 % mini protein SDS-PAGE gel and stacking gel 
was prepared (appendix B.2), upper and lower reservoirs were filled with SDS-PAGE 
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running buffer: 0.1 % SDS, 1x western gel buffer. Protein samples along with 10 μL 
Precision Plus Protein Dual Colour Standard (Bio-Rad) were loaded, and electrophoresis 
was carried out at 200 V for ~1 hour.  
 
 Immunoblotting 
A semidry transfer was performed, the gel was placed onto a piece of 0.2 μm nitrocellulose 
membrane layered between 9 pieces of Whatman paper and western transfer buffer (10% 
iso-propanol, 1x western buffer (Appendix A.2)) using a Bio-Rad Trans-blot Turbo 
transfer system. 
1. 12 V – 1.0 A – 10 minutes  
2. 25 V – 1.6 A – 45 minutes 
Membranes were blocked with 5% milk powder in PBS (Appendix A.2), with shaking at 
room temperature for 10 minutes. The membrane was probed with mouse anti-CDC45 
(Bio-Strategy cat. no. sc-55569), diluted 1:50, 1:100 or 1:200 and incubated with shaking 
for 1.5 hours at room temperature or 4 °C overnight. Nitrocellulose membranes were 
rinsed twice before being probed with IRDye 800CW goat anti-mouse secondary antibody 
diluted 1:25,000 (Millenium Science NZ) for 1 hour at room temperature (shaking). The 
membrane was washed three times in PBS, dried in the dark and imaged on a LI-COR 
Odyssey CLx instrument. The image was viewed and edited using Image Studio software. 
 
 Cell culture Media and reagents  
2.2.1 hTERT-RPE-1 media (Complete)  
hTERT-RPE-1 cells were grown in complete growth media (CGM): 10% fetal bovine serum 
(FBS) (Morgate Biotech), 1% penicillin-streptomycin (PenStrep) (Thermo Scientific), 0.01 
mg/mL Hygromycin B (Sigma-Aldrich) in Dulbecco's modified Eagle medium/nutrient 
mixture F-12 (DMEM/F12) 1:1, with 2.50 mM L-glutamine, 15 mM HEPES (Thermo 
Scientific or Hyclone).  
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2.2.2 Fibroblast Media (Complete) 
Primary fibroblasts were grown in DMEM (Thermo Scientific) supplemented with 10% 
FBS, 1x penicillin/streptomycin (Thermo Scientific).  
LB128 CDC45 patient fibroblasts were grown in DMEM (Thermo Scientific) 
supplemented 20% FBS, 1% penicillin-streptomycin and Fungizone (1:100 Dilution 
Factor) due to fungal contamination on arrival. KDM14.9 control fibroblasts grown at the 
same time were also grown with this medium. 
 
2.2.3 HeLa/ HEK293F media (complete) 
HeLa and HEK293FT were growth in Dulbecco's modified Eagle medium (DMEM) 
supplemented with 10% FBS (Morgate Biotech), 1% penicillin-streptomycin (Thermo 
Scientific). 
 
2.2.4 Freezing mix hTERT-RPE-1 and Fibroblasts 
Complete growth media as above 2.2.1/2.2.2 supplemented with 10% DMSO (Sigma-
Aldrich) and 60% FBS. 
 
2.2.5 HeLa and HEK293FT freezing mix 
Complete growth media as above 2.2.3 supplemented with 10% DMSO and 10% FBS. 
 
2.2.6 Transfection media 
All cell types were transfected in required media (Table 2.2) supplemented with 10% FBS 
(no antibiotics). HeLa and HEK293FT cells were transfected using Lipofectamine 2000 




2.2.7 MACS buffer 
MACS buffer was generated in the clean hood from autoclaved and EDTA stocks. FBS was 
added to give a final concentration of 1x PBS pH 7.2, 2 mM EDTA, FBS 1%. The buffer was 
filter sterilised (0.2 μm) into sterile 50 mL falcon tubes and stored at 4 °C. 
 
 Cell culture methods 
2.3.1 Cell Lines 
Aseptic technique was used to maintain a sterile environment in a Class II Microbiological 
Safety Cabinet. All cell lines were grown at 37 °C in a humidified incubator 5% CO2. Frozen 
hTERT-RPE-1 and fibroblasts were stored long term in the liquid nitrogen Dewar, while 
HeLa and HEK293FT cells were stored in the -80 °C freezer. Cell lines were grown in 
different media conditions and centrifuged at different speeds outlined in Table 2.2.  
Patient fibroblasts were derived from skin biopsies, collected and established in local 
diagnostic laboratories, using standard protocols. 
Table 2.2 Cell line sources, media, centrifuge speeds and long term storage.  






































* note fungal contamination was present in CDC45 patient fibroblast on arrival 
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2.3.2 Initiating cell culture from frozen stock 
One mL cryogenic vials were removed from liquid nitrogen or the -80 °C freezer and 
transported on ice to a 37 °C water bath. Cells were rapidly warmed for 2 minutes by 
gentle agitation in the 37 °C water bath before being added to 9 mL CGM (2.2.1, 2.2.2, 
2.2.3). Cells were pelleted by centrifugation at the appropriate speed (Table 2.2), 
supernatant was carefully aspirated to remove any DMSO, and cells gently resuspended 
in 6 mL CGM before being plated in a T25 flask.  
 
2.3.3  Cell maintancence 
Cells were visualised using the inverted cell culture room microscope daily to check 
confluency and health. Culture media was changed every three days until cells had grown 
in a monolayer reaching 60-95% confluency. To passage cells CGM was removed and 0.6 
mL 0.25% Trypsin-EDTA (Gibco) was added to detach the cells (*cells were only washed 
with sterile PBS when passaging from a 96 well plate). After 5-10 minutes, the cells were 
visualised under the microscope to check all had detached, 19.4 mL CGM was added and 
cells gently resuspended to give a 1:3 dilution. Cells were transferred to a T75 flask.  
The above protocol was also followed for passaging cells in T75 flasks (2 mL trypsin). 
hTERT-RPE-1 and HeLa cells were passaged using a dilution between 1:2-1:20, while 
HEK293FT and primary fibroblasts were split between 1:2-1:6. 
 
2.3.4  Cyropreservation 
Cells were detached as previously described and resuspended in 10 mL CGM, centrifuged 
at the recommended speed (Table 2.2) and supernatant removed. Cells from an 80% 
confluent T75 flask were resuspended in 4-20 mL freezing mix (2.2.4/2.2.5) and 1 mL 
aliquots were transferred to cryovials. Primary fibroblasts were placed in a Mr Frosty 
(Thermo Scientific) freezing vessel in the -80 °C freezer overnight to slowly cool the cells 
before being transferred to the liquid nitrogen Dewar. hTERT-RPE-1 cells were 
transferred directly to the liquid nitrogen Dewar, while HeLa and HEK293FT cells were 
placed directly in the -80 °C freezer. 
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2.3.5 Cell counting 
Cells were counted manually using a haemocytometer before freezing and transfections 
to confirm appropriate number of cells (Figure 2.4).  
 
Figure 2.4 Haemocytometer used for counting the number of cells in a cell suspension. Grey 
squares indicate 1x1 mm grids. The number of cells (represented by black circles) 
in each shaded grid were counted, and an average obtained by dividing the total 
number of cells by 5. The average was then multiplied by the dilution factor (if 
diluted) x 10,000 to get to the total number of cells per mL. e.g. (y+y+y+y+y)/5 x 
DF x 10, 000 = cells/mL 
 
2.3.6 Transfection of HeLa cells 
Transfections were performed with Lipofectamine 2000 (Thermo Scientific). Cells were 
plated on glass 16 mm coverslips in a 24 well plate 8-24 hours before transfection to allow 
cells time to attach. Media was replaced with transfection media immediately before 
transfection (2.2.6). Three μL of 1 mg/mL Lipofectamine 2000 (Thermo Scientific) was 
added to 50 μL OptiMEM (Thermo Scientific) in tube A, while 1000 ng plasmid DNA was 
mixed with another 50 μL OptiMEM in a tube B. The two tubes were combined and added 
to the cells. Cells were incubated for 24 hours (37 °C, 5% CO2). 
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2.3.7 Transfection of HEK293FT Cells 
HEK293FT cells were transfected with Lipofectamine 2000. Cells were plated at 90% 
confluence in a 6 well plate at the time of transfection. Sixteen μL of 1 mg/mL 
Lipofectamine 2000 was added to 200 μL of OptiMEM. Four thousand ng plasmid DNA 
was added to 200 μL OptiMEM in a separate tube. The two tubes were then combined and 
added to cells, which were incubated for 24 hours (37 °C, 5% CO2). 
 
2.3.8 Transfections of hTERT-RPE-1 cells 
Transfections were performed with Lipofectamine 3000. Fifty μL OptiMEM was combined 
with 1 μL Lipofectamine 3000, 1 μL P3000, between 250-1000 ng plasmid DNA and 0-4 
ng ssODN in an Eppendorf. Tubes were centrifuged briefly before being added to hTERT-
RPE-1 cells that were 70-90% confluent in a 24 well plate. Cells were plated 8-24 hours 
before transfection in antibiotic free media (2.2.6) to allow time for cells to adhere to the 
plates. Cells were visualised 24-48 hours post transfection. 
 
2.3.9 FACS preparation 
Cells were visualised under the fluorescence microscope to check for GFP expression 24 
or 48 hours post transfection. Cells were trypsinized, resuspended in CGM (2.3.3) and 
strained using a 70 μM cell strainer. Cells were centrifuged at 300 g for 5 minutes before 
being washed with MACS buffer to reduce any background fluorescence. Cells were 
centrifuged again and resuspended in 100 μL MACS buffer to be stained using Zombie NIR 
fixable viability kit (MediRay). This stain causes dead cells to fluoresce so they can be 
sorted out. Cells were washed again before being resuspended in 500 μL MACS buffer and 
transported on ice to the FACS suite 4th floor Microbiology. Spare MACS buffer was taken 
to dilute samples if required along with 15 mL Falcon tubes containing 5 mL CGM to 
collect cells. 
 
2.3.10  Flow Cytometry 
FACS was performed with the help of Michelle Wilson (Department of Microbiology and 
Immunology, University of Otago) on the BD FACS Aria instrument. A GFP positive bulk 
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cell sort was performed 24-48 hours after transfection with PX458 or PX458-mSA 
plasmids. A GFP negative single cell sort was performed 6 or 7 days after the bulk sort. 
Bulk sorted cells were collected in 15 mL Falcon tubes containing 5 mL CGM, which were 
transported back to the laboratory, centrifuged at 300 g before being resuspended in fresh 
CGM and plated or used for DNA extraction. For single cell sorts, U-bottom 96 well plates 
containing 100 μL CGM per well were transported on ice. Cells were not sorted into the 
outside wells as these are prone to drying out. Ninety-six well plates were transported 
back to the laboratory on ice and placed in the cell culture incubator. 
 
 
Figure 2.5 General FACS prep sorting protocol for CRISPR-edited cells. Transfections optimised in 
24 well plate before being scaled up to 6 well plates. Cells were trypsinized, resuspended, 
strained, washed and stained with Zombie NIR viability dye. GFP-positive Zombie dye 
negative cells were bulk sorted, plated at a low density and single cell sorted ~1 week later 
(Figure created with BioRender).  
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 Immunofluorescence and DNA fibrecombing 
2.4.1 Immunocytochemistry 
HeLa cells were plated on glass coverslips ~12 hours before transfection (2.3.6). Medium 
was removed, cells washed in PBS and fixed using ice cold methanol. Cells were blocked 
with PBS containing 2-7% serum and 0.01-3% triton X-100 (Appendix A.2). If using 
primary antibodies (anti-phospho-histone H2A.X (Ser139) (Merk Millipore), anti-
phospho histone H3 (serine 10) (Merk Millipore), or purified anti-active caspase-3 
monoclonal antibody (rabbit IgG) (BD Pharmingen)) cells were incubated in (1:500-
1:1500) overnight at 4 °C. Goat anti-mouse IgG (H+L) cross adsorbed secondary antibody 
Alexa Fluor 568 (Thermo Scientific) or Goat anti-rabbit IgG (H+L) cross adsorbed 
secondary antibody, Alexa Fluor 568 (Thermo Scientific) were mixed with blocking 
solution (1:500) and incubated for 1 hour at room temperature. DAPI (Sigma-Aldrich) 
(1:1500) was then added for 5 minutes. Cells were washed before being mounted with 
ProLong™ Diamond Antifade Mountant (Invitrogen). Further details available Appendix 
B.4. 
 
2.4.2 Quantification of DNA replication events and replication fork speed using DNA 
Fibre combing 
Fibroblasts were plated at ~40% confluent the day before. Twenty-five µM 5-chloro-2'-
deoxyuridine (CIdU) (Sigma-Aldrich) diluted in CGM (2.2.2) was added to the cells for 20 
minutes. Cells were washed in PBS before 250 µM 5-Iodo-2′-deoxyuridine (IdU) (SIGMA - 
I7125-5 g) was added for 20 minutes. Cells were trypsinized and resuspended in ice cold 
PBS. Cells were counted (2.3.5) and diluted to the optimal 50 x 104 cells/mL 
concentration. Two μL (1000 cells) were spotted on a clean slide labelled with a pencil 
and left to become crinkly around the edges. Seven μL spreading buffer (200 mM Tris pH 
7.5, 50 mM EDTA, 0.5% SDS) was spotted on top, swirled together with pipette tip and 
incubated for 2 minutes at room temperature. Slides were tilted to start drop moving 
down the slide and left at a smaller angle (PCR tube rack) to slowly spread DNA down the 
slide. Slides were placed in MeOH/ AcOH (3:1) for at least 10 minutes to fix DNA to the 
slide and de-proteinase the sample. Slides were stored 4 °C (for up to a year).  
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A PAP pen was used to draw a small square at the top of one of the slides, DNA was spotted 
into this square as the large amount of DNA in a small area was used for focusing the 
microscope.  
DNA was denatured by adding freshly diluted 2.5 M HCl (Thermo Fisher) to the slides for 
1 hour 15 minutes. This makes the ssDNA accessible to the antibody. DNA was blocked 
with 1% BSA, 0.1% Tween 20, in PBS for 1 hour. One hundred and fifteen μL primary 
antibodies (1:750 Rat anti-BrdU (anti-CIdU) (Abcam) and 1:750 Mouse anti-BrdU (anti-
IdU) (BD Biosciences)) were added to slides and held in place with a long coverslip, slides 
were incubated at 4 °C overnight. Slides were fixed with 500 μL 4% paraformaldehyde 
(Sigma-Aldrich) for 10 minutes. This fixes the antibody to the antigen. Slides were washed 
before 115 µl secondary antibodies (1:500 goat anti-rat Alexa Fluor 594 and 1:500 goat 
anti-mouse Alexa Fluor 488) was added to the slides and incubated for 1.5 hours at room 
temperature. Slides were washed and mounted using Fluoroshield histology mounting 




Transfected cell cultures were visualised using the Olympus IX71 inverted light 
microscope, both bright field and GFP (488 nm) images were taken. 
Slides were visualised using the Olympus BX53 upright microscope. Images were taken 
using the GFP (488 nm) channel for cells stained with Alexa Fluor 488 or transfected with 
GFP expressing plasmid (excitation/emission = 499 nm/520 nm), 594 nm 
(excitation/emission = 590 nm/618 nm) and 568 nm (excitation/emission = 579 nm/603 
nm) were used for respective fluorophores and the UV channel was used for DAPI 
fluorescence (excitation/emission = 359 nm/457 nm). Channels were overlaid using 
CellSens Dimensions software. 
 
2.4.4 Quantifying images 
HeLa immunofluorescence (GFP-DONSON localisation), GFP and DAPI images were taken 
at 40x or 100x magnification. GFP and DAPI images were overlaid using CellSens software, 
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cells were classified as diffuse, nuclear or aggregate by eye. Approximately 1200 cells 
across 5 experiments were counted for each plasmid.  
Fibre combing images were taken using the 40x or 100x lens. The 488 and 594 channels 
were combined and replication events were quantified. Tract lengths were measured 
using ImageJ software. The length of each tract in pixels was converted to μm using the 
scale bar on the images, μm was converted to kb based on the common conversion 
frequency 2.59 kb/1 μm (Daigaku et al., 2010; Jackson and Pombo, 1998; Quinet et al., 
2017). The length of tract in kb was divided by pulse time (20 minutes) to give replication 
fork speed in kb/min. The number of replication events, speed of fork progression and bi 
directional forks were measured.
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3 CRISPR editing to introduce patient variants 
 Introduction 
The aim for this chapter was to explore whether CRISPR-Cas9 can be used to knock in 
patient-specific MGS variants in hTERT-RPE-1 cells, disrupting essential DNA replication 
genes.    
CRISPR (clustered regularly interspaced short palindromic repeats) Cas9 genome editing 
is a new widely used technology that can be used to knockout genes or introduce specific 
variants into an organism’s genome (Adli, 2018; Rozov et al., 2019). This precise 
technology allows modelling of patient cells when patient cells are unavailable. CRISPR 
editing also allows creation of cell lines containing only the suspected disease-causing 
variant, controlling for background variation in a way that would not be possible using 
primary cells (Royba et al., 2017). CRISPR is commonly used for creating small insertions 
or deletions, preventing normal protein translation and therefore ‘knocking out’ a gene, 
but it is less efficient at knocking in specific variants (Mao et al., 2008; Rozov et al., 2019). 
This is because knocking in variants has a much lower efficiency than classical knockouts, 
due to the time and likelihood of the cell repairing the lesion via homology directed repair 
(HDR) (Mao et al., 2008). After the Cas9 protein has made a double-stranded break in the 
DNA the cell has two main options for repairing the DNA; error prone non-homologous 
end joining (NHEJ) or HDR (Mao et al., 2008). NHEJ is the predominant option, as it is 
active at all points in the cell cycle (Maruyama et al., 2015; Sargent et al., 1997), religating 
the phosphate ester backbone of two DNA molecules. Processing of the free ends of the 
DNA molecules can occur as part of this repair, causing removal or insertion of bases 
(Lieber, 2010). Repair of the Cas9-mediated cleavage site by this pathway leads to 
insertions or deletions (‘indels’) at the cut site.  
The second pathway is the HDR pathway, where the cell repairs the double-stranded 
break by copying an available template, either the other copy of the gene or a single-
stranded oligonucleotide introduced to insert a specific variant (Horii and Hatada, 2016). 
Some efficiency problems occur with this method in mammalian cells, as error prone end 
joining pathways are almost always favoured over homology-directed repair mechanisms 
(Savic et al., 2018). This is because HDR is more likely to occur during late S/G2-phase as 
the cell will already have the appropriate machinery active (Symington and Gautier, 2011; 
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Yao et al., 2017). HDR is more accurate but more time consuming than NHEJ and therefore 
is less likely to occur unless the cell is already in S-phase (Mao et al., 2008).  
Introducing a single missense variant, with CRISPR-Cas9 allows the ability to explore the 
effect this single bp change has on the protein and pathways, as well as the following 
consequences this has on DNA replication and cell cycle progression. The ability to use 
CRISPR Cas-9 to knock in patient variants in established diploid cell lines such as hTERT-
RPE-1 would allow functional analysis of the candidate genetic variation an isogenic 
system. Using patient-derived cells is problematic because individual background genetic 
variation may affect results or interpretation.  
hTERT-RPE-1 cells were chosen for this project as this cell line is near diploid (90% of 
counted cells contained 46 chromosomes) (https://www.atcc.org), grows in a monolayer 
and contains one normal and one derivative X chromosome. The derivative X 
chromosome contains additional chromosomal material at the terminal end of the q-arm, 
including telomerase reverse transcriptase (hTERT) and Hygromycin B resistance which 
allows the cell line to grow for at least 15 passages after cryopreservation. These cells 
represent a strong option for mimicking diploid patient cells, and are a standard cell 
model for studying DNA replication and DNA damage response (Bielinsky et al., 2019; 
Ercilla et al., 2016; Feringa et al., 2018; Kuznetsova et al., 2014; Lahtela et al., 2013; 
Shimada et al., 2017; Sokolova et al., 2017; Sun et al., 2017). hTERT-RPE-1 cells grow well 
in culture and have successfully been used previously for CRISPR editing (Bodnar et al., 
1998; Jiang et al., 1999; Katoh et al., 2017; Kuznetsova et al., 2014; Yiu et al., 2016). 
CRISPR utilises a repair system found in the adaptive immune system of bacteria (Cong et 
al., 2013; Mali et al., 2013a). Although CRISPR can be used to introduce specific variants, 
this can only be done within close proximity to a PAM site (Paquet et al., 2016), a 3 bp 
motif recognised by the Cas protein, NGG for Cas9 (Mali et al., 2013a). CRISPR works by 
creating a double-stranded break in the DNA at a PAM site, the protein is guided to the 
specific PAM site by a single-stranded guide RNA (sgRNA). The gene specific part of the 
sgRNA is ~20 bp long, the rest of the RNA forms a hairpin like structure that interacts 
with the Cas protein.  
CRISPR has a variable success rate and has been used in a variety of organisms with a 
variety of different Cas proteins and methods (Peng et al., 2016; Yu et al., 2018). Editing 
efficiency also seems to vary widely between areas of the genome (Moon et al., 2019), as 
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well as having different efficiencies in targeting between individual sgRNAs. Because of 
this there appears to be little consensus on the most optimal methods to induce HDR in 
diploid cell lines.  
There are many tools designed to help select the best sgRNA for a specific variant as the 
Cas protein needs to cut as close to desired variant as possible (Paquet et al., 2016) but 
the sgRNA must be specific and direct the enzyme cut only at this site, not other similar 
PAM sites.  
This project sought to introduce patient variants in the hTERT-RPE-1 cell line. The target 
genes are essential in the cell, due to the role of the encoded proteins in DNA replication 
machinery required for proliferation, so biallelic knockouts of these genes are not 
tolerated. Patient variants are hypomorphic, where they reduce protein function to a 
lower level but still retain a minimum threshold of functionality to permit cell survival 
and proliferation. Because of this the less efficient homology directed repair pathway was 
chosen to try and introduce a single base pair patient variants into the cell lines. 
 
 Patient variants 
3.2.1 Novel ORC1 variant (c. 1865T>C, p.L622P) 
The two patient variants chosen to investigate in depth by CRISPR knock in editing in 
hTERT-RPE-1 cells and cellular assays were both novel MGS variants. The first, LB005 
(ORC1 c. 1865T>C, p.L622P) was found to have a homozygous missense variant in an area 
of ORC1 not previously associated with MGS. Dr Karen Knapp identified this variant 
through whole genome sequencing. LB005 presented at the clinic age six, born to parents 
from the same village in Saudi Arabia, so likely distantly related. He had a proportional 
reduction in size; head size (OFC -4.1 SD), height (-4.2 SD), weight (-4.6 SD). Absent patella 
were confirmed by palpitation as patella had not fully ossified to be visualised by X-ray at 
this point. He also presented with micrognathia (small jaw), very small misshapen ears 
and a thin face, very typical of MGS. LB005 had otherwise normal development.  
Previous MGS patients with variants in ORC1 have all been found to have at least one 
variant in the BAH domain. This domain is required for important protein-protein 
interactions essential for ORC1 chromatin binding. Previous research by Kuo et al., 2012, 
suggested the ORC1 MGS phenotype was caused by the inability for ORC1 to interact with 
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H4K20me2. H4K20me2 is a common histone 4 modification present at origins of 
replication and though to be involved in stabilising the ORC complex at these origins (van 
Nuland and Gozani, 2016). In this research Kuo et al., 2012 demonstrated that ORC1 
depletion in zebrafish leads to a MGS-like phenotype; zebrafish depleted in H4K20me2 
also showed a similar reduction in size phenotype. This suggests the MGS phenotype may 
be caused by the inability of ORC1 to interact with H4K20me2 on chromatin. In this study 
zebrafish were rescued by the addition of WT human ORC1 but were not rescued by the 
addition of human ORC1 containing MGS variants in the BAH domain. This research 
suggests the BAH domain plays an important role in the MGS phenotype in patients with 
variants in this region. But this does not explain the same ORC1-MGS phenotype being 
seen in patients with neither variant in the BAH domain. The p.L622P variant investigated 
in this project is found in the Walker II motif of the AAA+ domain, important for ATP 
hydrolysis.  
This variant was chosen for CRISPR as it was a homozygous missense variant, requiring 
only one ssODN and one screening measure.  
 
3.2.2 Novel DONSON variant (c.631C>T, p.R211C) 
The second variant was also identified by whole genome sequencing carried out by Dr 
Karen Knapp. This variant in DONSON was, at the time novel. Four patients (24% of our 
MGS cohort) were found to have variants in DONSON, which suggested DONSON may be a 
relatively common novel MGS gene (Knapp et al., 2019). LB008 was chosen, firstly as the 
only one of four patients to contain a homozygous missense variant (c.631C>T, p.R211C), 
rather than compound heterozygous variants. Secondly the presentation of a very typical 
MGS phenotype could not be confused with the MISSLA phenotype. At the most recent 
examination, the patient (aged 9 years, 6 months) presented with a proportional 
reduction in size; head size (OFC -3.97 SD) and height (-3.48 SD). LB008 also presented 
with small dysplastic ears, micrognathia (small jaw) and absent patella. He also presented 
with delayed development, mild hearing loss, a high arched palate and hypopigmentation. 
LB008 of Turkey comes from consanguineous parents. 
As only one sgRNA and one ssODN was required to knock in this homozygous variant it 
was chosen for the CRISPR experiments. It had also been mentioned that if the cell does 
proceed to the HDR pathway it is likely to knock in on both alleles as the cell is most likely 
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in S-Phase (Personal communication Professor Andrew Jackson, Institute of Genetics and 
Molecular Medicine, University of Edinburgh). 
 
 
Figure 3.1 MGS patient variants cause amino acid changes in highly conserved protein regions. 
Regions of ORC1 and DONSON contain highly conserved regions between species, as 
these essential DNA replication genes are required in all eukaryotes. The red boxes 
indicate amino acid changes caused by homozygous single base pair variants found in 
MGS patients. ORC1 - c. 1865T>C, p.L622P, DONSON - c.631C>T, p.R211C. Both amino 
acids changed are highly conserved between species and in highly conserved areas of the 
protein. Figure adapted from Alamut Visual software (BioSoftware). 
 
 
Both variants are found in highly conserved regions of the protein (Figure 3.1), and both 
result in functionally important changes. While both leucine and proline are non-polar, 
proline is a helix breaker which can disrupt α helical backbone conformation (Li et al., 
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1996), this therefore is likely to be a functionally important change. Arginine is a 
positively charged amino acid while cysteine is a thiol containing amino acid, disulfide 
bonds are formed between two thiol groups and therefore the addition of a cysteine has 
the potential to change disulfide bonds in the secondary structure of DONSON (Qiu et al., 
2015). These amino acids are conserved through to C. elegans (ORC1) or Drosophila 
melanogaster (DONSON). This high conservation of amino acids between species suggests 
that these amino acids are important for protein function and change is not generally 
tolerated in this region.  
Along with the known role of these genes, indicates these variants are highly likely to be 
disrupting origin licensing and potentially delaying DNA replication (Bicknell et al., 
2011a). 
 
 Designing CRISPR guides and plasmid construction 
3.3.1 Guide RNA design 
Guide RNAs (sgRNAs) were designed using http://crispr.mit.edu/ a widely used tool at 
the time, which has since been retired. This tool assigns a score for each potential sgRNA 
based on a number of factors. The quality score takes into account off-targets in genes and 
non-coding regions as well as the number and position of mismatches between the sgRNA 
and the region. Two mismatches proximal to the PAM region will considerably reduce 
Cas9 activity (Anderson et al., 2015). Three or more interspaced mismatches or 5 
consecutive mismatches leads to almost no off-target binding (Hsu et al., 2013). There 
were limited options of sgRNAs to choose from as the cut site needed to be in close 
proximity to the desired substitution (Komor et al., 2016; O’Brien et al., 2019; Paquet et 
al., 2016). The PAM site should ideally also be scrambled to prevent re-cutting by the Cas9 
protein (Kwart et al., 2017; Mali et al., 2013a; Paquet et al., 2016). Other tools CHOPCHOP 
(Labun et al., 2019) and Benchling (Benchling [Biology Software], 2019) were used to 
confirm the sgRNA efficiencies were similar as the score given by different tools favour 
off-targets or on target efficiencies.  
 
 58 
 ORC1 p.L622P sgRNA design 
Guide 3 was chosen for ORC1-p.L622P for several reasons. First, the cut site was the 
closest to the desired variant site, maximising efficiency (Paquet et al., 2016). Second, 
introducing the patient variant would also result in the loss of a Taq (α) I restriction site 
(Figure 3.2), enabling a simple assay for genotyping cells. Third, only a single synonymous 
substitution was required to mutate the PAM of guide 3, while two variants would have 
been required to mutate the PAM site of guide 1, the guide with the highest quality score. 
Four guide 3 has 226 predicted off-targets but none lie within genes (Figure 3.2B). 
Because the PAM site, while in the intron, is in close proximity to the 3′ splice junction of 
intron 12, In silco analysis was undertaken to assess any possible effects on canonical 
splicing. Alamut Visual version 2.11 (Interactive Biosoftware, Rouen, France) was used to 
predict any changes to splicing. Alamut is an exploration software which incorporates 
databases such as NCBI, EBI, UCSC, gnomAD, ESP, Cosmic and ClinVar to make predictions 
about pathogenic variants. It also uses SpliceSiteFinder-like, MaxEntScan, NNSPLICE, and 
GeneSplicer to predict changes to splicing. Alamut predicted that a change to the first 
nucleotide in the PAM sequence would not lead to any change in splicing. Therefore guide 




Figure 3.2 sgRNA guide selection for ORC1 p.L622P variant. A) The top 5 sgRNAs for the region of 
interest, showing PAM sites (green), variant (highlighted yellow) and Cas9 cut site (dark 
grey), blue numbers next to guides 1-5 indicate quality score assigned by tool with 100 
being the highest and 0 being the lowest. Guide 3 was selected due to the appropriate 
score, and the cut site being the closest to the desired patient variant. A Taq (α) 1 
restriction site is also lost with introduction of the patient variant, important for 
screening. B) Selected output from design tool showing the selected sgRNA (guide 3) has 
226 potential off-targets; none are in exons, the top 20 off-targets are shown here. All 




Figure 3.3 sgRNA guide selection for p.R211C DONSON variant. A) The top 5 sgRNA for the region 
of interest, showing PAM sites (green), variant (highlighted yellow) and Cas9 cut site (dark 
grey), CRISPR tool quality score indicated by blue numbers (100 highest, 0 lowest). Guide 
2 was selected due to the appropriate score, and the cut site being the closest to the 
desired patient variant. A SacI restriction site is lost with the introduction of the desired 
variant and one silent variant – required for screening. B) Selected output for CRISPR 
design tool showing the selected sgRNA (guide 2) has 269 potential off-targets zero of 




Guide 2 was selected for DONSON p.R211C (Figure 3.3), for similar reasons as above. 
Guide 2 had the second highest score (67) with 269 off-targets, 0 in exons (Figure 3.3B), 
the cut site was also the closest of all guides for maximum efficiency. Guide two required 
two variants; a single synonymous substitution would lead to the deletion of a SacI 
restriction site for effective screening of colonies, and a second to introduce the patient 
variant and scramble the PAM site at the same time (Figure 3.3A). Two off-target sites 
contain only two interspaced mismatches (Figure 3.3B), while the other 267 off-targets 
contain 3-4 mismatches which considerably reduces the chances of off-target binding 
(Hsu et al., 2013). 
 
3.3.2 PX458 assembly 
After guides were selected, and then cloned into the PX458 vector (Addgene #48138) 
(Figure 3.4). PX458 was linearized at the gRNA scaffold by BbsI and NEB T4 ligase was 
used to join the two fragments together. To confirm the sgRNA was inserted and in the 
correct orientation, transformed colonies were analysed by colony PCR (cPCR) and 
Sanger sequencing (Figure 3.5). 
 
Figure 3.4 Schematic of PX458 plasmid containing Cas9-GFP complex and sgRNA scaffold. A) The 
PX458 plasmid contains a single sgRNA sequence under a U6 promotor to direct Cas9 to 
the appropriate area of the genome, a Cas9 protein for creating double-stranded breaks, 
and a GFP protein for optimising transfection and FACS sorting only the cells which contain 
the plasmid. B) Fluorescence GFP image of transfected hTERT-RPE-1 cells containing 
PX458 plasmid fluoresce green when imaged with Olympus IX71 inverted light microscope 
GFP (488) filter, allowing transfection efficiencies to be optimised by eye, as well as being 
appropriate to use with FACS.  
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The PX458 plasmid encodes a Cas9 protein fused to GFP, which is useful for sorting cells 
by flow cytometry to enrich for plasmid-harbouring cells, which is beneficial for cells with 
a low transfection efficiency. The plasmid also contains a cloning site for the sgRNA under 
a hU6 promoter. Having the sgRNA and Cas9 on the same plasmid increases efficiency of 
CRISPR as only one item needs to be introduced for the Cas9 protein to be directed to the 
correct site in the genome.  
Following sequencing confirmation, suitable plasmid stocks were prepared following the 
midiprep protocol (2.1.6.5) for transfection of hTERT-RPE-1 cells. Concentrations were 
measured using the NanoDrop (2.1.6.6).  
 
Figure 3.5 cPCR and Sanger sequencing confirmed correct sgRNA insert for both guides. A) cPCR 
was performed using the hU6_F plasmid specific primer and one insert specific primer 
(sgRNA_R). All colonies screened appeared to contain sgRNA insert. Negative control was 
run on a separate gel (not shown). B) Sanger sequencing confirmed correct sgRNA ORC1 
(top), DONSON (bottom) in the correct orientation. 
 
3.3.3 Repair template design 
Repair templates were designed with homology arms between 80 bp and 98 bp on either 
side of the desired knock in variant, due to maximum length of PAGE purified 
oligonucleotide from IDT being 200 bp. The recommended (Yang et al., 2013) length of 
homology arms is at least 90 bp, some repair templates had arms slightly under this due 
to size constraints for PAGE Ultramer® DNA oligonucleotide (IDT) being 200 bp.  
It is also recommended that the PAM site is scrambled to prevent the Cas9 protein cutting 
the repair template instead of the DNA, this also helps prevent any re-cutting of edited 
DNA by the Cas9 which could lead to indels after HDR (Paquet et al., 2016).  
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Both repair templates contained two variants, one to introduce the desired missense 
change and a second to disrupt the PAM site or disrupt a restriction digest site for easy 
screening. 
ORC1 p.L622P repair template (Figure 3.6) contained two variants. One missense T>C 
variant to introduce LB005 variant resulting in a leucine (L) to proline (P) amino acid 
substitution and a second silent c>t variant to disrupt the PAM site 8 bp before the start 
of exon 12. As mentioned earlier (3.3.1) Alamut predicted this substitution would not 
result in any splicing changes. This silent variant also results in the loss Taq (α) 1 
restriction site for screening. 
 
 
Figure 3.6 Important features of the ORC1 repair template. ORC1 ssODN contains one missense 
variant to introduce patient variant and one substitution mutation to disrupt the PAM 
site. The sgRNA is indicated by green letters and PAM site (black line) shows where the 
Cas9 protein will be directed to, the purple letter indicates the Cas9 cut site. The repair 
template contains a 98 bp 5′ end arm and an 89 bp 3′ end arm.  
 
DONSON p.R221C repair template also contains two variants (Figure 3.7). The first a 
LB008 missense variant C>T, resulting in an arginine (R) to Cysteine (C) amino acid 
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substitution. The second a silent C>A resulting in no amino acid change and resulting in 
scrambling the PAM site. This silent variant also scrambles the SacI restriction enzyme 
site which allows for easy screening.  
 
 
Figure 3.7 Important features of the DONSON repair template. DONSON ssODN containing 2 
variants, 1 to introduce missense variant and a second to disrupt the PAM and SacI 
restriction digest sites. The sgRNA in green and PAM site (black line) shows where the 
Cas9 protein will be directed to, purple letter indicates the Cas9 cut site. The repair 
template contains an 88 bp 5′ arm and an 89 bp 3′ arm.  
 
 CRISPR protocol 
Figure 3.8 depicts the general CRISPR protocol used in this project. The first step involved 
optimising plasmid transfections in 24 well plates as the transfection efficiency in hTERT-
RPE-1 cells was relatively low, by titrating different concentrations of plasmid and 




Figure 3.8 General CRISPR protocol for transfecting and sorting cells. Cells were transfected with 
10 ng ssODN and 250-1000 ng PX458 plasmid, GFP fluorescence was observed. Optimised 
transfection was scaled up for bulk GFP positive FACS sort. Bulk sorted GFP positive cells 
were plated in 24 well plates for 6-7 days before being FACS single cell sorted, allowing 
time for disappearance of GFP-PX458 plasmid confirming no cells had permanently 
integrated the plasmid, and increased number of cells growing in 96 well plates. This was 
based on a protocol shared by Professor Wojciech Niedzwiedz (Weatherall Institute of 
Molecular Medicine, University of Oxford, personal communication).  
 
PX458-ORC1-p.L622P was optimised at 1000 ng/μL 24 hours post transfection (Figure 
3.9) while PX458-DONSON-p.R211C was optimised at 500 ng/well 24 hours after 
transfection (Figure 3.10). Generally FACS sorts have been performed 48 hours after 
transfection (Giuliano et al., 2019, 2019; Li et al., 2014; Maguire et al., 2019; Park et al., 
2019), as this allows confirmation of GFP fluorescence by microscopy at 24 hours before 
preparing the cells for FACS at 48 hours. Many of the hTERT-RPE-1 cells had died off and 
were floating or were looking very unhealthy (rounding and about to detach) after 48 
hours, so flow cytometry sorting at 24 hours post transfection was decided upon for 





Figure 3.9  PX458-sgRNA-ORC1-p.L622P transfection test. hTERT-RPE-1 cells were transfected with 
250 ng, 500 ng or 1000 ng PX458 plasmid and observed 24 & 48 hours post transfection. 
The optimal GFP fluorescence and cell health was observed using 1000 ng plasmid, at 24 
hours post transfection (~10% transfection efficiency for 1000 ng compared to only ~2-




Figure 3.10 PX458-sgRNA-DONSON-p.R211C transfection test. Cells transfected with 500 ng PX458-
DONSON plasmid 24 hours post transfection showed optimal GFP fluorescence (~12.5% 
transfection efficiency) while maintaining healthy cells. GFP fluorescence was slightly 
improved at 48 hours post transfection (~15% transfection efficiency) the cell health had 
decreased with many cells dead or dying. (Transfection efficiency for 250 ng and 1000 ng 
was only around 3-8%). 
 
Once plasmid concentration using in the transfection was optimised by estimating GFP-
positive cells by eye (Figure 3.9 and 3.10), the experiment was scaled up to increase cell 
numbers and possible chance of HDR-mediated CRISPR editing. Cells were plated in 
triplicate in a 6 well plate and transfected with as optimised above, with 2500 ng PX458-
DONSON plasmid (equivalent of 500 ng in 24 well plate). Cells were collected 24 hours 
post transfection and prepared for FACS sorting. FACS sorting was performed by Michelle 
Wilson or Katie Young in the Microbiology FACS suite using the BD FACS Aria instrument.  
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FACS allows quantification of the transfection efficiency as all cells that pass through the 
laser are counted but only cells which are GFP positive and viable are sorted into a 
collection tube. Prior to flow laser capture, cells were stained with NIR Zombie viability 
dye, which stains only dead cells therefore cells negative for zombie dye were selected 
for. Cells which were GFP positive (containing the Cas9 protein) and zombie dye negative 
(viable) were bulk sorted by FACS before being plated at low confluency (2000-4000 
cells/24 well) to grow for 1 week. The cells were plated at a low density after the bulk sort 
so they did not need to be disturbed for passaging during the recovery phase (1 week). 
This approach also best supported edited cells, which may grow slower than non-edited 
cells due to disruptions to essential DNA replication genes and reduced the chances of 
edited cells being out competed by potentially healthier WT cells. After 1 week, the 
successive rounds of cell division should mean the plasmid would no longer be present 
and the cells should have lost GFP expression, confirming that Cas9 had not integrated 
into the genome and no more editing should occur. At this point, cells were individually 
sorted into the inner 60 wells of a 96 well plate (Figure 3.11) as the outer wells had a 
tendency to dry up. The media was changed every 3-4 days for up to five weeks, to ensure 
no slow growing clones were missed. Once single cells had grown colonies covering >60% 
of the well bottom surface area (~2-3 weeks), cells were expanded to 24 well plates. DNA 
was extracted from cells when expanding to 24 or 6 well plates and cells were genotyped 




Figure 3.11 FACS BD Aria was used to single cell sort 60 GFP negative, Zombie dye negative 
potentially edited hTERT-RPE-1 cells in to a 96 well plate. Single cells were sorted into 
the inner 60 wells of a 96 well plate using FACS BD Aria instrument, as the outer wells had 
a tendency to dry up. (Figure created with BioRender). 
 
The first CRISPR editing experiment was undertaken using the repair template designed 
for ORC1 p.L622P. This was chosen as the Taq (α) 1 restriction endonuclease digest had 
already been tested on reference and patient DNA confirming the digest as an effective 
screening measure (Figure 3.12).  
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Figure 3.12 A Taq (α) 1 restriction endonuclease digest is an effective screening method for ORC1 
p.L622P edited clones. A) A 500 bp fragment of ORC1 was amplified by PCR from 
reference (WT) and patient DNA. B) A Taq (α) 1 endonuclease digest was performed and 
confirmed as an effective screening measure for ORC1 p.L622P edited colonies. The Taq 
(α) 1 restriction site is lost with the addition of the desired patient variant. Therefore only 
WT DNA not containing this variant is digested (giving two bands). 
 
The first FACS sort showed a low transfection efficiency with only 0.4% GFP positive cells 
(Figure 3.13), suggesting scaling the experiment up to 6 well plates was not optimal. The 
gate determining “positive” GFP fluorescence was therefore set quite low (very close to 
GFP negative cells background fluorescence) to try and increase the number of cells 
obtained (Figure 3.13 C). All GFP positive cells were collected (8284), and resuspended at 
8000 cells/mL, these were plated at 2000 or 4000 cells per 24 well. DNA was extracted 
from the remaining ~2284 cells and following PCR amplification the Taq (α) 1 restriction 
digest was performed to test for edited alleles, but no uncleaved bands, indicative of the 




Figure 3.13 PX458-sgRNA-ORC1-p.L622P GFP fluorescence of transfected hTERT-RPE-1 cells. PX458-
sgRNA-ORC1-p.L622P transfected hTERT-RPE-1 showed lower GFP expression than 
expected based on fluorescence observed in 24 well plates. A-B) GFP and bright field 
images show healthy cells with a lower than expected transfection efficiency when scaled 
up to 6 well plates compared to optimised transfection in 24 well plate (Figure 3.10). C-
D). GFP expression was quantified during the first bulk FACS sort and confirmed cells 
transfected with PX458-ORC1-sgRNA-p.L622P expressed low levels of GFP expression. C) 
A total of 8284 hTERT-RPE-1 cells were gated GFP positive (0.4% of total cells), confirming 
low transfection level. D) 2.2% of cells sorted 6 days later were still expressing GFP.  
 
Six days later a single cell FACS sort was performed for GFP negative cells. This was 
undertaken to avoid any cells that may have permanently integrated Cas9-GFP plasmid 
into the genome. The first single cell sort showed 2.2% of the cells were still expressing 
GFP, however subsequent single cell sorts were all performed 7 days after the initial bulk 
sort and showed very low levels (<0.1%) of GFP expression present. Based on these 
observations, it is likely these few remaining cells would have stopped expressing GFP in 
the next couple of days.  
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Three-hundred cells were sorted into the inner wells of 5 x 96 well plates. The media was 
changed every 3-4 days and wells were expanded at >60% confluency. DNA was extracted 
and cells frozen once ~80% confluent in a T25 flask. A 500 bp PCR amplification and Taq 
(α) 1 restriction digest was performed to analyse the 43 clones (Figure 3.14A). All clones 
were found to be WT by the restriction digest. Eleven of the clones (~25%) were Sanger 
sequenced. This showed no deletions or insertions present (Figure 3.14 B). 
 
 
Figure 3.14 Restriction digest and Sanger sequencing confirms no editing of ORC1-p.L622P single 
cell clones. A). A 500 bp PCR was performed on crude DNA from 14 cell lines, due to the 
crude nature of the DNA extraction only seven of these showed successful amplification 
to be screened by restriction digest, 500 bp PCR was repeated on these failed samples 
until successful PCR amplification was achieved for all 43 clones. The seven samples 
showing successful 500 bp PCR were digested by Taq (α) 1 restriction digest this confirmed 
no editing present in these clones. This was repeated with the other 36 clones to check 
for the p.L622P variant, all came back WT. B) Sanger sequencing was used to screen 11 
clones (~25%) to confirm no other editing was present (as indels would not likely be picked 
up by this screen). No editing was identified.  
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 Allele-specific PCR to optimise repair template concentration 
While FACS allows us selection of only cells expressing the GFP-Cas9 construct, the 
number of cells that have taken up the repair template required for HDR was unknown.  
To optimise the amount of repair template (ssODN) introduced we used allele-specific 
PCR (AS-PCR) to identify pools of cells with the highest levels of editing. Pools of cells 
were transfected with the optimised plasmid concentration (Section 3.4) and varying 
levels of ssODN. Previous research by Cooper, 2016 in mouse stem cells found an increase 
in HDR editing was observed when lower concentrations of repair template (2 nM) were 
used. This is contrary to the general consensus on HDR editing with many new methods 
attempting to increase ssODN concentration at a cellular or nuclear level (Aird et al., 2018; 
Dupré et al., 2006; Liu et al., 2019; Savic et al., 2018). 
Two forward primers matching either the WT DNA or repair template and a common 
reverse primer were designed using primer BLAST (Ye et al., 2012). The mutant forward 
primer matched the repair template therefore contained two mismatches from WT DNA 
at the 3′ end of the primer (-1 and -2 bp) (Figure 3.15A). The WT forward primer 
contained no mismatches to WT DNA. This meant there were two mismatches between 
the edited cells and WT reducing the chance of primer mis-binding (Figure 3.15A). Allele-
specific primers were tested on WT hTERT-RPE-1 DNA and patient DNA. The M primer 
set did not bind to WT DNA using a high annealing temperature (Figure 3.15A). The WT 
primer set was more likely to bind to and amplify patient DNA (Figure 3.15B); note the 
faint band LB008 lane amplified by WT primers at 69.3 °C and 67.4 °C. It is likely this is 
due to only one mismatch being present between WT and patient DNA, as the specificity 
of the mutant primer pair was the most important and the WT primer pair is just being 







Figure 3.15 AS-PCR design and optimisation. A) Allele-specific primers for the DONSON p.R211C 
variant were designed. The mutant primer pair includes two mismatches from WT DNA at 
the 3′ end, these two changes match the patient variant and silent PAM site variant 
present in the repair template. B) Primer sets were optimised using WT (hTERT-RPE-1) 
and patient (LB008) DNA, a negative control (-ve) was run at each extension temperature. 
With a high extension temperature (above 68 optimised at 70 °C) the mutant primer set 
does not bind to WT DNA. At an extension temperature below 70 °C the WT primer set 
amplified the patient DNA likely due to only one mismatch being present, as the WT 
primer set was being used as a control this was considered acceptable.  
 
An attempt was also made to design AS-PCR primers for the p.L622P ORC1 variant as well 
but unfortunately no primers could be designed that were robust enough to be used as a 
screening measure (data not shown).  
Pooled cells were transfected with 500 ng PX458 plasmid and 2 nM, 3 nM, 5 nM or 10 nM 
of repair template. After being scaled up to 6 well plates and prepared for FACS, GFP 
positive cells were bulk sorted, and DNA was extracted for the AS-PCR test (Figure 3.16). 
This showed that higher levels of editing were present when cells were transfected with 
a smaller amount of repair template (2 and 3 nM) and more importantly in this 
experiment when GFP expression was low. Cooper, 2016 only looked at differences in the 
amount of repair template added, but interestingly the biggest difference observed was 
between the high GFP and low GFP expression rather than between repair template 
concentrations. Low GFP and lower repair template (2 ng and 3 ng) showed much higher 




Figure 3.16 Allele-specific PCR for optimisation of ssODN concentration. Allele-specific PCR was used 
to optimise repair template concentrations on ~200 pooled cells 24 hours post 
transfection. Pooled of were cells transfected with 500 ng PX458-DONSON and different 
concentrations of repair template between 2-10 ng. A FACS sort was performed 24 hours 
post transfection and cells were sorted based on GFP expression level low (<104) or high 
(>104). Amplification by the mutant primer set (indicating editing) can be seen for 2 ng 
Low, 3 ng low and 10 ng low. Other fainter bands are present in the band but 
unfortunately cannot be seen here. 
 
We hypothesized that decreased HDR editing in pooled cells with high GFP expression 
could be due to more Cas9 activity. High Cas9 activity could be causing more double-
strand DNA breaks and therefore an increased likelihood of indels due to NHEJ being 
introduced before the cell has an opportunity to undertake HDR-mediated repair (Mao et 
al., 2008). If the repair template is not used for HDR-mediated repair the Cas9 will 
continue to recognise the PAM site and can therefore keep cutting until an indel is 
introduced leading to the Cas9 protein being unable to recognise the PAM or sgRNA site. 
The proportion of cells expressing GFP decreased when higher concentrations of repair 
template were added, suggesting high levels of ssODN result in a lower transfection 




Figure 3.17  GFP expression decreased with increase ssODN concentration. Blue dots = low GFP 
fluorescence, purple dots = high GFP fluorescence. A) 2 ng DONSON ssODN, 1.1% of cells 
expressing low GFP, 0.6% of cells expressing high GFP. B) 3 ng DONSON ssODN, 0.6% of 
total cells expressing low GFP, 0.3% of total cells expressing high GFP. C) 5 ng DONSON 
ssODN, 0.3% of cells expressing low GFP, 0.2% of cells expressing high GFP. D) 10 ng 
DONSON ssODN 0.2% of cells expressing low GFP, 0.1% of total cells expressing high GFP.  
 
One week after this bulk sort 317 cells from the 2 nM and 3 nM low GFP bulk pooled cells 
were single cell sorted into 5.3 x 96 well plates (four plates contained cells from 2 nM 
pooled cells and 1.3 plates contained cells from the 3 nM pooled cells). Cells in 223 wells 
from the original 317 cells grew and were genotyped using AS-PCR and Sanger 
sequencing. A SacI restriction enzyme site should have been lost with HDR editing; 
unfortunately the restriction enzyme was found to incompletely cut WT control DNA 
when following the manufacturer’s protocol (data not shown), suggesting allele-
discrimination would not be possible. Due to time constraints, AS-PCR was chosen to 
genotype the cells. AS-PCR unfortunately started to show some unspecific bands from the 
mutant primer set (Figure 3.18A). While there were still no bands in the negative control, 
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this could possibly been due to slight differences in the PCR machines as this PCR was 
relatively sensitive to changes in temperature and had been optimised on the most heavily 
used PCR machine. 
Sanger sequencing was used to investigate a proportion of cells exhibiting this second 
fainter band from the M-primer set. When sequenced, samples with these smaller bands 
tended to show small indels (Figure 3.18B). These small indels were only ever present in 
one allele (heterozygote), as two indels at this point in the gene would be lethal to the cells 
(Evrony et al., 2017). These indels confirmed that the sgRNA was effective at guiding the 
Cas9 protein to the correct site and the Cas9 was successfully creating double-stranded 
breaks. Therefore it seemed the main issue in obtaining HDR editied cells was getting 
sufficient cells to undergo HDR-mediated repair.  
 
Figure 3.18 AS-PCR of single cells show amplification from WT and mutant primer pairs. A) WT 
amplification is shown for all 15 samples, mutant amplification is seen in four samples 
although not quite at the expected size. The red square indicates 1.E7 cell line which was 
chosen for Sanger sequencing. B) Sequence chromatogram for 1.E7 shows a 1 bp insertion 
directly after the cut site on one allele (indicated by arrow).  
 
 Improvement in HDR using a biotin mSA interaction 
Due to the inability to produce cells containing desired patient variant other ways to 
increase HDR efficiency were investigated. A recent paper by Gu et al., 2018 increased 
HDR editing in 2 cell mouse embryos up to 95% by adding a biotin tag to their repair 
template and an mSA protein to their Cas9 protein. The biotin-mSA interaction tethers the 
ssODN in close proximity to the cut site, since the repair machinery requires the template 
to be nearby this proximity may be helpful in increasing HDR efficiency.  
The PCS2 + mSA plasmid did not contain any florescent tag for sorting, but given the low 
transfection efficiency in hTERT-RPE-1 cells, a selection marker was required to identify 
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positively transfected cells. To overcome this Gibson assembly was used to clone the mSA 
fragment from the PCS2 + mSA plasmid to the C-terminus of the Cas9-GFP complex in the 
PX458 plasmid, creating a Cas9-GFP-mSA complex (Figure 3.19).  
 
Figure 3.19 Schematic of Cas9-GFP-mSA complex plus sgRNA and ssODN interacting with DNA at 
desired cut site. Schematic shows how the addition of an mSA protein to the Cas9-GFP 
complex and a biotin tag on the repair template should increase HDR editing due to the 
repair template being held in close proximity to the cut site. (Figure created in PowerPoint 
DNA template adapted from https://smart.servier.com/).  
 
Gibson assembly was used to create three Cas9-GFP-mSA plasmids (Figure 3.20), one 
empty PX458-mSA plasmid, for use as a negative control and also to clone in any future 
sgRNAs, PX458-mSA-ORC1-sgRNA-p.L622P (PX458-mSA #3.3) and PX458-mSA-
DONSON-sgRNA-p.R211C (PX458-mSA #22.15). 
As described in previous sections, plasmid concentrations for hTERT-RPE-1 transfections 
were optimised by eye in 24 well plates at 1000 ng per well for PX458-mSA #22.15 48 
hours post transfection. The experiment was scaled up to multiple wells in a 6 well plate 
and a bulk FACS (GFP positive, Zombie negative) and single cell FACS sort (GFP negative, 
Zombie negative) were performed a week apart. As above AS-PCR was used to screen 
pooled cells for HDR editing. Based on results from Gu et al., 2018 an increase in HDR 
editing was expected, compared to the original PX458 plasmid. 
In this experiment pooled cells were transfected with varying levels of repair template 





Figure 3.20 Gibson assembly was used to clone the mSA fragment into the PX458 plasmid A) The 
mSA fragment was amplified from the PCS2 + Cas9-mSA plasmid by Phusion PCR, using 
Gibson assembly primers (containing an overlap to the cut site of PX458). B) The plasmid 
map shows where the BsrGI restriction enzyme was used to cut PX458 (end of the Cas9-
GFP complex) and where the mSA fragment sits in relation to the Cas9 and GFP in the new 
PX458-mSA plasmid (pink). C) cPCR was used to screen potential colonies for the correct 
insert, note 4 potential colonies (2, 3, 5, 6) differences in band brightness likely due to PCR 
amplification being done directly from E.coli colony resuspended in MilliQ water. D) 
Sanger sequencing was used to confirm the correct insert for the PX458-mSA-empty, 
PX458-mSA-ORC1-p.L622P and PX458-mSA-DONSON-p.R211C plasmids. 
 
Unfortunately, AS-PCR didn’t show any major differences in editing levels between the 
two plasmids (Figure 3.21). We hoped this experiment would replicate the original 
finding that HDR editing levels increased in cells transfected with 2 or 3 nM ssODN and 
sorted based on low GFP expression, unfortunately this was not the case. The differences 
in HDR editing between high GFP and low GFP was definitely not as striking as previously 
(Figure 3.16) but some subtle differences were observed. 
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Figure 3.21 AS-PCR compares editing levels in bulk sorted cells transfected with either PX458 or 
PX458-mSA. Cells were transfected with 1000 ng of either PX458 or PX458-mSA, and 
between 1-20 nM ssODN per 24 well. Cells were bulk FACS sorted into high and low GFP 
conditions as laid out in previous experiment. DNA was extracted from all collected cells 
and editing levels were compared using AS-PCR. Mutant primer set (top of gels) shows 
editing levels and WT primer set (bottom of gels) is run as a control. 
 
Previously 2 nM, 3 nM and 10 nM low GFP bulk sorted cells had significantly more HDR 
editing occurring than other bulk sorted cells. Here PX458 3 nM low GFP (lane 22-3L) still 
had the highest level of HDR editing (Figure 3.21). In the previous experiment 2 nM low a 
strong band suggesting a higher level of editing, however this was not replicated here, 
with the 2 nM low band approximately the same intensity as 2 nM high band (Figure 3.21, 
compare 22-2L with 22-2H). For the new PX458-mSA plasmid three bands showed 
relatively high levels of HDR editing; 2 nM low, 10 nM low and 20 nM high (Lanes 15-2L, 
15-10L and 15-20H). Two of these fit with what was previously observed, in that lower 
GFP expression leads to more HDR editing (Figure 3.16). The main difference between the 
two plasmids used, was that the biotin-mSA interaction should retain the ssODN in close 
proximity with the Cas9 protein. Therefore some differences were expected in pooled cell 
samples containing the highest HDR editing compared to the standard PX458 approach. 
The high GFP, high repair template concentration showed enhanced editing. A high level 
of repair template would allow all Cas9 proteins in a cell to have an ssODN tethered to it 
therefore increasing the chance of an HDR edit. A cell with high GFP and high level of 
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repair template would therefore contain multiple Cas9-ssODN complexes directed to the 
targeted area of the genome increasing HDR potential. Unfortunately across all the pooled 
samples there did not seem to be more HDR editing using the mSA tag approach which 
was disappointing.  
 
3.6.1 Investigating a reduction in editing levels between bulk and single cell FACS 
sort 
The occurrence of HDR editing 48 hours post transfection in multiple concentrations as 
indicated by positive mutant bands in the AS-PCR, indicated that Cas9, sgRNA and ssODN 
were all being introduced into the cell and guided to the correct area of the genome to 
allow HDR editing to occur, and this was successfully occurring to some extent. After 
finding none of the 223 cells from the first AS-PCR CRISPR sort contained the desired 
variant, it was hypothesised the edited cells may not be surviving the sorting and plating 
process. It was also noted that when plating cells after a bulk FACS sort, many of the GFP 
positive CRISPR cells would die off in comparison to WT control cells. As both WT and 
potentially edited cells has been exposed to transfection by Lipofectamine with empty or 
sgRNA containing PX458/PX458-mSA, FACS preparation and FACS sorting a similar levels 
of death from FACS sorting associated stress on cells was expected. The only difference 
between the cells was that potentially edited cells contained an active Cas9 protein with 
the ability to be guided to the DNA to create double-stranded breaks and a repair 
template. Due to this it was considered that perhaps any cells containing homozygous 
edits were not surviving to the single cell sort stage.  
The FACS sorting process is quite stressful on the cells and leads to a high level of cell 
death in healthy cells. Only around 40% of WT cells would survive one sort and our 
protocol required two FACS sorts. Previous experiments had only confirmed editing was 
present 48 hours post transfection, directly after bulk FACS sorting. However it was 
unknown how many edited cells remained with by the time the single cell FACS sort was 
performed.  
The next experiment was designed to investigate whether the editing level was reducing 
due to cell death between the bulk FACS sort and the single cell FACS sort. To test this the 
four plasmid and ssODN concentrations with the strongest bands (highest editing levels) 
as seen in Figure 3.21 (22-3 low, 15-2 low, 15-10 low and 15-20 high) were chosen. These 
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concentrations were bulk sorted into high and low GFP as previously mentioned and half 
of the cells were taken for DNA extraction while the other half were plated at >8000 
cells/mL in 24 well plates. Medium was replaced after 3 days and only WT (unedited) cells 
needed to be passaged over this time due to becoming over 60% confluent. One week after 
the bulk FACS sort (9 days post transfection) cells were trypsinized and DNA was 
extracted.  
AS-PCR showed moderate levels of editing was present for the majority of samples at 48 
hours post transfection, however at 7 days post FACS the majority of this editing had 
disappeared (Figure 3.22). It was hypothesised that HDR resulting in cells homozygous 
for the patient variants leads to insufficient proliferation in the absence of fully functional 
protein and replication stress. 
 
Figure 3.22 AS-PCR demonstrates a reduction in editing between bulk and single cell sorts. The 
pooled cells showing best HDR editing (brightest bands) from previous experiment were 
chosen to be investigated further. DNA was extracted from 50% of the bulk sorted cells 
48 hours post transfection (after bulk FACS sort). The remaining 50% of cells were plated 
at ≥8000 cells/mL in wells of a 24 well plate. DNA was extracted from these cells seven 
days later (when a single cell FACS sort would normally occur), this showed a decrease in 
editing across all samples. Samples run on top half of gel were amplified with the mutant 
primer set. Samples run on the bottom half of the gel were amplified with the WT primer 
set. Three controls were run at the end of the gel (WT = wild type control DNA – only 
amplified by the WT primer set, M = patient DNA, -ve = negative water control).  
 
For the final CRISPR experiment we decided to not undertake the initial bulk FACS sort. 
We hypothesized this would reduce the chance any edited cells would not survive by 
reducing the stress on the cells as they only had to survive one FACS sort. While in some 
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of the previous experiments an increase in HDR editing was seen when transfecting cells 
with lower levels of ssODN, successful editing was not observed when screening 
individual cells. The highest editing levels for PX458-mSA was observed at 20 nM, high 
GFP expression (Figure 3.21). We therefore decided to attempt a final CRISPR experiment 
using no bulk sort, a higher ssODN concentration and high GFP expression. The remaining 
ssODN was added to cells at 40 nM and 80 nM 2-4x higher than previously used. These 
cells were sorted directly into 24 x 96 well plates (1440 single cells). The plates were 
media changed every 3-4 days as in previous sorts. After 2 weeks 7 wells showed growth 
which were expanded and genotyped. Plates were kept for five weeks total and no more 
growth occurred. All cells were genotyped via restriction digest, AS-PCR and Sanger 
sequencing – all were confirmed WT.  
As seen in previous experiments FACS sorting is stressful on the cells leading to only 
~40% of WT cells surviving. It was observed that HDR editing levels decreased a week 
after the first FACS sort. This final experiment attempted to reduce the chance of any 
edited cells being out competed by WT cells, by only single cell FACS sorting the cells. 
Editing was present at the time of sorting however no CRISPR edited cells survived. 
Compared to 40% of WT cells surviving a single cell FACS sort, only 0.6% of these 
potentially edited cells survived. This helped confirm that any DONSON HDR edited cells 
were not surviving the single cells sorting process. 
 
 Discussion  
3.7.1 CRISPR experiment limitations and improvements 
CRISPR-Cas9 gene editing is a complex process, with many variables involved which could 
lead to the lack of HDR editing, seen in the hTERT-RPE-1 cells. Firstly, based on previous 
research it is known that HDR is a relatively inefficient process (Liu et al., 2019; Nambiar 
et al., 2019; O’Brien et al., 2019; Xu et al., 2018). Due to this, a large number of cells must 
be grown and genotyped to increase the chances of finding cells containing the correct 
patient variants produced by HDR repair. Secondly, hTERT-RPE-1 cells also have a low 
transfection efficiency and low FACS survival rate. This leads to a limited number of cells 
available to be single cell sorted, which is therefore a likely contributor to the lack of HDR 
edited cells. Third, it is known that RPE human diploid cells do not tend to tolerate change 
as well as embryonic, stem or cancer cell lines do (Haapaniemi et al., 2018). Due to 
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requiring these CRISPR edited cells to investigate subtle changes in DNA replication and 
cell cycle progression, the cell type could not be changed to an easier to edit cell line. 
Double-stranded breaks can cause cell death by apoptosis (Kaina, 2003; Kashiwagi et al., 
2018). When the Cas9 protein creates a double-stranded break, this DNA damage is 
monitored by the cells. In non-cancerous cells the creation of double-stranded breaks can 
cause the cell to activate the apoptosis pathway, while in cell lines with mutated p53 this 
is less likely to happen (Gurley et al., 1998; Kaina, 2003; Menon and Povirk, 2014). 
Unfortunately cell lines with mutated p53 are not suitable as a model for MGS as these cell 
lines are less likely to remain diploid. As although they are easier to CRISPR edit 
(Haapaniemi et al., 2018; Ihry et al., 2018), a lack of p53 is likely to lead to more variants 
arising, as a result of DNA damage not leading to cell cycle arrest or apoptosis. 
 
 FACS sorting 
As mentioned above hTERT-RPE-1 cells did not tolerate FACS sorting well. Due to the low 
transfection efficiency FACS sorting was required to separate GFP positive cells 
(containing Cas9), and separate out single clones. FACS sorting resulted in ~60% cell 
death in control cells. Cells which has been transfected had a higher death rate than this 
(as observed by eye), although whether this was due to the stress of transfection or due 
to Cas9 activity is uncertain. The FACS sorting process was especially detrimental for any 
potentially edited cells, which were likely already not growing as well as control cells, due 
to altering of essential DNA replication genes. As two FACS sorts were required for our 
CRISPR protocol, it is likely any edited cells did not survive this sorting process.  
 
 Accidental knockouts 
A biallelic knockout of ORC1 or DONSON is lethal (Dickinson et al., 2016; Reynolds et al., 
2017), due to both genes being essential for DNA replication. MGS is a recessive disorder 
which requires biallelic knockdown variants, however, any cells which obtained two 
indels causing a knockout would not survive. MGS has a severe growth phenotype, it is 
therefore possible any cells that obtained one missense (knockdown of function) and one 
knockout variant may not have survived due to too little protein remaining for the cell to 
function correctly. This would however depend on how severe a phenotype the missense 
variant caused. As neither the ORC1 nor DONSON variant understudy segregated with a 
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knockout allele it is presumed that a knockout may not be tolerated with these variants. 
A knockout on one allele may lead to not enough of this semi functional protein to meet 
the minimum threshold required for DNA replication and cell cycle progression. When 
added to the stress of transfecting and FACS sorting, this lack of functional protein could 
be contributing to the death of any edited cells. 
 
 Delayed growth 
Another variant that could be contributing to the lack of HDR edited cells, is that edited 
cells may be out competed by non-edited cells during the week between the bulk and 
single cell FACS sort. Plating cells at a low density was done to attempt to control for this, 
however if HDR editing was having an effect on the cells ability to grow at the same speed 
as non-edited cells, then over the course of the week we will have accidentally biased the 
population of cells towards unedited cells. It is therefore less likely edited cells would 
have been sorted into single wells, as there wasn’t enough time or plates to sort all of the 
cells from the bulk sort. Some cells were also lost when preparing for FACS, any edited 
cells lost here would reduce our chance of edited clones growing after the single cell sort. 
 
 sgRNA efficiency 
Screening measures were designed to only identify HDR edited cells, rather than cells with 
small indels. This was due to the low proportion of cells undergoing HDR compared to 
NHEJ (Mao et al., 2008). Therefore, the overall editing level of the sgRNA was not 
measured. Because the screen was not designed to identify indels, and only a small 
proportion of cells were Sanger sequenced, this gave the impression that the overall 
editing level was low. NHEJ is the preferred method of repair by cells not in S-phase (Mao 
et al., 2008; Maruyama et al., 2015; Sargent et al., 1997; Symington and Gautier, 2011), it 
is therefore likely the overall editing level of these sgRNAs was higher than was observed, 
although this cannot be confirmed. As the overall editing level was not investigated, it is 
possible the chosen sgRNAs were not as effective at guiding the Cas9 protein to the 
regions of interest as presumed based on it guide score (Section 3.3.1). If this were true 
the lack of endonuclease activity by Cas9 could have been a contributing factor to the 
overall lack of HDR editing.  
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Ideally multiple guide RNA’s would have been tested for each gene, but due to a lack of 
suitable guides in the region there were very few options available without changing Cas 
proteins/species. It is recommended that the Cas9 cut site be as close as possible (within 
5 nucleotides) to the desired knock in variant (Komor et al., 2016; O’Brien et al., 2019). As 
indels were observed when using the DONSON-p.R211C-sgRNA, this gives some 
confidence the Cas9 protein was being directed to the correct area. 
 
 Overview  
Before taking into account the many new methods available for CRISPR-HDR editing, 
which arose after the initial design of this CRISPR experiment, there are many variables 
at play that could have been contributing to the lack of editing observed. Due to the time 
constraints of this project, we decided to focus our efforts on investigating our novel MGS 
variants using other techniques. We had originally planned on using our CRISPR edited 
cells to investigate the effects these variants had at a molecular and cellular level. Due to 
the length of time CRISPR required if we had continued to investigate new CRISPR 
techniques we would not have been able to investigate any of the effects these MGS 
variants were causing.  
 
3.7.2 New CRISPR methods 
CRISPR methodologies to increase HDR editing efficiencies are improving all the time. A 
large volume of studies investigating improvements of HDR editing efficiency were 
published during the time course of this project. The CRISPR experiments were originally 
designed in March 2018, with methods and experimental protocols being redesigned and 
carried out until August 2019. Therefore we only had the opportunity to try one new 
method to increase the HDR editing efficiency, using the biotin-mSA interaction as 
published in Gu et al., 2018. This meant we did not have the opportunity to try any other 
methods published in newer studies. 
 
 P53 knockdown 
As touched on briefly above Cas9 induces double-stranded breaks activating the p53 DNA 
damage pathway, inhibiting CRISPR Cas9 editing (Haapaniemi et al., 2018; Ihry et al., 
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2018). Cell lines containing non-functional p53 are at an increased risk for variants and 
chromosomal rearrangements (Hanel and Moll, 2012), making them unsuitable for future 
experiments. However a temporary transient knockdown of p53 decreases the long term 
risk. Schiroli et al., 2019 showed transient inhibition of p53 in hematopoietic stem cells 
lead to increased editing without compromising genome stability. While short term 
inhibition of p53 may not lead to increased mutational burden it may allow cells whose 
genome has been damaged during the editing process itself to escape notice (Haapaniemi 
et al., 2018), therefore greater screening of any edited clones may be required to confirm 
other variants are not present. 
 
 Cas9 nickase 
Cas9 nickase creates single-stranded nicks instead of double-stranded breaks (Gasiunas 
et al., 2012). Therefore two Cas9-nickase proteins and two sgRNAs are required to create 
a double-stranded break by making two nicks on the different strands (Jinek et al., 2012). 
This system can be tailored towards HDR by altering overhang length, leading to 
decreased NHEJ repair and increase HDR (Mali et al., 2013b, 2013a; McConnell Smith et 
al., 2009; Satomura et al., 2017). Because two sgRNAs and Cas9 proteins are required to 
create nicks on either strand in order for a double-stranded break to occur (Gasiunas et 
al., 2012; Jinek et al., 2012), Cas9 nickase has lower off-target effects, as both sgRNAs 
would need to mis-bind in close proximity to each other for double-stranded breaks to 
occur (Ran et al., 2013b).  
 
 Asymmetrical repair template 
Research by Richardson et al., 2016 showed that Cas9 asymmetrically releases the 3’ end 
of the cleaved DNA. An asymmetric repair template comprised of 36 bp (PAM-distal) and 
91 bp (PAM-proximal) was tested and improvement of 57% (± 5%) was observed in 
HEK293FT cells (Richardson et al., 2016). When originally designing the CRISPR 
experiment, this paper was missed due to the large volume of CRISPR literature available 
at the time. After this another laboratory member decided to investigate improvement 
using an asymmetrical repair template, this experiment had not been performed at the 
time. Therefore when redesigning our experiment we did not chose to also include this. 
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Future experiments could be designed using the recommended 36 and 91 bp arms, to see 
if this leads to improvements in HDR in hTERT-RPE-1 cells. 
  
 CRISPR base editors 
Base editors can be used to introduce C>T or A>G substitutions (Komor et al., 2016). Base 
editors use cytidine deaminase or adenine deaminase fused to an inactive Cas9, nickase 
Cas9 or nuclease deficient Cas9 (Ryu et al., 2019). They do not require a repair template 
and do not create double-stranded breaks (Gaudelli et al., 2017; Komor et al., 2016; 
Nishida et al., 2016), avoiding some of the issues associated with ds breaks such as 
increased cell death due to activated p53 and eliminating the chance of NHEJ occurring. 
Base editors have been successfully used to model human disease in mouse models (Kim 
et al., 2017a; Lee et al., 2018; Liu et al., 2018; Ryu et al., 2018). 
While base editors tend to have a higher efficiency for introducing specific variants due 
to the lack of NHEJ (Gaudelli et al., 2017; Komor et al., 2016; Nishida et al., 2016), there 
are specific issues associated with them (Ryu et al., 2019). As with other Cas proteins a 
PAM site is required for recognition. The window available for the cytidine deaminase or 
adenine deaminase to work is therefore very small and specific (Nishida et al., 2016). 
Generally all C or A nucleotides within this window will be replaced with T’s or G’s 
respectively (Komor et al., 2016). Kim et al., 2017b successfully reduced the editing frame 
of these base editors from 5 nucleotides to 1-2 nucleotides decreasing off-target changes 
within the editing window. Unfortunately the placement of the correct PAM site in the 
desired area is required to be able to make these correct base pair changes at the desired 
location (Kim et al., 2017b). Therefore depending on location and composition of the 
desired knock in area, these base editors may not be suitable for all experiments. Due to 
this, using base editors in the project was not possible, however they could be useful in 
the future for editing other patient variants depending on their location. 
 
 Small molecules 
Small molecule inhibitors have been shown to increase HDR efficiency by either 
stimulating proteins important for HDR or inhibiting proteins required for the faster and 
preferred NHEJ repair pathway (DiNapoli et al., 2020; Frit et al., 2014; Mao et al., 2008; 
Pinder et al., 2015).  
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KU70/80 play an essential role in NHEJ as they are recruited along with the catalytic 
subunit of DNA-dependent protein kinase (DNA-PKcs) to reattach the two cut pieces of 
DNA (Li et al., 2011; Lieber et al., 2010; Robert et al., 2015). Inhibition of KU70 or KU80 
has been shown to increase HDR by inhibiting NHEJ 2-3 fold (Chu et al., 2015; Maruyama 
et al., 2015; Robert et al., 2015) 
DNA Ligase IV is required for sealing of double-strand breaks during NHEJ (Srivastava et 
al., 2012). A 70% increase in HDR editing was observed in Drosophila embryos mutated 
for DNA Ligase IV when using Zinc-finger nuclease editing (Beumer et al., 2008; Singh et 
al., 2015). This lead to the discovery of the small molecule SCR7 an anti-cancer compound 
which interferes with the DNA binding ability of DNA Ligase IV (Srivastava et al., 2012). 
SCR7 has been used in mouse embryos to significantly increase CRISPR HDR editing 7-19 
fold (Chu et al., 2015; Maruyama et al., 2015; Singh et al., 2015). Interestingly in rabbits 
SCR7 had little effect on improving HDR or inhibiting NHEJ (Song et al., 2016). Song et al., 
2016 also observed severe death in human pluripotent stem cells. 
Since its discovery SCR7 has been used to increase CRISPR HDR in a range of cell lines and 
species including a 2-3 fold increase in porcine foetal fibroblasts (Li et al., 2017), a 3 fold 
increase in A549 human epithelial cells, 19 fold increase in melanoma cell lines and a 13 
fold increase in mouse dendritic cells (Maruyama et al., 2015) 
RAD51 is a key HDR protein (Bozas et al., 2009; Rozov et al., 2019) and the small molecule 
RS-1 (Rad51 - stimulatory compound) has been found stabilise RAD51 association with 
DNA (Jayathilaka et al., 2008; Pinder et al., 2015). This small molecule had been found to 
increase HDR efficiency 2-6 fold, without interfering with the NHEJ pathway (Pan et al., 
2016; Pinder et al., 2015; Song et al., 2016). However Zhang et al., 2017 actually found 
addition of RS-1 and RAD51 lead to a decrease HDR editing in HEK293 cells. 
As with many of the improved CRISPR protocols the actual increase in HDR efficiency of 
these methods relies heavily on the cell line used. As shown with many of the small 
molecule enhancers or repressors the fold change in editing efficacy varies wildly 
between cell types. Therefore when designing improvements to CRISPR experiments it is 
important to take into account whether these protocols have been used in similar cell 
lines as this can lead to the difference between an increase in HDR editing and a decrease.  
In relation to this thesis an end point had to be decided upon, as CRISPR experiments are 
time consuming as it takes a long time to grow cell lines from a single cell sort in order to 
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genotype them. As we didn’t expect it to take so long to successfully edit in our MGS 
variants using CRISPR, we decided to end our attempts at CRISPR editing and use other 
techniques to explore the cellular consequences of these novel MGS variants.  
Getting CRISPR set up in the laboratory as a technique to be used to study the cellular and 
molecular effect of suspected single base pair disease causing variants in a relatively easy 
to work with diploid cell line would be advantageous, as it would allow us to more easily 
explore how variants within a gene can cause different phenotypes. For example it would 
allow us to investigate how missense variants in different areas of DONSON can be causing 
both the MISSLA and MGS phenotype.  
CRISPR HDR editing would also allow us to confirm that patient’s variants suspected to 
be responsible for their phenotype is actually causing their disorder. As CRISPR editing 
allows us to control for background variation, resulting in easier conformation that these 
missense variants are responsible for the phenotype seen. 
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4 Investigating the effects of novel MGS variants at a molecular 
level 
After unsuccessfully editing in the desired MGS variants via CRISPR, it was decided to 
investigate these novel MGS variants using other cellular techniques. Some of these 
experiments were undertaken as a precursor to attempting CRISPR editing as functional 
evidence that these variants were likely pathogenic was desired, before investing time 
and resources into undertaking CRISPR editing to establish isogeneic cell lines. 
As well as the novel variants in ORC1 and DONSON, fibroblasts from two siblings with a 
suspected CDC45 splicing variant (via collaborator Dr David Chitayat, Toronto, Canada) 
were obtained for further investigation. CDC45’s role in DNA replication fit in between 
ORC1 and DONSON as it is important in the preIC as well as during replication fork 
progression while ORC1’s role is in early replication (preRC) and DONSON’s known role 
is later in replication at the replication fork. 
In this chapter, different techniques are presented to investigate these three novel MGS 
variants, in proteins required at different stages of DNA replication. This chapter is 
divided into sections concentrating on each variant.  
 
 ORC1: p.L622P – testing splicing effects by minigene assay  
ORC1 is an essential DNA replication gene and its encoded protein is involved in the 
initiation of DNA replication during late M/early G1 phase (Klein and Gilbert, 2016). 
LB005 contains a homozygous missense two base pairs into Exon 13 ORC1, causing a 
p.L622P amino acid change. This amino acid residue is highly conserved (as seen in Figure 
3.1) and is expected to be contributing to the phenotype. After unsuccessful CRISPR 
editing, and in the absence of patient derived cells we considered how else to investigate 
the molecular effect of this variant. As the variant is at the start of an exon near a splice 
site, we wished to confirm whether or not splicing was contributing to the phenotype. 
Before designing the CRISPR experiment Alamut Visual software (as mentioned section 
3.3.1) was used to check for any potential splicing effect, however no changes in splicing 
efficiency were predicted. Given the limitations in splicing predictions (Bonizzoni et al., 
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2006; Pervouchine, 2018; Spurdle et al., 2008), a minigene splicing assay was undertaken 
to further investigate this (Kishore et al., 2008). 
Gateway cloning was used to introduce a 3 kb fragment of ORC1 containing exons 12-14 
plus >200 bp ajoining introns into the p.SpliceExpress vector. This fragment was PCR 
amplified from control DNA using gateway primers containing attB overlaps. A BP clonase 
Gateway cloning reaction was performed; Gateway cloning uses the attB sites on the ORC1 
insert to recombine with the attP sites present in the pSpliceExpress vector (Figure 4.1), 
removing the toxic ccdB gene from the pSpliceExpress vector. If this recombination event 
hasn’t occurred the E.coli should die. Transformed E.coli were plated on ampicillin 
containing agar plates and undertook colony PCR (cPCR) to screen colonies for the correct 
insert. This suggested that all colonies screened contained the desired insert. Two 
colonies were selected for plasmid purification and Sanger sequencing. Sequencing 
showed that the insert specific primers were mis-binding to the plasmid and neither 
plasmid contained the insert. New Gibson assembly primers and insert specific cPCR 
primers were designed for the next Gateway cloning attempt, however colony number 
stayed reasonably similar and the new cPCR primers also showed mis-priming. This time 
five plasmids were selected for plasmid purification and Sanger sequencing and one 





Figure 4.1 Gateway cloning was used to introduce ~3 kb of ORC1 into the pSpliceExpress vector. A) 
PCR Phusion amplification of ORC1 exons 12-14 including >200 bp intron DNA either side. 
B) cPCR confirms correct insert, colony 3.3 chosen for plasmid prep and Sanger 
sequencing due to strong band at correct size. C) Plasmid map of the pSpliceExpress-ORC1 
vector shows insertion of the ORC1 minigene between two Rat exons. D) Sanger 
sequencing of both ends of the ORC1-pSpliceExpresss overlap confirms the ORC1 insert is 
present in the vector. 
 
Due to inefficiency with Gateway cloning and screening, site-directed mutagenesis was 
used to introduce the LB005 c.1865T>C variant into the plasmid. The site-directed 
mutagenesis primers contained the single bp change in the middle of the 27 bp primer 
(Figure 4.2). The plasmid was then amplified from these primers leading to a newly 
synthesised plasmid containing the single bp change. This allows a single bp change to be 
made relatively easily. DpnI was used to digest any original plasmid before E.coli 
transformation, plasmid purification and Sanger sequencing. Both plasmids selected for 




Figure 4.2  Mutagenesis introduced patient c.1865T>C variant into pSpliceExpress-ORC1 vector. A) 
Mutagenesis primers contains single bp change highlighted in red in the middle of the 27 
bp primers. B) A bright band at the correct size confirms successful amplification of the 
pSpliceExpress-ORC1 vector using the mutagenesis primers, plasmid preps were then 
performed. C) Sanger sequencing confirms successful mutagenesis, with new plasmid 
pSpliceExpress-ORC1-c.1865T>C containing the patient missense variant. 
 
Plasmid concentrations were originally measured using the NanoDrop (2.1.6.6) but were 
confirmed using Qubit (2.1.6.7) before HEK293FT cells were transfected. After 24 hours 
RNA was extracted and cDNA was synthesised. RT-PCR was performed to investigate any 
splicing changes (Figure 4.3). This assay produced some unexpected bands. The 200 bp 
band represents plasmid to plasmid splicing, while the 578 bp band represents both 
plasmid exons plus all three ORC1 exons. The other two bands were unexpected as WT 
ORC1 is not expected to be splicing in this region. The Sanger sequencing results of the 
ORC1 - pSpliceExpress plasmid were re-examined. 
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Figure 4.3 RT-PCR and Sanger sequencing reanalysis confirmed wrong orientation of ORC1 
fragment. A) RT-PCR gel shows unexpected results with many more bands than expected 
appearing from both the WT and c.1865T>C plasmids. B) Re-examination of the Sanger 
sequencing results confirmed the ORC1 fragment was inserted backwards. ORC1 
sequencing alignment against the instered ORC1 minigene fragment shows incorrect 
orientation. The reverse primer plasmid sequencing (green arrows) matches the 
origentation of the ORC1 fragments however the forwards primer sequencing (red 
arrows) should be in the same orientation for the promotor and plasmid exons to be 
situated in the correct orientation.  
 
Reanalysis of the plasmid sequencing showed the ORC1 fragment had been inserted in the 
wrong orientation which was missed when sequencing results were first analysed. 
Unfortunately, due to time constraints and ongoing issues cloning the ORC1 fragment into 
the pSpliceExpress vector this experiment was not sucessfully repeated prior to 
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submission of this thesis. However in the future, it would be beneficial to confirm this 
ORC1 variant does not have a splicing effect. 
 
 CDC45 splicing assay 
CDC45 is part of the preinitiation complex (preIC). The preIC forms at the G1/S-
interphase, after the preRC and is involved in unwinding the DNA to allow polymerase 
access (section 1.1.2.1). This complex is therefore essential for the initiation and 
progression of DNA replication. CDC45 is required for origin firing as it is the rate limiting 
step (Karnani and Dutta, 2011; Köhler et al., 2016). CDC45 also acts by binding single-
stranded DNA and facilitating DNA displacement at the replication fork (Fenwick et al., 
2016; Pacek and Walter, 2004; Parker et al., 2017). Missense and splicing variants have 
previously been found in MGS patients presenting with craniosynostosis and/or anorectal 
malformations (Fenwick et al., 2016). These studies found a marked reduction in 
expression of CDC45 protein expression and canonical transcripts (Cooper, 2016; 
Fenwick et al., 2016). CDC45 is involved slightly later in the replication initiation 
programme than other known MGS genes, as CDC45 is involved in both the initial 
replication initiation and progression of DNA replication. Previous patients with variants 
in CDC45 have presented with a slightly different phenotype than other MGS patients as 
mentioned above, which may be due to the different role CDC45 plays in replication.  
Previous patients with missense or splicing variants in CDC45 presented with 
craniosynostosis or MGS (Fenwick et al., 2016). The majority of the MGS patients also 
presented with mild to severe craniosynostosis, and the majority of the craniosynostosis 
patients presented with mild MGS phenotypes (slight reduction in height, hypoplastic 
ears, and MGS facial features such as small mouth) but no a/hypoplastic patella. CDC45-
MGS patients are therefore presenting with a different phenotype than is typical for 
patients with variants in other genes. Along with craniosynostosis these MGS patients also 
presented with other secondary phenotypes such as thin eyebrows and anal 
abnormalities not normally associated with MGS. This difference in phenotype could be 
due to CDC45 working at different points in replication. Other genes involved in MGS work 
early and only in initiation of DNA replication (Bicknell et al., 2011b), while CDC45 works 
initiating DNA replication but also during S-phase at the replication fork (Pacek and 
Walter, 2004; Wong et al., 2011). 
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Here we report two severely affected foetuses, both terminated around 20 weeks 
gestation due to severe growth defects including severe chest and bone malformations. 
The parents were healthy and consanguineous (first cousins). They were both aged 25 
during the first pregnancy and had no family history of inherited conditions, recurrent 
miscarriages, congenital abnormalities or mental retardation (Figure 4.4A). 
  
Figure 4.4  Two severely affected siblings from healthy consanguineous parents present with a 
homozygous splicing variant. A) Family pedigree shows parents of two affected siblings 
were first cousins with the mothers’ mother and father’s father being siblings. B) Sanger 
sequencing of patient fibroblasts confirms homozygous c.1441-2A>G suspected splicing 
variant (RefSeq: NM003504.4). C) Images of both siblings show small nose and mouth, 
absent eyelids, sloped shoulders, prominent occiput (back of head), hypoplastic external 
genitalia abnormal limbs including club feet with hypoplastic big toes, and hypoplastic 
thumbs. D) c.1441-2A>G splicing variant, results in the loss of the Exon 16 splice acceptor 
site. We predicted this may lead to the entirety of exon 16 being skipped out as there did 
not appear to be any other potential splice acceptor sites nearby. Figure created with 
BioRender 
 
Foetuses suffered severe intrauterine growth restriction (~3 weeks delayed growth by 
20 weeks gestation). Both foetuses also had severe malformations including absent 
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eyelids, cardiac abnormalities, oligohydramnios (deficiency of amniotic fluid), 
dolichocephaly (tall, narrow head), cerebral ventriculomegaly (increased cerebrospinal 
fluid in the brain), kyphotic (outward curvature of the) lumbar spine, lordotic (inward 
curvature of the) thoracic spine, thin ribs, absent clavicles and absent genitalia (Figure 4.4 
C). This phenotype is considered more severe than what has previously been seen in MGS-
CDC45 patients.  
Both foetuses were found to have the same homozygous suspected splicing variant in 
CDC45 c.1441-2 A>G (Figure 4.4 B). Alamut predicted the loss of the Exon 16 splice site 
acceptor motif when the variant is present (Figure 4.5). Such an alteration could lead to 
several consequences, including skipping of exon 16 due to no strong acceptor site, or the 
activation of a cryptic acceptor site which might change the sequence of the transcript. Of 
note, there were no such cryptic sites predicted nearby the canonical site (Figure 4.5). 
 
Figure 4.5 Exon 16 splice acceptor site lost due to c.1441-2A>G variant. Alamut predicts this CDC45 
variant will lead to the loss of the Exon 16 splice acceptor site (as indicated by green 
boxes), as there are no other obvious splice sites nearby it is unknown where this will 
splice to.  
 
4.2.1 RT-PCR was used to investigate splicing effect 
Fibroblasts derived from both siblings (LB191 and LB192) were obtained from our 
collaborators in Canada (Professor David Chitayat – University of Toronto and Professor 
Jacques L. Michaud Université de Montréal). On arrival the patient fibroblasts were found 
to harbour a severe fungal infection, making them difficult to grow and required the 
addition of Fungizone (1:100 DF) to control contamination. Patient cell line LB192 was 
used for all experiments as this cell line was growing better than the LB191 cell line, due 
to less fungal contamination. The experiments which could be performed with these cells 
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was limited, as the addition of Fungizone can alter cell cycle progression (Zhang and Rao, 
2007). Growing time was kept as short as possible for these cells to reduce the chance of 
this fungal contamination spreading to other cell lines in our laboratory or laboratory 
group. KDM14.9 control fibroblasts were also grown in the presence of Fungizone to 
control for any effects the addition of Fungizone may have had on the cells. Due to the 
fungal contamination, experiments to investigating the effect of this splicing variant on 
cell cycle progression using BrdU staining and FACS could not be performed, as the chance 
of spreading infection within the department was too big of a risk. 
Sanger sequencing was used to confirm LB192 fibroblasts contained the c.1441-2A>G 
variant (Figure 4.4B). To do this LB192 cells were pelleted by centrifugation and high 
quality DNA was extracted (2.1.1.3) before being PCR amplified (2.1.2). Exonuclease I 
digest was used to remove additional nucleotides (2.1.2.3) before the PCR product was 
Sanger sequenced (2.1.4). 
 
Figure 4.6  RT-PCR shows no obvious size difference due to splicing changes between patient and 
control fibroblasts. When RT-PCR amplification was kept under 30 cycles (shown above) 
the control band appears brighter than patient indicating less amplification from LB192. 
This was not seen with longer PCR cycles due to saturation. Other primer sets covering a 
larger area of CDC45 were also used to look for any larger splicing changes, but none were 
observed (data not shown). 
 
RT-PCR was performed to investigate potential splicing changes caused by the patient 
variant (2.1.7.4). RNA was extracted (2.1.7.1) and cDNA synthesised using oligonucleotide 
(dT)18 and random hexamer primers (2.1.7.2). We predicted RT-PCR may show all of 
exon 16 or a larger proportion of CDC45 may be spliced out due to the loss of the exon 16 
splice acceptor site. This was not observed (Figure 4.6) as both KDM14.9 and LB192 
products were approximately the same size (predicted size was 491 bp). A range of 
primers were used to look for smaller and larger changes across the transcript by RT-PCR, 
but nothing was noted (data not shown), although the patient band did consistently 
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appear slightly dimmer than control. The RT-PCR products were extracted from the 
agarose gel and Sanger sequencing was performed to look for any small changes, as even 
a one base splicing change could lead to frameshift. Sanger sequencing showed a deletion 
of 6 bp at the start of exon 16 in the cDNA (Figure 4.7) causing the deletion of two amino 
acids but keeping the transcript in frame.  
 
Figure 4.7 Sanger sequencing reveals 6 bp deletion at the start of exon 16 in patient cDNA. RT-PCR 
bands were gel extracted and Sanger sequenced to investigate small splicing changes. As 
observed LB192 patient cDNA showed a 6 bp in frame deletion at the start of exon 16. 
 
4.2.2 Amino acid investigation 
We examined the conservation levels to investigate the effect of this 6 bp deletion had at 
a nuclear and protein level. Five of the six deleted nucleotides were highly conserved 
between species (Figure 4.8A), as this deletion is at the splice site the high conservation 
of nucleotides is to be expected (Diamond et al., 1988; Wolter et al., 1988). The only 
nucleotide without high conservation is the third base of the first codon, this is expected 
as changing the last bp will not change the amino acid. Although the nucleotide 
conservation was high, Alamut did not rank the two deleted amino acids as highly 
conserved. The two amino acids were conserved between human to zebrafish and frog 
respectively (Figure 4.8B). This is a similar conservation to five out of nine missense 
variants from Fenwick et al., 2016. 
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Figure 4.8  CDC45 exon 16 conservation. CDC45 c.1441-2A>G variant causes the deletion of the first 
6 nucleotides of exon 16, leading to a two amino acid in frame deletion. A) Five of six 
deleted nucleotides show high conservation. B) Two deleted amino acids are not 
predicted to be highly conserved between species 
  
Although not predicted to be particularly highly conserved, due to the severity of the 
patient phenotype where these amino acids sit in CDC45 in relation to the tertiary 
structure of the rest of the pre-initiation complex was investigated. To consider whether 
these amino acids could be important for interacting with other proteins in the preIC or 
replication fork leading to ineffective DNA replication. Protein schematics showed that 
the two deleted amino acids sit on the outside of CDC45 and do not seem to be important 




Figure 4.9 CDC45 protein interaction with other members of the pre-initiation complex. Schematic 
of CDC45 interacting with other members of the pre-initiation complex shows Human 
CDC45 (red) overlaid S.cerevisiae CMG complex structure (PDB ID: 3JC6), with the two 
deleted these amino acids (purple) which do not seem to be required for interacting with 
other proteins. Red arrow indicated position of two deleted amino acid residues (credit 
Dr Karen Knapp). 
 
4.2.3 CDC45 transcript levels in patient-derived cells 
While the splicing machinery was making use of a cryptic splice site 6 nucleotides into the 
exon, the efficiency of this splicing was not clear, and it was hypothesized that it was less 
efficient as bands produced from RT-PCR were less intense (Figure 4.5). Due to the severe 
phenotype seen in both siblings, we expected that this cryptic splice site may be leaky, 
leading to only a small proportion of mRNA being made into cDNA and the rest being 
degraded by nonsense mediated decay (Brogna and Wen, 2009). Therefore it was 
hypothesised that this ineffective splice site would likely be causing a reduction in stable 
mRNA expression, leading to the patient phenotype.  
The reduction in CDC45 expression was confirmed by RT-qPCR using primers >200 bp 
apart, located across the transcript. This showed a severe knockdown (72.9%) of CDC45 
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expression across the gene compared to control (Figure 4.10). RNA was extracted and 
cDNA synthesised from control (KDM14.9) and patient (LB192) fibroblasts on three 
separate occasions. Three technical RT-qPCR replicates of each reaction were performed 
for each of the three biological replicates (appendix C.2). CDC45 expression levels were 
measured using the comparative CT method (2-∆∆CT)-relative to RPS18. Patient values 
were normalised to control values set at 1. 
 
 
Figure 4.10 CDC45 splicing variant causes a significant reduction in CDC45 expression in fibroblasts. 
Makeshift splice site causes 72.9% reduction in CDC45 expression across the gene. RT-
qPCR 2-ΔΔct values normalised to RPS18 are plotted from control (KDM14.9) and patient 
(LB192), RT-qPCR performed in triplicate with three biological replicates performed. A 
72.9% reduction in CDC45 expression was seen across the gene. Multiple T-tests showed 
significant reduction in CDC45 expression (** <0.01, *** < 0.001, **** <0.0001) 
 
Cooper, 2016 and Fenwick et al., 2016 saw a 93% reduction in CDC45 levels in a pair of 
sibling’s presenting with a compound heterozygous splicing variant alongside a missense 
variant. These siblings present with a much milder phenotype than the siblings 
understudy here do and yet they have a greater reduction in CDC45 expression levels. Due 
to this we decided to investigate if there was an effect on protein stability due to the two 
amino acid deletion. As mentioned previously other previously reported CDC45 patients 
with splicing variants have had a similar or larger reduction in CDC45 expression but a 
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far less severe phenotype. Due to this we decided it was important to follow up other 
potential causes of the phenotype. 
 
4.2.4 Immunoblot  
A western immunoblot was performed using patient (LB192) and control (KDM14.9) 
fibroblasts, as well as untransfected HEK293FT cells and HEK293FT cells transfected with 
a flag-tagged-CDC45 plasmid encoding the canonical protein.  
The endogenous signal was undetectable due to low protein expression levels in 
fibroblasts. The same CDC45 antibody has successfully been used to detect protein levels 
in LCL cell lines (Fenwick et al., 2016), which have 21 fold higher protein expression level 
than fibroblasts (https://www.gtexportal.org/) explaining why expression was not 
detected in this assay. 
As the antibody gave a weak signal for transient CDC45 in HEK293FT cells (data not 
shown) we decided to use a transient transfection of engineered plasmids encoding either 
wild type or mutant protein to test relative levels by western blot analysis. 
Site-directed mutagenesis was used to introduce the 6 bp cDNA deletion into a flag tagged 
CDC45 vector (made previously by Dr Karen Knapp). Following transformation of the 
mutagenesis PCR product into E. coli, plasmids were purified and subjected to Sanger 
sequencing to confirm successful mutagenesis.  
HEK293FT cells were transfected (2.3.7) with the 6 bp deletion CDC45 vector or the WT 
flag-CDC45 vector, 24 hours before protein extraction (2.1.8). Immunoblotting was 
performed to look for potential differences in protein stability (Figure 4.11).  
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Figure 4.11 CDC45 protein levels are similar between WT and Patient. Immunoblot with anti-CDC45 
shows little difference in CDC45 protein expression between HEK293FT cells transfected 
with WT or 6 bp-del CDC45. Alpha tubulin (50 kD) confirmed consistent loading.  
 
Unfortunately no clean band was observed for either the WT or 6 bp deletion CDC45 (60 
kD). Because of this, it wasn’t possible to accurately quantify protein expression levels 
(Figure 4.11). Therefore this experiment should be repeated before any conclusions can 
be drawn. The membrane was counterstained with alpha tubulin to confirm equal loading 




While previously described CDC45-MGS patients have often presented with 
craniosynostosis – a slightly different phenotype to other MGS patients – the phenotype 
is not generally more severe. Here we reported two severely affected siblings who both 
inherited a homozygous splicing variant in CDC45. Due to the severity of the phenotype it 
was hypothesised that this splicing variant may lead to an almost complete reduction of 
gene expression. RT-PCR and RT-qPCR analysis showed a 72.9% knockdown of CDC45 
function with 100% of the mRNA expressed containing a 6 bp deletion. 
The first major limitation of this study was the fungal contamination present in the patient 
fibroblasts when they arrived. Due to this contamination we were unable to grow the 
fibroblasts for long periods of time, to reduce the chance of spreading the infection. This 
meant we were unable to investigate the effect of the mutant protein at a cellular level. 
Other experiments could have included EdU pulse chase assay to investigate the effect of 
this variant on cell cycle progression or fibre combing to examine the effect of DNA 
replication events and speed. This would have allowed us to gain a better understanding 
of the overall effect of this splicing variant at a cellular level. 
Expression levels vary between cell types and developmental stages (Cardoso-Moreira et 
al., 2019). The second limitation of this experiment was the difference in age between the 
patient and the control fibroblasts and lack of other CDC45 patient fibroblasts. This study 
compared CDC45 expression levels between fibroblasts from a 20-week gestation foetus 
and a 14 year, 9-month-old boy, as this was the youngest cell line, we had access to. A 
younger control cell line would likely give a more accurate representation of the 
difference in CDC45 expression. Due to the age of the patient (20 weeks gestation) 
accurately matching a control cell line is realistically not possible but repeating this 
experiment with a younger control cell line (ideally <1 year old) may be beneficial in 
obtaining more meaningful results. It is expected that CDC45 would have higher 
expression during development (Shaikh et al., 1999). Specifically earlier in development 
when increased DNA replication is required to keep up with the large amount of cell 
division occurring during a short timeframe for brain development (Kalogeropoulou et 
al., 2019). Although this period had likely passed it would still be expected to see an 
increase in CDC45 expression levels compared to non-foetal samples. Access to other 
CDC45 patient fibroblasts would allow comparison of both splicing and protein 
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expression differences between patients presenting with a severe phenotype and patients 
presenting with a moderate CDC45 phenotype.  
Cooper, 2016 and Fenwick et al., 2016 saw a 93% reduction in full length CDC45 
expression in one of their patients with compound heterozygous splicing variants 
(c.203A>G, p.Gln68Arg (splicing effect) & c.333C>T, p.Asn111 = exon skipping effect). 
While this reduction in expression is more extreme than what was observed here, it is 
hard to accurately compare this knockdown in expression as they were using different 
cell lines and different housekeeping genes. In their study Cooper and Fenwick used 
patient derived LCLs to investigate knockdown in full length CDC45 expression. As 
mentioned earlier CDC45 expression levels vary between different cell lines. In the 
previously mentioned study GAPDH was used as a housekeeping gene, GAPDH although 
widely used as a control gene can have variable expression in LCLs and therefore is not 
necessarily the most accurate or stable control gene (Brouwer et al., 2006). In fibroblasts 
GAPDH is considered one of the most unstable genes in terms of expression (Panina et al., 
2018), therefore RPS18 was used for normalising RT-qPCR data. All of this can lead to 
differences in results making it hard to accurately compare the knockdown of CDC45 
expression between these two patients. The difference in age between their CDC45 
patient and control cell line is unknown, but it is likely a more accurate control than our 
control cell line as they were using LCLs derived from a 7 year old (Cooper, 2016; Fenwick 
et al., 2016). 
The (c.203A>G, p.Gln68Arg & c.333C>T, p.Asn111=SE) compound heterozygous splicing 
variants were seen in both the patient mentioned above and his younger brother. 
Interestingly, although both had the same compound heterozygous splicing variants in 
CDC45 the older sibling presented with a relatively mild phenotype while the younger 
sibling had a more severe phenotype. The older sibling was born at 42 weeks gestation; 
length (-1.4 SD), weight (-1.5 SD). Measurements at the most recent examination (7 years 
old) were, height (-1.3 SD), OFC (-2.3 SD) and weight (-0.4 SD). He also presented with 
microtia, absent patella, thin eyebrows (associated with MGS), high arched palate and a 
mircopenis (associated with MGS). He did not present with developmental delay or 
craniosynostosis. His younger brother was born at term; length (+0.5 SD), OFC (-1.7 SD), 
weight (-1.2 SD). Measurements at his most recent examination (16 months) were, height 
(-2.5 SD), OFC (-4.7 SD) and weight (-3.7 SD). MGS phenotypes included microtia and thin 
eyebrows but no absent patella. Similar to his older sibling he presented with no 
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developmental delay, however he did present with bicoronal craniosynostosis with 
widely patent metopic and sagittal sutures associated with CDC45 variants. CDC45 
expression levels were not investigated in this patient but presumed to be similar to the 
first, as both presented with the same CDC45 splicing variants. 
The difference in craniosynostosis and MGS phenotypes between these two CDC45 
patients demonstrates incomplete penetrance. While these two siblings presented with a 
more severe knockdown of CDC45 expression compared to the two CDC45 patients 
presented in this study, they showed a much milder phenotype. The splicing variants in 
these patients from Fenwick et al., 2016 affected the 5′ end of the gene while the splicing 
variants in this study affect the 3′ end of the gene. In the case of our CDC45 affected 
siblings we see a very similar severe phenotype in both siblings, this may be due to 
potential protein effects as well as the splicing effect.  
Although the Fenwick et al., 2016 patients showed a 93% knockdown in CDC45 
expression the remaining 7% mRNA expressed encoded the full length WT CDC45 
transcript. In this study, the remaining 20% mRNA expression did not encode the full 
length WT transcript but a transcript containing a 6 bp deletion at the start of exon 16, 
causing a two amino acid deletion. This could contribute to why we see such a severe 
phenotype in these patients. 
This 6 bp deletion leads to an in frame two amino acid deletion in the protein. These amino 
acid residues were conserved to a similar level as 5/9 of the missense variants described 
in Fenwick et al., 2016, while the remaining four missense variants were more highly 
conserved. 
Western immunoblot was used to investigate relative protein levels, as a decrease in 
protein levels may help explain the extreme phenotype seen in these patients. As seen 
above there was no obvious difference is CDC45 expression in transfected HEK293FT 
cells. Comparing protein expression in transfected HEK293FT cells is not the ideal way to 
look at protein expression but unfortunately CDC45 expression in fibroblasts was too low 
to give a signal, even in WT cells. While this experiment suggests that the 6 bp deletion 
may not influence protein stability we cannot rule out it may affect the protein in other 
ways. For example, this deletion may lead to a reduced ability of CDC45 to interact with 
other proteins involved in DNA replication.  
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Protein interactions impacted by this two amino acid deletion CDC45 was not something 
we were able to investigate during this project. We would also have liked to investigate 
the effect this splicing variant had on cell cycle progression, but unfortunately due to the 
fungal infection in the cell lines we could not investigate this. 
After reporting these functional results back to our collaborators, they were not entirely 
convinced this 72.9% reduction in CDC45 expression would be enough to explain the 
severe phenotype. Due to this they wanted to re-examine the exome sequencing to look 
for other potential variants shared by both siblings which could be contributing to the 
phenotype. At the time of submission, nothing had been reported back. However as we 
could not analyse this sequence ourselves, we cannot rule out the potential of other 
variants or risk alleles which may be contributing to the phenotype. 
While where this deletion in CDC45 sits in relation to other proteins in the preIC was 
investigated, we did not investigate how this deletion may affect the role of CDC45 plays 
during replication, specifically relating to elongation and leading strand displacement. 
This ties into the next section of our project as DONSON’s role in DNA replication was only 
recently discovered (Evrony et al., 2017; Reynolds et al., 2017). Exactly how and which 
proteins DONSON interacts with in the replisome is uncertain. It is therefore possible this 
small deletion in CDC45 could lead to issues during DNA replication that is not understood 
yet.  
 
 DONSON sub cellular localisation 
DONSON works during S-phase to stabilise replication forks (Figure 4.12). Previous 
research by Reynolds et al., 2017 found that DONSON missense variants causing the 
MISSLA phenotype (section 1.2) often resulted in the mislocalisation of DONSON-GFP 
protein in the cytoplasm of HeLa cells rather than in the nucleus where WT DONSON 
localises (Figure 4.13). HeLa cells transfected with the wild type pEGFP-DONSON vector 
showed only nuclear expression while the majority of the MISSLA patients showed 
diffused localisation in the cytoplasm (Figure 4.13). The exception to this was p.S28R & 
K489T variants which showed mainly nuclear expression, here western blot analysis was 
used to show p.K489T decreased protein stability, causing marked reduction in protein 
levels (Reynolds et al., 2017). Although the MISSLA phenotype is different to the MGS 
phenotype the inability of the DONSON protein to localise to the nucleus would be a strong 
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indication that these variants are pathogenic. We reasoned this would be a good first 
experiment to examine whether the p.R211C variant was likely pathogenic before we 
embarked on CRISPR engineering focusing on this variant. 
At the start of this project DONSON was considered a novel disease gene associated with 
MGS, as it had only been described to be involved in MISSLA (Reynolds et al., 2017) and 
MIMIS (Evrony et al., 2017). Therefore we wanted to investigate the cellular localisation 
of pEGFP-DONSON in HeLa cells, as the inability for DONSON protein to localise to the 
nucleus where WT DONSON is expressed would give us more confidence that this variant 
is pathogenic. 
 
Figure 4.12 DONSON is required for replication fork stability in S-phase. In the presence of DONSON 
replication forks are stabilised and restarted after replication stress. In the absence of 
DONSON replication stress leads to double-stranded breaks. This leads to chromosomal 
instability and eventual cell death. Figure adapted from (Reynolds et al., 2017) 
Supplementary Figure 22, copyright obtained from Springer Nature - 4850530174277. 
 
As mentioned previously DONSON works during S-phase to stabilise replication forks. 
This is important for chromosomal stability as without sufficient functioning DONSON 
these replication forks can collapse leading to chromosomal instability and cell death 
(Figure 4.12). Patient genotypes suggest hypomorphic variants (significantly reduced 




Figure 4.13 DONSON cellular mislocalisation of MISSLA variants A) Proportion of transfected HeLa 
cells with diffuse or cytoplasmic p.EGFP-DONSON expression fixed 24 hours post 
transfection (n = 5 independent experiments). B) Phenotype of pEGFP-DONSON variants 
as well as empty and WT controls. Figure from (Reynolds et al. 2017) Supplementary 
Figure 9, copyright obtained from Springer Nature 4850530174277. 
 
4.3.1 DONSON-p.R211C Localisation 
We were kindly sent the empty pEGFP vector along with WT DONSON and the seven 
vectors containing MISSLA patient variations from our collaborator Professor Grant 
Stewart, University of Birmingham. 
When transfected in HeLa cells, empty-p.EGFP is diffuse in the cytoplasm while pEGFP-
WT DONSON is localised to the nucleus, as this is where it works to stabilise replication 
forks when they stall during S-phase. WT DONSON has two main phenotypes; diffuse in 
the nucleus (Figure 4.14 A) or small uniform spots (Figure 4.14B) when DONSON is acting 
to stabilise replication forks (Figure 4.14). 
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Figure 4.14 pEGFP-WT-DONSON is localised to the nucleus of HeLa cells. DONSON protein is either 
diffuse in the nucleus or localised to replication foci. Note there is normally no localisation 
in the cytoplasm.  
 
Site-directed mutagenesis was used to introduce LB008 c.631C>T missense variant into 
the pEGFP-DONSON vector. Once Sanger sequencing confirmed successful mutagenesis 
(Figure 4.15), HeLa cells plated on glass coverslips were transfected with this plasmid. 
Cells were fixed 24 hours post transfection and stained with DAPI before being mounted 
and viewed under the Olympus BX53 upright microscope.  
 
 
Figure 4.15 Sanger sequencing confirms successful mutagenesis of pEGFP-DONSON vector. 
 
Preliminary transfection tests with MISSLA variants showed similar results (Reynolds et 
al., 2017) (Figure 4.13) with majority of cells showing cytoplasmic expression (data not 
shown). MISSLA variant p.F292L variant was used as a positive control for all 
experiments.  
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Only a few cells transfected with the pEGFP-DONSON-p.R211C plasmid showed 
cytoplasmic expression (Figure 4.16). Immediately the most noticeable p.R211C 
phenotype was the number of cells containing bright GFP aggregates (Figure 4.17). While 
some of these aggregates were occasionally seen in WT (Figure 4.14/4.18) there were 
generally less aggregates and less cells expressing these aggregates. Such condensations 
were rarely seen with WT-DONSON and other MISSLA patient plasmids, it is likely these 
were ignored or presumed to be DONSON acting at replication forks in previous 
experiments. This GFP-aggregate phenotype was not seen at all with the p.EGFP-empty 




Figure 4.16 Cellular localisation of pEGFP empty or pEGFP-DONSON plasmids transiently expressed 
in HeLa cells fixed 24 hours post transfection. Novel p.R211C sometimes showed 
cytoplasmic expression. A) pEGFP-empty shows only cytoplasmic expression. B) WT-
DONSON shows only nuclear expression. C) pEGFP-DONSON-p.F292L positive control 
MISSLA variant from Reynolds et al., 2017 shows mostly cytoplasmic expression. D) Some 
















































































































































































































































































































































































































































































































































































While occasionally we saw an aggregate phenotype in WT cells it was generally less severe 
than what is seen in p.R211C and far less cells showed this phenotype. The majority of WT 
cells which did not have diffuse nuclear expression had a uniform spotty phenotype 
(Figure 4.18 B-D).  
This difference in phenotype observed between p.R211C and WT gave us confidence this 
DONSON variant was worth investigating further by establishing isogenic cell lines using 
CRISPR as described in the previous chapter (3.0).  
 
4.3.2 Quantifying DONSON localisation 
Next we quantified the p.R211C pEGFP-DONSON expression based on nuclear (WT), 
cytoplasmic (empty) or this new aggregate phenotype. By this point we had a total of four 
DONSON-MGS patients with five missense changes and one splicing variant between them 
(Table 4.1, Figure 4.19). 
 
Table 4.1 MGS-DONSON patient variants, inheritance and population frequency (Table previously 
published in Knapp et al., 2019).  
Patient Variant 1 
gnomAD 





































Figure 4.19 Four of our MGS patient cohort (~25%) contain 5 missense and one splicing variant in 
DONSON. A) MISSLA and MIMIS variants shown in black tend to cluster around the C-
terminus of the protein while all but one MGS-DONSON variant are found at the N-
terminus. B) All 5 missense variants are found in relativity highly conserved regions of the 
protein. (Figure previously published in Knapp et al., 2019). 
 
Dr Karen Knapp used site-directed mutagenesis to introduce the other four missense 
variants into the pEGFP-DONSON vector. Five out of the six DONSON-MGS variants 
clustered at the N-terminus of the protein while MISSLA and MIMS variants were located 
more towards the centre and C-terminus of the protein. All DONSON-MGS missense 
variants were in relatively highly conserved regions of the protein (Figure 4.19A).  
HeLa cells were transfected with the five MGS-DONSON variant plasmids, two MISSLA 
variant positive controls (p.F292L and p.Iso543_Pro544insLys), empty pEGFP or WT-
DONSON. A total of ~1200 cells were counted for each plasmid across five transfection 




Figure 4.20 DONSON subcellular localisation comparing DONSON-MGS variants to WT and MISSLA 
variant controls. A) GFP Representative images of GFP, WT-DONSON, the five DONSON-
MGS variants (p.Phe165Ser, p.Arg211Cys, p.Pro224Ser, p.Tyr270Cys and p.Pro545Leu) 
and two MISSLA control variants (p.Phe292Leu and p.Iso543_Pro544insLys) transfected 
in HeLa cells. p.Arg211Cys is co-stained with DAPI to show aggregate nuclear phenotype 
different to other variants which show diffuse cytoplasmic expression. B) Quantification 
of DONSON subcellular localisation of nine previously mentioned plasmids (a) (n=1200 
cells/plasmid over five biological replicates, one-way ANOVA allowing for multiple 
comparisons). Figure previously published in Knapp et al., 2019.  
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Table 4.2 Subcellular expression percentages for MGS-DONSON variants and controls. 
Plasmid Nuclear localisation Aggregate localisation Cytoplasmic localisation 
Empty 0.08  0 99.9  
WT 80.9  8.9  10.2  
p.F292L 5.4  10.1   84.5  
Ins-K 6.6  15.5   77.9  
p.R211C 23.3  50.3   26.4  
p.F165S 9.1  13.1   77.8  
p.P224S 9.1  10.7   80.1  
p.Y270C 7.5  8.0   84.4  
p.P545L 7.9  13.8   78.3  
 
All MGS-DONSON patients showed similar results to what was seen in Reynolds et al., 
2017, with the majority of cells showing a cytoplasmic expression (Figure 4.20). Due to 
the cytoplasmic expression, it is thought that perhaps the variants in DONSON are 
resulting in the majority of the DONSON protein no longer being able to successfully 
localise to the nucleus to act stabilising replication forks, leading to the patient phenotype. 
The exception to this was the p.R211C plasmid, mentioned above. The majority of these 
cells showed an aggregate phenotype seen rarely in WT and other DONSON variants 
(Figure 4.20/4.21). WT DONSON shows a speckled phenotype, reflecting replication foci 
when DONSON is active stabilising replication forks. This is generally seen as relatively 
uniform small spots in the nucleus (Figure 4.14) (Reynolds et al., 2017). The aggregate 
phenotype seen is much larger clumps of GFP-DONSON. What could be causing these 
aggregates is unknown, as it doesn’t appear to be nucleolar or P bodies (Ling et al., 2014; 
Luo et al., 2018; Panico and Forti, 2013). The p.R211C variant generally showed a less 
extreme cytoplasmic expression than other variants and had a higher proportion of 












































































































































4.3.3 DONSON in Mitosis 
Further immunocytochemistry experiments were performed after ending the CRISPR 
experiments early. This gave us the opportunity to follow up the aggregate GFP-DONSON 
phenotype in more detail. This aggregate phenotype was seen in 50.3% of p.R211C cells 
but only 8.0-15.5% of other variants. As shown in Figure 4.18 there was some cross over 
between normal spotty and abnormal aggregate phenotype.  
First a mitosis marker (histone H3) was used to investigate whether these aggregates or 
DONSON protein in general was localising to the nucleus during mitosis. We chose to stain 
with a mitosis marker as we had previously seen a few p.R211C transfected cells showing 
very bright aggregate GFP expression just after they appeared to have undergone mitosis. 
As DONSON has only been described to act during S-phase (Reynolds et al., 2017), we 
thought this would be interesting to follow up. If these DONSON aggregates localised at 
mitosis, this would indicate DONSON was active earlier in replication than previously 
thought. After staining we observed 100% of these aggregates did not localise with 
mitosis at all (Figure 4.22). 
 
Figure 4.22  DONSON aggregates localisation in mitosis. DONSON protein aggregates did not appear 
to localise with the histone H3 mitosis marker in p.R211C cells. HeLa cells plated on glass 
coverslips were fixed 24 hours post transfection, stained with histone H3 mitosis marker 
and DAPI before being visualised using the Olympus BX53 microscope. 
 
Empty, WT-DONSON and p.R211C transfected HeLa cells were all stained with mitosis 
marker (histone H3). There was no obvious localisation of WT or p.R211C-DONSON with 
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the mitosis marker at all, indicating DONSON is not active during mitosis. This fits with 
published data on the role of DONSON during replication fork stability during S-phase 
(Reynolds et al., 2017). 
 
4.3.4 DONSON DNA damage 
Next transfected HeLa cells were stained with Y-H2AX (DNA damage marker) (Ichijima et 
al., 2005; Sone et al., 2014). As DONSON is required for stabilising replication forks during 
S-phase, MISSLA-DONSON variants lead to increased DNA damage, chromosome 
instability and cell death. As our MGS-DONSON patients presented with a different 
phenotype to these MISSLA patients we investigated the effects of the DONSON-p.R211C 
variant on DNA damage (Figure 4.23). 
 
Figure 4.23 DNA damage marker is reduced in cells transfected with WT or p.R211C-DONSON. HeLa 
cells transfected with control or DONSON-p.R211C plasmids were fixed 24 hours after 
transfection, and stained with γ-H2AX DNA damage marker. A) Panel shows 
representative staining of γ-H2AX antibody. B) DNA damage foci were counted by eye and 
ranked into the above categories (N=160, one replicate).  
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Due to time constrains only one replicate (N=160 cells) were counted. Therefore, any 
results are only indicative of what may be happening, but more replicates and larger cell 
counts are required for a more accurate representation.  
The most DNA damage was present in HeLa cells transfected with empty GFP (Figure 
4.23). This decreased dramatically in cells transfected with WT-DONSON with the 
majority (89.2%) of cells containing only 0-4 DNA damage foci, 10.2% containing 5-9 foci 
and only 0.6% of cells with more than 10 foci. Cells transfected with the p.R211C plasmid 
also showed a decrease in DNA damage with 78% cells containing <4 foci, 17.6% with 5-
9 foci and 4.4% containing over 10 DNA damage foci, but this was not as extreme as seen 
in WT.  
This may suggest that transient WT and p.R211C DONSON may be working to protect 
against DNA damage in HeLa cells. 
 
4.3.5 Discussion 
Mislocalisation of GFP-DONSON protein confirmed these DONSON variants were likely 
pathogenic. The difference in cellular expression between other MISSLA and MGS variants 
and the p.R211C aggregate phenotype was unexpected. There are no obvious phenotypic 
differences between LB008 (homozygous for p.R211C) and other patients with other 
DONSON-MGS variants. This aggregate cellular phenotype had not previously been 
reported. As only a small proportion of WT-DONSON cells (and other variants) showed an 
aggregate phenotype, it is likely this phenotype was ignored as it may have been thought 
to be a variation on the normal speckled WT-DONSON phenotype. 
50.3% of p.R211C cells showed an aggregate phenotype while MISSLA and MGS-DONSON 
variants tested, showed at least 77.8% cytoplasmic expression. As there is no noticeable 
difference in phenotype between LB008 and the other DONSON-MGS patients this may 
suggest the aggregate DONSON protein is completely non-functional. However this is 
counteracted with a higher proportion (23.3%) of WT expression compared to only (7.5-
9.1%) with the other DONSON-MGS variants. Both cytoplasmic and aggregate DONSON 
expression suggests protein mis-folding or inability for the protein to get into the nucleus. 
As MISSLA is caused by DONSON dysfunctioning at replication forks leading to double-
stranded breaks, chromosome instability and cell death we would expect MGS-DONSON 
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variants leading to the inability of DONSON localising to the nucleus to cause similar 
problems. Limited DNA damage data indicates that p.R211C is almost as good as WT 
DONSON at reducing DNA damage in transfected HeLa cells. This and phenotypic data 
suggests that these DONSON variants are not leading to increased DNA damage or at least 
not as severe DNA damage as is seen with MISSLA variants (Reynolds et al., 2017). 
Although this work needs to be expanded to better understand the effect of MGS-DONSON 
variants on double-stranded breaks, this is briefly followed up in the next section. 
GFP-DONSON does not localise to the nucleus during mitosis. Although this is not entirely 
unexpected, we found that DONSON, specifically aggregate DONSON was not present 
during mitosis. We chose to followed this up based on an observation early in the DONSON 
localisation experiment where one cells showing bright GFP aggregates looked to have 
just undergone mitosis. While we did not find DONSON to localise with mitosis, if we had 
it would have been a strong indication that DONSON has a much earlier role in DNA 
replication than previously thought. 
Previous research has shown that GFP can self-aggregate based on pH and concentration 
transfected (Krasowska et al., 2010). In this experiment we controlled for aggregates 
caused by GFP with control plasmids, empty and WT-DONSON. The empty-GFP plasmid 
showed no cells with GFP aggregates, while our WT plasmid showed some cells ranked as 
aggregate (8.9%), however the majority of these were likely WT spotty cells which 
showed a slightly more aggregate phenotype and were therefore classified as aggregate 
based on our ranking criteria decided upon before counting all cells. 
Aggregates causes by GFP are also more likely to be found in dividing cells (Kopito, 2000; 
Stiess et al., 2010), therefore the mitotic staining confirmed these GFP aggregates are a 
result of the DONSON protein, not GFP. 
As all other MGS genes work early in DNA replication (preRC or preIC) we hypothesised 
that DONSON may play another currently undiscovered role earlier in DNA replication. 
Following on from this and based on previous research (Reynolds et al., 2017) we expect 
the inability of DONSON to localise to the nucleus would lead to replication fork instability, 




 DONSON fibre combing 
As MGS is a replication disorder, we wanted to utilise fibre combing as an assay to 
investigate the proportion of replication events occurring in MGS-DONSON patients. This 
dataset could also give us an insight into different consequences of MGS vs MISSLA 
DONSON variants. Reynolds et al., 2017 found MISSLA patients had less progressing 
replication forks and more stalled forks than control cells. 
As the majority of our previous work had been on LB008 (p.R211C) we wanted to follow 
up what effects (if any) this p.R211C DONSON variant had on replication events. 
Unfortunately, we could not obtain cells from the p.R211C individual. We did however 
have access to cells from LB128. This patient has two missense variants (c.670C>T, 
p.Pro224Ser and c.809A>G, p.Tyr270Cys) similar to LB008, and has the very typical triad 
of MGS phenotypes; global reduction in size, microtia, and bilateral absent patella. LB128 
was born at 32 weeks gestation, measuring 37 cm length (-1.97 SD), 28 cm occipital 
frontal circumference (OFC) (-0.94 SD), 1.08 kg (-1.85 SD). At his most recent examination 
(8 years 0 months) he was 98.4 cm tall (-5.26 SD), OFC 47 cm (-4.45 SD) and 12.3 kg (-
7.27 SD). Facial dysmorphism included submucosal cleft and bifid uvula. Developmentally 
he presented with motor and speech delay, hypotonia and normal cognition. Skeletal 
abnormalities included bilateral congenital knee dislocations, hyperextension and 
dislocation of both knees at birth. Other abnormalities included conductive hearing loss 
(external auditory canal stenosis), spontaneously resolved nystagmus, mild left optic 
nerve hypoplasia, bilateral inguinal hernia and bilateral single incomplete palmar creases. 
While both the height and head circumference are more extreme than seen in LB008 
height 115 cm (-3.48 SD), OFC 48 cm (-3.97 SD), both patients presented with a relatively 
similar phenotype (Figure 4.24); global reduction in size, microtia and absent patella. 
LB008 also presented with delayed development, high arched palate, micrognathia, mild 
hearing loss and hypopigmentation. 
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Figure 4.24 LB008 homozygous DONSON variant (p.R211C) and LB128 compound heterozygous 
DONSON variant (p.P224S & p.T270C) presents with very typical MGS symptoms. Note 
the small misshaped ears, absent kneecaps, tapering fingers and shortened toes. Figure 
adapted from (Karaca et al., 2019 & Knapp et al., 2019) copyright obtained from John 
Wiley and Sons – 4850530640988 and under the Creative Commons Attribution 4.0 
International License.  
 
4.4.1 Quantifying Replication events by DNA fibre combing 
Fibre combing or molecular combing can be used as a quantitative measure of origins of 
replication in the genome (Herrick and Bensimon, 1999), as well as a number of other 
replication events such as progressing replication forks (Schwab and Niedzwiedz, 2011). 
Fibre combing uses surface tension (water-air) to uniformly stretch the DNA along a glass 
slide (Kaykov et al., 2016; Michalet et al., 1997), before florescent probes are added, to 
stain actively replicating DNA.  
Patient and control cells were incubated with two nucleotide analogues CldU and IdU for 
20 minutes each. The cells were then lysed and the DNA was uniformly spread along a 
glass slide using surface tension to stretch out the DNA. Staining was performed with rat 
and mouse BrdU antibodies which, despite their name, specifically recognise CldU and IdU 
respectively (Quinet et al., 2017). Fibre combing can be used to quantify multiple 
replication events such as progressing forks, stalled forks, new origins of replication, 
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bidirectional forks and termination/collision of forks based on the red/green pattern 
(Figure 4.25). The speed of progressing forks and bidirectional forks can also be 
measured. To do this the length of tracts were measured using specialised software, 
ImageJ (Quinet et al., 2017). Track lengths were then converted from μm to kb using the 
common conversion 2.59 kb/1 μm (Daigaku et al., 2010; Jackson and Pombo, 1998; Quinet 
et al., 2017). Length in kb was then divided by 20 minutes to give speed in kb/minute. 
Further information on fibre combing protocol is available in section 2.4.2. 
 
Figure 4.25 Five replication events can be quantified using fibre combing. Cells were pulsed for 20 
minutes each with CldU and IdU before being stained with BrdU antibodies, images taken 
on Olympus BX53 upright microscope and tracts analysed using ImageJ software. Five 
distinct replication events can be quantified by fibre combing, including replication fork 
progression, termination, bi directional initiation, new origins and stalled forks.  
 
 
As presented in Table 4.3 and Figure 4.26, although not statistically significant there were 
some minor differences in replication events between MGS vs WT cell lines noted. The 
percentage of stalled replication forks was slightly higher for LB128 (22.5%) than the 
control (11.2%), this is similar but less severe than what was seen in MISSLA patients 
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(Reynolds et al., 2017). There were also slightly fewer new origins of replication initiated 
in patient cells (19.1% WT, 12.1% LB128), particularly bi-directional replication forks 
(10.8% WT, 4.8% LB128). The number of progressing and terminating/colliding 
replication forks was the same between both groups (Figure 4.24). In MISSLA patients 
there were less progressing replication forks compare to WT, which is another point of 
difference. Based on this experiment it seems the MGS-DONSON phenotype has a less 
severe effect on the DNA replication than is seen in MISSLA cell lines.  
 
Figure 4.26 Percentage of fibre combing events in control and patient cells. Percentage of replication 
events in WT control cells and DONSON patient fibroblasts were quantified (N=601 total 
across three replicates). Number of new, stalled, bidirectional, terminating and 
progressing forks were counted and measured using image J. (Percentage of replication 





Table 4.3 Percentage of replication events in control or patient fibroblasts.  
 WT LB128 
Progressing forks 54.1% 55.6% 
Stalled forks 11.2% 22.5% 
New forks 19.1% 12.2% 
Bi directional forks 10.8% 4.8% 
Collision/termination of 
forks 4.8% 5.0% 
  
4.4.2 Replication velocity 
Tracts were measured and converted to kb/minute as described in section 4.4.1. 
Approximately 200 tracts were counted for each replicate as recommended by Quinet et 
al., 2017; Técher et al., 2013. A total of 601 tracts were counted across all three replicates 
for each cell line. 
Replication fork speed localised around 1 kb per minute in WT cells, while there tended 
to be much more variation in the replication fork speed in LB128 cells (Figure 4.27).  
 
Figure 4.27 MGS-DONSON variants lead to changes in replication fork velocity. Red and green tracts 
from progressing replication forks were measured using ImageJ software, converted to 
kb/minute and plotted using Prism GraphPad. Mean of triplicates: WT first pulse = 1.32 
kb/min, LB128 first pulse = 1.76 kb/min, WT second pulse = 0.97 kb/min, LB128 second 
pulse = 1.40 kb/min. 
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The range of mean replication fork speed in WT was 0.81-1.44 kb per minute while in 
LB128 it was 1.01-2.13 kb per minute. Overall, this suggests that LB128 cells seem to be 
replicating their DNA faster than WT cells. While this is not consistent with the reduced 
growth phenotype, it is similar to what was seen when Reynolds et al., 2017 knocked 
down DONSON expression using siRNA. Due to the large range of replication fork velocity 
present in LB128 cells we considered if this overall increase in replication forks was due 
to replication fork asymmetry. This is where one side of the replication fork replicates 
faster than the other side, this can lead to replication fork collapse and DNA damage as a 
result of double-stranded breaks. Replication fork asymmetry could also help explain the 
large amount of variation seen in replication fork speeds (Figure 4.27). 
We briefly followed up replication fork asymmetry by reanalysing fibre combing images 
to increase the number of bidirectional forks we had to analyse. Due to time constraints 
we were unable to count the recommended 100-200 tracts so this data is just a brief 
estimate at what may be going on. This needs to be repeated to increase the number of 
tracts counted from each replicate. 
As bidirectional tracts are not as common as progressing tracts (Figure 4.26) there were 
fewer tracts available to analyse. Ideally this experiment would be repeated to improve 
the number of tracts counted across the replicates. Although the number of bidirectional 
tracts counted was low there didn’t appear to be any obvious differences in replication 
fork symmetry (Figure 4.28). If such a conclusion holds, this could explain why we do not 
observe cellular or clinical phenotypes related to chromosomal instability in our MGS 





Figure 4.28 Replication fork symmetry. Replication fork symmetry appears similar between WT and 
LB128. Only one replicate performed due to time constraints.  
 
Potentially an increase in DNA replication speed could make up for delays elsewhere in 
replication explaining why a normal growth curve is seen in MGS patients after 1 year of 
age. Conversely this difference in replication speed could be an artefact and normal 
growth in DONSON-MGS patients may be due to a less severe effect on the DONSON 
protein which is tolerated better by the cells. 
In other MGS patients with variants in genes involved in early DNA initiation, we would 
not expect to see differences in replication speed between patient and WT. But as 
DONSON’s only known role is during replication it is interesting that we see increased 
replication speed but not due to replication fork asymmetry. 
Other MGS variants are thought to cause delays at the initiation of DNA replication not 
during replication so it would be interesting to repeat this experiment with other MGS cell 
lines to investigate differences in replication speed. Perhaps MGS growth is normal as G1 
phase may be delayed but is made up for in S-phase. To investigate this further this fibre 
combing experiment should be repeated with all DONSON-MGS patients as well as control 
cell lines from MISSLA, MIMIS and other MGS patients. 
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4.4.3 Discussion 
In this section we investigated differences in DNA replication initiation, progression and 
termination events in a patient-derived cell line harbouring biallelic DONSON variants. We 
saw a slight decrease in new replication origns and a slight increase in stalled forks but 
this was not significant or as extreme as is seen in MISSLA patients (Reynolds et al., 2017). 
More surprisingly we saw an increase in replication fork progression which does not 
correlate with the reduction in size seen in MGS patients. This was followed up by 
analysing replication fork symmetry, both to compare to the previous literature 
(Reynolds et al., 2017), and to investigate whether this increase in replication fork speed 
may be due to bidirectional replication forks progressing in a varying speeds leading to 
asymetrial replication forks – which are likely to stall. This also was not observed. As 
neither the change in replication events or increase in speed is particularly large perhaps 
this slight increase in replication speed compensates for the slight reduction in new forks 
and increase in stalled forks. 
Differences in the proportion and type of replication events in control and LB128 
fibroblasts suggests this MGS-DONSON variant may cause different effects at the 
molecular level than MISSLA-DONSON variants. As MISSLA and MGS patients present with 
different phenotypes it is expected we would see differences at the molecular level, 
however how DONSON functions at a protein level to cause these differences is unknown. 
Brain tissue is primarily affected in MISSLA and MIMIS patients (Evrony et al., 2017; 
Reynolds et al., 2017). The inability of DONSON to stabilise replication forks in tissues 
which undergo a large amount of cell division during development (i.e brain tissue) is 
obvious in these patients presenting with severe microcephaly. As our MGS-DONSON 
patients do not present with severe microcephaly we hypothesised that DONSON may 
play another role earlier in DNA replication which was contributing to the MGS 
phenotype.  
Based on evidence in this section and previous research (Abdelrahman et al., 2019; 
Evrony et al., 2017; Karaca et al., 2019; Reynolds et al., 2017; Schulz et al., 2018), it seems 
these DONSON-MGS variants may be causing a less extreme MISSLA phenotype. MGS-
DONSON variants cluster at the N-terminus of the protein, and while MGS-DONSON 
variants causing a less extreme phenotype explains the microcephaly differences it does 
not explain why MGS patients present with a global reduction in size, (or a more severe 
 133 
growth phenotype) than what is seen in MISSLA patients. How these differences in 
phenotype are caused is still unknown as we do not know the exact function of DONSON 
during replication. 
One hypothesis explaining the growth phenotype in MGS patients is that defective DNA 
replication proteins function relatively normally under standard conditions. However at 
a critical point in development when extra pressure is put on DNA replication due to 
maximal proliferation needed to keep up with standard development, the overall number 
of cells is reduced due to the inability to replicate ones DNA fast enough (Klingseisen and 
Jackson, 2011). This could help explain the subtle differences seen between control and 
LB128 especially in relation to the proportion of replication events 
Based on the research in this chapter, it is unknown how variants in DONSON are causing 
issues with nuclear localisation as DONSON does not appear to cause issues associated 
with replication fork stability in these patients, and yet does seem to cause issues with 
DNA replication initiation (a reduction in new origins). Previous research showed MISSLA 
was caused by the inability of DONSON to stabilise replication forks (Reynolds et al., 
2017), due to mis-localisation or reduced protein levels. In this chapter we showed that 
all five MGS-DONSON variants showed similar levels of mis-localisation either due to 
cytoplasmic or aggregate expression, however there is no evidence that this mis-
localisation of DONSON is leading to increase DNA damage or chromosomal instability 
associated with MISSLA. How exactly DONSON is still functioning at a level to stabilise 
these replication forks during S-phase is unknown. This may suggest that DONSON plays 
another currently undefined role earlier in DNA replication, and the small proportions of 
DONSON which is localising to the nucleus is successfully stabilising replication forks 
therefore not leading to the MISSLA phenotype. However as MGS is caused by defects in 
proteins essential for the initiation of DNA replication leading to an overall reduction in 
size it is thought that DONSON may play another role here which is not being tolerated 
either by the reduced protein levels due to mis-localisation or the position of missense 
variants in a domain important for this function. 
As DONSON plays such an important role in replication stability it would be beneficial to 
follow up double-stranded DNA damage and chromosomal instability in MGS patients. 
Although not directly investigated during this project, based on phenotypic data and 
limited replication fork dada we do not seem to see any markers of chromosomal 
instability. How DONSON is functioning normally (enough) to not lead to ds breaks and 
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yet still leading to the MGS phenotype is unknown and something that future studies 
should follow up. 
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5 Discussion and future directions 
MGS is caused by the inability to replicate one’s DNA in an appropriate time frame. In this 
study we investigated three novel MGS variants in three DNA replication genes. These 
genes caused varying levels of severity in terms of the MGS phenotype. These three 
variants are in genes known to act at three different stages of DNA replication: pre-
replication complex (late M-phase/ early G1 phase), pre-initiation complex (G1/S 
interphase) and replication fork progression (S-phase). 
 
 Novel AAA+ domain ORC1 variants 
ORC1 functions the earliest in DNA replication. It is active during late M/early G1 phase, 
as it is an important component of the ORC complex, the first complex to bind to origin of 
replication sites in the genome to initiate DNA replication. ORC1 has previously been 
reported to be involved in MGS. In previously published literature it was thought the MGS 
phenotype was caused by variants in the BAH domain (Kuo et al., 2012). The BAH domain 
is important recognising H4K20me2 present on the chromatin at origin of recognition 
start sites and loading the ORC complex onto the chromatin (Kuo et al., 2012; Zhang et al., 
2015). All previously reported ORC1-MGS patients had at least one variant in the BAH 
domain, therefore it was thought this may be the crucial domain, which leads to the often 
more severe height phenotype seen in ORC1 patients (Kuo et al., 2012; de Munnik et al., 
2012b). 
Although we did not manage to explore this gene in as much depth as we would have liked 
to during this study, we can still be reasonably confident this p.L622P variant is causing 
the MGS phenotype seen in this patient. LB005 c.1965T>C variant causes a p.L622P amino 
acid change in a highly conserved area of the protein. The AAA+ domain is important for 
ATP hydrolysis, as well as a range of other cellular activities essential for DNA replication 
including remodelling and loading subunits involved in DNA replication (Herbig et al., 
1999; Neuwald et al., 1999). LB005 is homozygous for a missense variant in the AAA+ 
domain. Previous literature has described other MGS patients to have heterozygous and 
homozygous missense and truncating variants in the AAA+ domain of ORC4, CDC6 and 
MCM5 (Bicknell et al., 2011b; Bongers et al., 2001; Guernsey et al., 2011; Kerzendorfer et 
al., 2013; Vetro et al., 2017). Due to this and the important role the AAA domain plays in 
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DNA replication (Herbig et al., 1999; Neuwald et al., 1999), it is likely this homozygous 
c.1965T>C variant is causing the MGS phenotype seen in this patient.  
This variant is also not present in gnomAD giving some evidence that it is not generally 
tolerated, however as this patient is of Saudi Arabian decent this population is under 
represented gnomAD and therefore may actually be present at a slightly higher 
proportion in this population. As the ORC1 splicing assay, was unable to be completed 
during this project, it should still be carried out to ensure our assumptions are correct and 
this c.1965T>C variant does not cause a splicing effect. 
Issues in the initiation of DNA replication by any member of the ORC complex will likely 
lead to fewer licenced origin of replication sites, leading to a delay in G1 phase progression 
or a reduction in back up licenced origins (Blow et al., 2011). In healthy cells there are 
always more origin of replication sites licenced than needed (dormant origins), which act 
as a reservoir ready for activation during replication to ensure timely completion of S-
phase (Ge et al., 2007). As only a small proportion of these origins are actively replicating 
at one time (McIntosh and Blow, 2012), there are plenty of back up sites which can be 
used if replication forks stall or terminate early due to replication stress (Woodward et 
al., 2006). During replication stress, dormant origins will fire leading to DNA replication 
being completed in a timely fashion (Blow and Ge, 2009; Blow et al., 2011; Ge et al., 2007; 
Woodward et al., 2006, 2006). ORC1-MGS variant likely lead to less efficient binding by 
ORC1 at the chromatin, leading to less dormant origins. During normal replication a large 
proportion of these dormant origins will not be required (Ibarra et al., 2008; McIntosh 
and Blow, 2012), however these dormant origins will be required in times of replication 
stress or increased proliferation during development. In these MGS patients we predict 
there are not enough of these origins present and so, when replication forks stall, they 
must wait to be restarted or there may end up being fewer active progressing replication 
forks altogether, leading to increased duration of S-phase DNA replication duration.  
ORC1 which does not function as it should could also lead to delays during G1 phase as it 
may take longer for the ORC complex to bind and recruit other proteins required for the 
preRC. Future research should investigate whether AAA+ domain ORC1 variants lead to 
fewer origins of replication during S-phase or delayed G1 phase progression. 
Bicknell et al., 2011a and Kerzendorfer et al., 2013 observed delayed S-phase entry and 
slower S-phase progression in patient cells harbouring ORC1 variants in the BAH domain 
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compared to control. S-phase progression was investigated using pulse BrdU labelling and 
pan-nuclear γ-H2AX immunostaining. To investigate delayed S-phase entry due to 
prolonged G1 phase, cells were serum starved to synchronise cells in G0, G1 phase was 
initiated by the addition of serum and BrdU was added to monitor S-phase entry by FACS. 
Experiments similar to this could be used to investigate the effect of the AAA+ domain 
variants on ORC1’s ability to function in cell cycle progression. Other experiments such as 
fibre combing could also be used to investigate whether these delays in S-phase are due 
to a lack of new origins or slower replication fork speed during S-phase  
Future study of these non-BAH domain ORC1-MGS variants should include investigating 
the chromatin loading ability of these, proportion of replication events during S-phase (as 
above) and the cells ability to progress through the cell cycle (as above).  
Previous research by Bicknell et al., 2011a showed a reduction in protein levels of both 
unbound and chromatin bound ORC1, as well as a reduction in other preRC proteins ORC2 
and MCM2. This was investigated by immunoblot of soluble and insoluble protein as well 
as chromatin-enriched fractions generated by micrococcal nuclease digestion (Bicknell et 
al., 2011a).  
The licencing ability of mutant ORC1 was also investigated by monitoring the replication 
of Epstein-Barr virus episomes (Bicknell et al., 2011a; Kerzendorfer et al., 2013). Epstein-
Barr virus is a 165 kb double-stranded DNA virus which requires a functional ORC 
complex to replicate (Dhar et al., 2001), therefore variants in ORC1 affecting the assembly 
of the ORC complex and its ability to load chromatin will result in less amplification than 
WT. 
As many of these techniques require cell lines containing the patient variants, it would 
therefore be extremely beneficial to have CRISPR editing working as a technique to 
achieve this in our laboratory, as patient cell lines were not available for these ORC1 
variants (as discussed in Section 3.7). 
 
 Novel CDC45 splicing variants lead to a severe MGS phenotype 
The next of our three novel variants to work in DNA replication is CDC45, this protein is 
important for preIC firing and displacing the leading strand during replication fork 
progression (Karnani and Dutta, 2011; Köhler et al., 2016; Pacek and Walter, 2004; Wong 
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et al., 2011). CDC45 is therefore different to other published MGS genes which tend to 
work earlier in DNA replication (preRC). Previously described CDC45 patients also 
generally present with a slightly different phenotype to other MGS patients (Fenwick et 
al., 2016). It was thought this difference in phenotype may be due to CDC45 working later 
in replication than the other MGS genes.  
RECQL4 is a replication gene which is involved in a range of disorders and associated 
phenotypes. Variants in RECQL4 cause Rothmund-Thomson syndrome, Ballier–Gerold 
syndrome and RAPADILINO syndrome. These syndromes cause a wide range of disorders, 
with Rothmund-Thomson syndrome patients presenting with short stature (delayed 
growth) and increased risk of cancer (overgrowth). While precise geneotype-phenotype 
correlations are not fully understood (Kellermayer, 2006), this range of phenotypes is 
thought to be due to RECQL4 interacting with many different proteins and pathways 
during DNA replication and cell cycle progression (Capp et al., 2010; Khakhar et al., 2003; 
Kitao et al., 1998; Matsuno et al., 2006; Sangrithi et al., 2005; Siitonen et al., 2009). 
As the CDC45 variant (c. 1441-2 A>G) studied here lead to a more severe phenotype, it is 
hypothesised that the severe knockdown alongside the lack of any CDC45 canonical 
transcript being present in the cell has led to CDC45 functional issues at multiple point in 
replication, therefore leading to the more severe MGS and secondary phenotypes. 
The CDC45 patients studied, presented with a more severe phenotype than typically seen. 
Due to this we hypothesised these patients may have a more severe knock down of CDC45 
than previously described. While our collaborators hypothesised these siblings may have 
an almost complete loss of CDC45, it is unlikely an embryo with a complete knockout of 
CDC45 would be viable, as CDC45 plays such an integral role in DNA replication. The 
72.9% reduction in CDC45 expression is less severe than what has been seen in previous 
CDC45 patients presenting with a less severe phenotype (Cooper, 2016; Fenwick et al., 
2016). Due to this we expected to see differences in protein stability between the WT-
CDC45-FLAG plasmid and the 6bp_del-CDC45-FLAG plasmid. Unfortunately it was hard to 
tell from our western blot whether or not there was a reduction in protein stability. 
Unlike in our CDC45 patients previous CDC45 splicing variants resulted in some full length 
canonical transcript remaining (Fenwick et al., 2016). In LB192 the remaining 27.1% 
CDC45 protein expressed contained a two amino acid deletion, although this two amino 
acid deletion did not appear to cause problems with protein stability, it could be leading 
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to other issues in DNA replication which we were not able to cover during this project. 
Issues could include CDC45′s ability to displace the leading strand during replication or 
interact with other components of the replication fork during S-phase. We can also not 
rule out the possibility these patients contain another variant(s) in a different gene(s) that 
could be contributing to the phenotype.  
Future study of this CDC45 splicing variant is required to better understand the full effect 
of this novel variant. Future work could include investigating the effect of this two amino 
acid deletion on the ability of CDC45 to interact with other members of the preIC and 
replication complex, as well how this splicing variant affects the cells ability to progress 
through the cell cycle. 
The difference in phenotype between the CDC45 splicing variant in this study and in the 
CDC45 splicing variant in Fenwick et al., 2016 is striking. Between two splicing variants in 
CDC45 we saw phenotypes ranging from mild MGS to craniosynostosis to the very severe 
phenotype seen in LB191 and LB192. These major differences in phenotype could be 
better investigated in animal models of development, such as Danio rerio or Mus musculus. 
It is possible other proteins during development are somehow compensating for the 
reduction in CDC45 expression in certain tissues during development, this may not 
happen all of the time therefore leading to a less severe phenotype in some patients but 
not others.  
Using an animal model would also allow us to investigate how proteins such as DONSON 
may interact with other members of the preIC and replication fork during development. 
As DONSON’s role in DNA replication was only recently discovered, exactly how and 
which proteins DONSON interacts with is uncertain. As both CDC45 and DONSON cause 
MGS as well as other diseases future studies should investigate their role and possible 
interactions during development. D. rerio would allow us to attempt to rescue CDC45-MGS 
or DONSON-MGS phenotype using other proteins suspected to be involved in the pathway. 
An animal model could also be used to further investigate when in development the MGS 
phenotype arises giving us some idea of the time point that knockdown of DNA replication 
is not tolerated in an organism 
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 Novel MGS gene DONSON’s role in MGS 
While variants in CDC45 causes a difference in phenotype, thought to be due to it working 
later in replication, we do not see a difference in phenotype between our MGS-DONSON 
and other MGS patients. In terms of protein function this is unexpected, as DONSON’s only 
known role is during S-phase, later in DNA replication than other MGS genes are known 
to act. All other MGS variants play integral roles in early DNA replication, to us this 
suggests that DONSON may have other undiscovered roles earlier in DNA replication. Due 
to no differences in phenotype between DONSON-MGS patients and other MGS patients, 
this suggests that all variants cause similar problems in DNA replication, leading to the 
same overall effect on the cells and individual as a whole.  
The majority of MGS-DONSON variants clustered away from other MISSLA and MIMIS-
DONSON variants. This could suggest the N-terminal of DONSON may be important for 
interacting with other proteins/pathways during replication. 
Four of the five MGS-DONSON variants showed diffuse cytoplasmic expression. 
Suggesting that MGS-DONSON variants cause similar issues with DONSON localising to 
the nucleus as MISSLA variants do. While indicative that these variants are pathogenic, 
this does not explain the difference in phenotype between these different syndromes. It 
is expected that issues with DONSON localising to the nucleus would also impair 
DONSON’s ability to stabilise replication forks. Based on our limited fibre combing data, 
we did not see this as there was no difference in replication fork symmetry. Data in this 
project suggest that these DONSON-MGS variants may be causing a more subtle effect on 
DONSON than what is seen in MISSLA patients.  
As DONSON’s role in replication has only recently been discovered, there is still much we 
do not understand about how it functions and what proteins it interacts with. Therefore 
DONSON’s molecular role in MGS requires more extensive research to better understand 
the role it is playing in MGS and DNA replication.  
 
 Future directions 
Next I will describe some suggestions for future studies. These include, following up 
replication forks asymmetry and confirming this is not the cause of increased replication 
fork speed seen in LB128.  
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As done in previous research (Reynolds et al., 2017) we could also add replication stress 
to these cells in between pulses to investigate how this effects the cells ability to restart 
DNA replication. Adding replication stress to DONSON-MGS variants would likely 
exacerbate any differences seen between patient and control, as DONSON would be 
required to stabilise these stalled replication forks for a period of time. Therefore we 
would be able to see if our MGS-variants are better or worse at stabilising replication forks 
and restating replication than MISSLA-DONSON variants are. As we don’t seem to see any 
chromosomal instability in our MGS patients we would expect MGS-DONSON variants are 
better at stabilising replication forks than MISSLA-DONSON variant are. 
Fibre combing could also be used to investigate the proportion of replication events in 
other MGS patients, ORC1 vs CDC45 vs DONSON, as this could give us an insight into how 
MGS variants in different DNA replication genes effect DNA replication events and speed. 
We would expect to see slight differences in replication events depending on what gene 
the variant is in. For example with our CDC45 variant we would expect to see less new 
origins firing as CDC45 is a rate limiting step in replication as it is recycled between 
origins (Musiałek and Rybaczek, 2015). While in ORC1 variants we may expect to see 
normal replication under normal conditions as these variants are thought to primarily 
effect G1 phase (Stiff et al., 2013). If we exposed these ORC1 variants to replication stress 
by the addition of hydroxyurea (which inhibits the incorporation of nucleotides (Vesela 
et al., 2017)), we may see fewer newer origins as we hypothesise there may be less 
dormant origins due to ineffective chromatin loading by ORC in G1 phase. This could 
potentially lead to a better understanding of why MGS patients with variants in ORC1 and 
ORC4 present with the most severe height phenotype.  
One aspect of the project we still do not understand is what the GFP-aggregates present 
in p.R211C transfected HeLa cells are and what they could be localising with. We 
confirmed that these aggregates are not localising with mitosis and they don’t seem to 
lead to an increase in DNA damage but more experiments need to be performed to confirm 
this.  
As mentioned previously the effect of MGS-DONSON variants on DNA damage is 
something that requires further investigation. Not enough cells or replicates were 
performed (due to time constraints) with p.R211C plasmid to definitively conclude the 
effect of this variant on DNA damage. The experiment should be repeated with all five 
MGS-DONSON variants as well as controls and MISSLA variants to investigate the 
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differences in DNA damage between MGS-DONSON variants and MISSLA-DONSON 
variants. 
There is no solved structure of DONSON, therefore it is difficult to understand how 
variants in different areas may be affecting the protein as DONSON shows no similarities 
to other proteins and no clear domains are predicted (Reynolds et al., 2017). One option 
for exploring what areas of the protein are important could be to delete different sections 
of the gene and observe the effect on DONSON function. As the majority of our MGS-
DONSON variants cluster towards the N-terminus of the protein we may find that small 
deletions or missense changes in this area lead to a MGS effect whereas deletions or 
missense changes at the C-terminal lead to a MISSLA or MIMIS phenotype.  
This project describes differences in phenotypic and molecular consequences of DONSON 
variants in MGS and MISSLA patients. Many of these experiments lead us to believe 
DONSON may play another role earlier in DNA replication than previously thought. Due 
to the lack of knowledge about how DONSON directly interacts with proteins of the 
replisome during replication it is important to follow on from this project to better 
understand DONSON’s role in DNA replication. In depth investigation of DONSON’s 
interactions with components of the preIC could be performed via pulldown. Based on 
experimental data, we hypothesize that we may see DONSON localising with some 
components of the preIC although what role it may be playing in early DNA replication is 
unknown.  
 
 DNA replication 
Overall, these three novel MGS variants show how variants at multiple stages of DNA 
replication can lead to disease. Although all three variants cause effects on DNA 
replication in different ways, they all lead to the same overall phenotype of a global 
reduction in size. While there is still much to be uncovered about these MGS genes and 
variants this project has given us a good baseline on where to move forward from here.  
Replication disorders cause a range of disorders and phenotypes from delayed growth to 
overgrowth (Jackson et al., 2014; Klingseisen and Jackson, 2011; Mazouzi et al., 2014; 
O’Driscoll, 2017). There are many genes involved in many stages of DNA replication which 
lead to disease, due to the essential role these encoded proteins play in the cell (O’Driscoll, 
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2017). DNA replication is a complex process, involving many more proteins and pathways 
than are discussed in this thesis. Primordial dwarfisms are a group of disorders which 
group together as they are all cause restricted growth throughout development and are 
caused by genes working in similar pathways (Khetarpal et al., 2016; Müller et al., 2012). 
As shown in this thesis and previous literature single genes can cause a wide range of 
phenotypes due to the diverse role many of these proteins play in the cell. Many proteins 
for example CDC45 and RECQL4 act in multiple stages of the cell cycle and therefore lead 
to a range of phenotypes and disorders. This is likely due to these proteins interacting 
with multiple other proteins and pathways. Therefore depending on where the variant is 
the phenotype may differ due to different pathways being effected.  
Replication disorders give us a unique opportunity to study the effects of single proteins 
on replication and cell cycle progression as a whole. While this process is complex, the 
ability to study the effects of these replication disorders helps better our general 
understanding of the different roles and pathways these proteins are involved in. 
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6 Conclusions 
This project investigated the effect of three novel MGS variants on DNA replication using 
a variety of techniques. While we were unsuccessful at using CRISPR techniques to knock 
in these variants in near-diploid cell lines we gained some valuable insight as to what 
doesn’t work and how it might be going wrong. This along with new techniques being 
published on a regular basis may allow us to successful use CRISPR to knock in our patient 
variants in the future. Although in depth analysis of all three variants could not be 
performed within the scope of the project, this project allowed us to gain valuable insight 
into how these variants effect DNA replication at different stages, and lead to disease. 
While there is still much to explore, this project has allowed us to better understand how 
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Appendix A 
General reagents and primers 
A.1 General reagents 
- 0.25% Trypsin-EDTA (Thermo Scientific - 25200-072) 
- 0.5 M EDTA pH8 (Thermo Scientific - 180-500G) 
- 10% APS (Sigma-Aldrich - A3678-25G) 
- 10% SDS (Sigma-Aldrich - 436143-100G) 
- 100 bp DNA ladder (Genesearch - N3231L) 
- 10x Buffer G (Thermo Scientific - BG6) 
- 10x FastAP Buffer (Thermo Scientific - EF0651) 
- 1 kb DNA ladder (Genesearch N3232S) 
- 1 M CaCl2  (Thermo Scientific - AJA127-500G) 
- 1 M NaCl (LabServ - BSPSL944.500) 
- 1 M NaOH (Sigma-Aldrich - S5881-500G) 
- 1x cOmplete™ Mini, EDTA-free Protease Inhibitor Cocktail mix (Sigma-Aldrich – 
4693159001) 
- 2x ReddyMix PCR Master Mix (Thermo Scientific - ABGAB-0575/DC/LD/A) 
- 2.1 buffer (NEB - B7202S) 
- 2x Phusion Flash PCR Master Mix (Thermo Scientific - F548S) 
- 3 M Sodium acetate (Thermo Scientific - R1181) 
- 50% Glycerol (Thermo Scientific - BSPGL885-500ML) 
- 5x big dye buffer (GAS Otago) 
- 70% ethanol (Pathology Store) 
- Acetic acid (BDH – Lot K286717101) 
- Agarose (MediRay - FBAG100) 
- Amphotericin B aka Fungizone (Thermo Scientific – 15290018) 
- Ampicillin (Sigma-Aldrich - A5354-10ML) 
- Anti-mouse 488: Alexa Fluor (Thermo Scientific - A-11001) 
- Anti-phospho-Histone H2A.X (Ser139) (merk millipore 05-636) 
- Anti-Rat 594: Alexa Fluor (Thermo Scientific - A-11007) 
- Bbsl Restriction enzyme (Thermo Scientific - ER1011) 
- Big Dye Master mix (GAS Otago) 
- Blocking solution - (7% FBS, 0.1% Triton X-100 in PBS) 
- BSA (Sigma-Aldrich - A3733-50G) 
- BsrGI restriction enzyme (Genesearch - R0575S) 
- CDC45 antibody (Bio-Strategy - sc-55569) 
- Chemically competent E.coli Top10 
- CldU: (Sigma-Aldrich - C6891-100 mg) 
- Cutsmart buffer (NEB - B7204S) 
- DAPI (Sigma-Aldrich - D9542-1MG) 
- DMEM (Thermo Scientific - 11995.065) 
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- DMEM/F12 (Thermo Scientific – 11330032) 
- DMSO (Sigma-Aldrich - D8418-50ML) 
- DNeasy Blood & Tissue Kit (Bio-Strategy - 69504) 
- DpnI restriction enzyme (Genesearch - R0129S) 
- DreamTaq Green PCR Master Mix (2X) (Thermo Scientific - K1082) 
- Ethanol (Pathology Store) 
- Exonuclease (Thermo Scientific - EN0582) 
- FastAP alkaline phosphatase (1 u/μL) (Thermo Scientific - EF0651) 
- Fetal bovine serum (Morgate Biotech - Batch #48827103) 
- GeneJET Gel Extraction Kit (Thermo Scientific - K0691) 
- Gibson Assembly® Master Mix (Genesearch - E2611S) 
- Glycerol (Thermo Scientific - BSPGL885-500ML) 
- HCl: 30% (Lab Supply - MER103181000) 
- Hygromycin B (Sigma-Aldrich – 10843555001) 
- IdU: SIGMA (I7125-5 g) (Abcam - ab142581) 
- IRDye 800CW goat anti-mouse secondary antibody diluted 1:25,000 (Millenium 
Science NZ) 
- Isopropanol (BDH - 102246L) 
- Kanamycin (Sigma-Aldrich K0254-20ML) 
- LB Agar (Oxoid - CM0131) 
- Loading Dye Purple (6X) no SDS (NEB - B7025S) 
- Lipofectomine 2000 (Thermo Scientific - 11668-027) 
- Lipofectomine 3000 (Thermo Scientific - L3000001) 
- Methanol (Fisher Scientific - M/4000/17) 
- GeneJET Midi Plasmid prep kit (Thermo Scientific - K0481) 
- GeneJET Mini Plasmid prep kit (Thermo Scientific - K0502) 
- Mounting medium: SIGMA (F6182-20 ml) 
- Mouse anti-BrdU: Becton Dickinson (347580) 
- Mouse anti-CDC45 (Bio-Strategy cat. no. sc-55569) 
- Opti-MEM reduced serum media (Thermo Scientific - 31985062) 
- Paraformaldehyde (Sigma-Aldrich - P6148-500G) 
- PCS2+Cas9-mSA (Addgene plasmid #103882) 
- Penicillin/Streptomycin (Thermo Scientific - 15140-122) 
- Pierce™ Rapid Gold BCA Protein Assay Kit (Thermo Scientific - A53226) 
- PowerUp™ SYBR™ Green Master Mix (Thermo Scientific - A25741) 
- Precision Plus Protein Dual Colour Standard (Bio-Rad – 1610374) 
- ProLong™ Diamond Antifade Mountant (Thermo Scientific - P36965) 
- pSpCas9(BB)-2A-GFP (PX458) (Addgene plasmid #48138) 
- Qubit™ dsDNA BR Assay Kit (Thermo Scientific - Q32850) 
- QuickExtract™ DNA Extraction Solution (Mediray - QE0905T) 
- Rat anti-BrdU: (AbD SeroTec (OBT0030G) 0.25 mg) 
- RIPA buffer (Thermo Scientific - 89900) 
- RNeasy Mini Kit (Bio-Strategy - 74104) 
- SacI restriction enzyme (Genesearch - R3156S) 
- Sodium acetate solution (Thermo Scientific - R1181) 
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- Sodium chloride (NaCl) (LabServ - BSPSL944.500) 
- SuperScript™ IV VILO™ Master Mix with ezDNase enzyme (Thermo Scientific - 
11766050) 
- SYBRSafe (Thermo Scientific - S33102) 
- 10X T4 ligation buffer (NEB - B0202S) 
- T4 PNK (10 u/μL) (NEB - M0201S) 
- Taq (α) 1 restriction enzyme (Genesearch - R0149S) 
- TEMED (Sigma-Aldrich - T9281-25ML) 
- Tris UltraPure (Invitrogen 15504020) 
- Triton X-100 (Sigma-Aldrich - T8787-50ML) 
- Tryptone (Oxoid - LP0042) 
- Tween 20 (Sigma-Aldrich - P1379) 
- Yeast extract (Oxoid - LP0021) 
- Zombie NIR™ Fixable Viability Kit (MediRay BIO423105) 
 
 
A.2 General buffers 
1x Phosphate Buffered Saline (PBS)  
- Add one Oxoid Phosphate Buffered Saline (Dulbecco A) tablet per 100 mL of 
distilled water.  
- Mix until dissolved and autoclave at 121 °C for 20 minutes + to sterilise. 
 
LB media 
- Dissolve 10 g Tryptone, 10 g NaCl, & 5 g Yeast extract in 1 litre of distilled water.  
- Add no more than 400 mL LB per 500 mL Schott bottle and autoclave at 121 °C for 
at least 20 minutes to sterilise. 
 
MACS buffer  
- Autoclave PBS and EDTA solutions 
- In a clean hood make a 1X PBS pH 7.2, 2 mM EDTA solution  
- Add FBS to a final concentration of 1% and filter sterilise (0.2 μm) MACS buffer 
into sterile 50 mL Falcon tubes 
- Store at 4 °C. 
 
Tris-HCl 
- 0.5 M, 1 M pH 7.4, 1.5 M pH7.5 or 2 M pH5 Tris-HCl solutions were made by 
dissolving the appropriate amount of UltraPure Tris in MilliQ water before 
adjusting to the desired pH using HCl. 
 
Tris/Borate/EDTA (TBE) solution (2.5x stock) 
- Dissolve 26 g Tris and 12.75 g Boric acid in ~900 mL distilled water.  
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- Once dissolved add 10 mL 0.5 M EDTA pH8 and make up solution to 1 litre.  
- Dilute 2.5x TBE stock to 0.5x TBE before use. 
 
10x Western Buffer  
- Dissolve 144 g Glycine and 30 g Tris in a total volume of 1 litre. 
 
A.3 Primer list 
CRISPR  
ORC1 sgRNA_F caccggCCACAGAAGGTCGAGctgcc 
ORC1 sgRNA_R aaacggcagCTCGACCTTCTGTGGcc  





ORC1 CRISPR seq_F aaagtcctggctcccttctc 
ORC1 CRISPR seq_R aaagtgcggggtttacagg 
DONSON sgRNA_F caccggGGCTCTGCTGGAAGGTACAA 







DONSON CRISPR Seq_F cggcttaccattacatctgg 




























mSAfrag_cPCR_R TCCATTCAACACGCCATTCCAG  
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DONSON 
Mutagenesis   
DONSON_pR211C_S  CAAACTCTCCTCTGAGCTCTGTTGTACCTTCCAGCAG 
DONSON_pR211C_AS  CTGCTGGAAGGTACAACAGAGCTCAGAGGAGAGTTTG 
DONSON_pY270C_S  GTGAGCTTTACTTCTCTATGTAATTTGCTGAAGACAAAAC 
DONSON_pY270C_AS  GTTTTGTCTTCAGCAAATTACATAGAGAAGTAAAGCTCAC 
DONSON_pP545L_S  GAGCAACTTAGTCAAATACTGTTACTTGGGAAATCATC 
DONSON_pP545L_AS  GATGATTTCCCAAGTAACAGTATTTGACTAAGTTGCTC 
DONSON_pP224S_S  CTTATCTATTGGCTCCACTCTGCTTTGTCTTGGCTAC 
DONSON_pP224S_AS  GTAGCCAAGACAAAGCAGAGTGGAGCCAATAGATAAG 
DONSON_pF165S_S  GTCTATCAAAACGCGACTCCTTTCCACCTCTTCTCAACCC 
DONSON_pF165S_AS  AAGGGTTGAGAAGAGGTGCTAAGGAGTCGCGTTTTGATAG 
DONSON Sequencing 
primers   
DONSON_seq_F1  GTACTGAGTTACCCGTAGATTGGTCTATC 
DONSON_seq_F2 GACATACTTTCTATCAAGCTGCG 
DONSON_seq_R1  ACAGATTCAGGTCTGTGATCC 
DONSON_seq_R2 TGCCCAGGTAAAGGGTTGAG 
DONSON_seq_F3  TCATGTTAGCTGATAAAATCTTTAGG 
DONSON_seq_R3  TGCAAAGGAGAGCATTTCAC 
DONSON_seq_F4  GGCTTACCATTACATCTGGCTC 
DONSON_seq_R4  CCTTCTGCCATTAACGTATCC 
DONSON_seq_F5  GCGAGTCCTCATAACCAATTTC 
DONSON_seq_R5  AAAAGTTTGCGGACTGCTG 
DONSON_seq_F6  TGTCTCATGCATCTCAGTTGG 
DONSON_seq_R6  ATTTCCCATTTGCAAGGAAG 
EGFP_seq_F1  GGAGTACAACTACAACAGCC 
EGFP_seq_R1  TCCGTCGGAGCCGCACTAC 
pEGFP_seq_F1  CAGAGCTGGTTTAGTGAACCGTCAG 
pEGFP_seq_R1  AGGCACAGTCGAGGCTGATC 
M13F  GTAAAACGACGGCCAG 
M13R  CAGGAAACAGCTATGAC 
RT-PCR   
RT-PCR_F GCCTCTCCAGGAGTAACCTG 
RT-PCR_R GGACAGGAGGGAAATAAGTG 
























cPCR_R CTG TAA GGG TCT TAC TCC CTT G 
cPCR_R_2 TGC CGC ATG GTT GGC TGT TG 
RT-PCR 
oligonucleotides  
Rat_F Rat_INS2_Ex2_F CCTGCTCATCCTCTGGGAGC 
Rat_R Rat_INS2_Ex3_R AGGTCTGAAGGTCACGGGCC 








B.1 Chemically competent E.coli top10 protocol 
 
50 mL of the following solutions were prepared and autoclaved: 
1 M CaCl2 
1 M Tris-HCL pH 7.4 
50% Glycerol 
 
Chemically competent E.coli Top10 preparation: 
- 10 mL LB was inoculated with approx. 5 μL of an aliquot of Karen’s competent 
E.coli Top10 cells. 
- The culture was incubated overnight at 37 °C, 200 rpm 
 
Chemically competent E.coli Top10 prep: 
- 2 mL of the overnight culture was used to inoculate 200 mL LB in a sterile 1 L 
conical flask. 
- The culture was incubated at 37 °C, 250 rpm for 2-4 hours until an OD600 nm of 
0.2-0.5 (~5 x 107 cells/mL) was reached (measurements were take every 30-60 
minutes). 
- OD600 nm = 0.047 (NanoDrop measurement) 
- The flask was chilled on ice for 10 minutes. 
- The culture was transferred to sterile 50 mL falcon tubes and centrifuged (3220 
g, 15 min, 4 °C). 
- The supernatant was discarded, and the cells were resuspended in 100 mL ice-
cold 50 mM CaCl2, 10 mM Tris-HCL pH 7.4. 
- Cells were incubated on ice for 15 minutes and then re-centrifuged (3220 g) 15 
min, 4 °C). 
- The supernatant was discarded, and the cells were resuspended in 5 mL ice-cold 
50 mM CaCl2, 10 mM Tris-HCL pH 7.4, 10% Glycerol. 
- Cells were aliquoted (100 μL) into small Eppendorf tubes, snap frozen with liquid 
nitrogen and placed in the -80 °C freezer. 







B.2 SDS PAGE gel 
2x 10% 1 mm separating gels: 
Separating buffer  – 3 ml 
40% bis acrylamide – 3 mL  
10% SDS  – 120 μL 
10% APS  – 120 μL 
TEMED  – 10 μL 
MilliQ water  – 5.75 mL 
 
2x 1 mm stacking gels: 
Stacking buffer – 2.5 ml 
acrylamide  – 1 mL  
10% SDS  – 100 μL 
10% APS  – 100 μL 
TEMED  – 10 μL 
MilliQ water   – 6.29 mL 
 
B.3 CRISPR FACS protocol 
Bulk FACS sort 
Cells were visualised under the cell culture room microscope and appeared healthy. 
Cells were visualised under the Olympus IX71 inverted light microscope with brightfield 
and GFP (488) filter. Both bright field and GFP images were taken for reference. 
 
- Approx. 10 mL of prewarmed fresh Complete Growth Medium (10% FBS, 0.01 
mg/mL Hygromycin B, 1x penicillin/streptomycin in Hyclone DMEM: F12 
medium) was added to each well.  
- The samples were then passed through sterile 70 μm cell strainers into a 50 mL 
falcon tubes.  
- Cells were harvested by centrifugation (300 g, 5 minutes at room temperature).  
- Cell pellets were resuspended in 1 mL sterile MACS buffer.  
*Note: MACS buffer (1X PBS pH 7.2, 2 mM EDTA, 1% FBS) was generated in the clean 
hood from autoclaved PBS and EDTA stocks. The buffer was filter sterilise (0.2 μm) into 
sterile 50 mL falcon tubes after FBS was added and stored at 4 °C.  
- Cells were transferred to 15 mL falcon tubes. 
- A 250 μL aliquot of the not transfected hTERT-RPE-1 control sample was taken 
for heat-kill treatment.  
- The heat-kill aliquot was incubated at 80 °C for 2 minutes.  
- 250 μL non heat-killed not transfected hTERT-RPE-1 control sample was added 
to the heat-killed aliquot resulting in a 1:1 ratio of live to dead cells.  
- Cells were again harvested by centrifugation (300 g, 5 minutes at room 
temperature).  
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- Cell pellets were resuspended in 100 μL sterile MACS buffer.  
- 1 μL Zombie dye was added to each of the cell suspensions to generate the 
following samples:  
 
C1. hTERT-RPE-1 cells – not transfected (unstained).  
C2. hTERT-RPE-1 cells – not transfected (with Zombie dye).  
C.3 hTERT-RPE-1 cells – GFP positive cells.  
1. hTERT-RPE-1 cells – CRISPR Experiment. 
 
- The samples were kept in the dark after the addition of the Zombie dye.  
- Samples were incubated at room temperature for 30 minutes.  
- The cells were harvested by centrifugation (300 g, 5 minutes at room 
temperature).  
- Cell pellets were resuspended in 0.5 mL sterile MACS buffer and placed on ice.  
 
15 mL labelled falcon tubes containing 5 mL CGM, the samples and spare sterile MACS 
buffer (on ice), were taken over to the Microbiology building, 4th floor Room 414.  
- Michelle Wilson calibrates and tests the drop delay of the FACS Aria instrument.  
- Samples were bulk sorted.  
- Once transported back to Pathology cells were plated ~2000-4000 cells per 24 
well.  
- Cell cultures were incubated 37 °C, 5% CO2. 
 
Single cell FACS sort (1 week later)  
- The cells were visualised under the cell culture room microscope and appeared 
healthy and ~80% confluent. 
- Following the removal of media from the 24-well plate (using aseptic technique in 
the cell culture hood), cells were trypsinized by adding 0.1 mL Trypsin solution (per 
well) and incubating at 37 °C, 5% CO2 for 10 minutes. 
- Two mL of prewarmed fresh Complete Growth Medium (10% FBS, 0.01 mg/mL 
Hygromycin B, 1x penicillin/streptomycin in DMEM:F12 medium) was added to 
each well. 
- Samples were passed through sterile 70 μm cell strainers into 50 mL falcon tubes. 
- Cells were harvested by centrifugation (300 g, 5 minutes at room temperature). 
- Cell pellets were resuspended in 1 mL sterile MACS buffer. 
- Control cells were split into two 0.5 mL aliquots. 
- A 250 μL aliquot of the untransfected control sample was taken for heat-kill 
treatment. 
- The heat-kill aliquot was incubated at 80 °C for 2 minutes. 
- This was added to the remaining 250 μL control cells (not heat killed) resulting in a 
1:1 ratio of live to dead cells. 
- Cells were again harvested by centrifugation (300 g, 5 minutes at room 
temperature). 
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- Cell pellets were resuspended in 100 μL sterile MACS buffer. 
- Cells were transferred to 15 mL falcon tubes. 
- One μL Zombie dye was added to each of the cell suspensions to generate the 
following samples: 
1. hTERT-RPE-1 cells – not transfected (unstained). 
2. hTERT-RPE-1 cells – heat killed (with Zombie dye). 
3. hTERT-RPE-1 CRISPR sample (with Zombie dye). 
 
- Samples were kept in the dark after the addition of the Zombie dye. 
- Samples were incubated at room temperature for 30 minutes. 
- All samples were harvested by centrifugation (300 g, 5 minutes at room 
temperature). 
- Cell pellets were resuspended in 0.5 mL sterile MACS buffer and placed on ice. 
- 96 well U bottom plates containing 100 μL CGM per well were prepared. 
- The samples, 96 well U bottom plates (containing 100 μL CGM) and spare MACS 
buffer were taken over to the Microbiology building, 4th floor Room 414.  
- A single cell was sorted into the inside wells in the 96 well plate (60 cells/plate).  
- Plates were transported back to the laboratory on ice. 
- Incubate cell cultures at 37 °C, 5% CO2. 
 
Media change  Every 3-4 days 
- Replace media in 96-well trays with prewarmed fresh Complete Growth Medium.  






PBS     100 mL 
Bovine serum albumin (BSA) 0.25 g 
Triton X-100    300 μL 
 
Blocking solution 
PBTx-BSA       980 μL 
Normal serum (species that secondary was made in) 20 μL   
 
- Wash cells 4 x 2 minutes in PBS at room temperature. After removing the final 
PBS wash, add 500 μL blocking solution & incubate at room temperature for 1 h. 
- Dilute the primary antibody in 200 μL blocking solution add to each well. 
- Incubate overnight at 4 °C. 
- Wash 4 x 2 minutes in PBS.  
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- Make up fluorescent secondary antibody solution in PBTx-BSA and add ~250 μL 
room temperature for 1.5 h. 
- Wash 4 x 2 minutes in PBS. Leave coverslips in the final rinse. Mount coverslips 
onto glass slides by inverting onto drops of fluorescent mounting medium. Leave 
in the dark to cure for a couple of hours. 
 
B.5 DNA fibre combing 
Reagents 
Spreading buffer: 200 mM Tris pH 7.5, 50 mM EDTA, 0.5% SDS. 
HCl: 37% Fisher Scientific. 
Blocking solution (200 ml): 2 g BSA, 200 µl Tween 20, made with PBS (non-sterile). 
Rat anti-BrdU (1:750): AbD SeroTec (OBT0030G) 0.25 mg. 
Mouse anti-BrdU (1:750): Becton Dickinson (347580). 
Anti-Rat 594 (1:500): Alexafluor. 
Anti-mouse 488 (1:500): Alexafluor. 
Mounting medium: SIGMA (F6182-20 ml). 
Fixative: Methanol / acetic acid (3:1). 
CldU: SIGMA (C6891-100 mg). 
IdU: SIGMA (I7125-5 g). 
 
CldU: 6.6 mg in 10 mL medium. Vortex to dissolve. Store at -20 °C. 
IdU: 8.9 mg in 10 mL medium. Heat to 60 °C and vortex to dissolve. Store at 4 °C. Prior to 




Prepare everything for the experiment so cells are maintained in correct conditions at 
all times, including ice box for PBS and tubes. 
- Grow sub-confluent cells within 6-well plate (minimal size being a 24-well plate) 
with volume of 2 mL medium. 
- Add 25 µM CIdU to cell samples and incubate cells at 37 °C for 20 minutes. 
- Remove CldU and rinse 3x with warm PBS. 
- Add 250 µM IdU to the cells and incubate cells at 37 °C for 20 minutes. 
- Remove medium/ IdU solution and wash cells 2 x with PBS (non-sterile). 
- Trypsinize cells from the well. 
- Re-suspend cells in 1 mL ice-cold PBS and transfer to ice-cold 1.5 mL eppendorf. 
 
Counting cells 
Make sure cells are suspended well in the tube before taking a small sample. 
Count cells using the MOXI counter. 
Optimal concentration: 50 x 104 cells/ml. 
Calculate concentration and adjust accordingly to optimal. 
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At this stage, cells can be stored on ice for a maximum of 1-2 hours. 
 
Spreading fibres on slides 
- Upon a piece of paper towel, lay out 5 slides per sample (accounting for things 
going wrong) and number with pencil. 
- Make small aliquots of the spreading buffer (200 mM Tris pH 7.5, 50 mM EDTA, 
0.5% SDS) for each sample i.e. ~40 µl/tube for each sample. 
- Place 2 µl of the sample onto each slide, near to the frosting, and allow to slightly 
dry, i.e. the edges of the drop become crinkly: ~6 minutes. 
- Directly on top of each, place 7 µl of the spreading buffer (using the same tip, 
taking care not to touch the slide) and then stir the two together on the slide with 
the tip (~ 5 x). 
- Incubate for 2 minutes at RT. 
- Tilt the slides briefly to set the drop moving and then leave at a smaller angle 
(slide sitting on the end of a PCR test tube rack), for drops to slide down the slide 
gradually, however don’t allow the drop to dry. 
- Allow excess liquid to run off the end, and leave to air-dry for at least 2 minutes. 
- Place slides directly into MeOH/ AcOH (3:1) in the coplin jar for at least 10 
minutes (can be left for longer). This fixes the DNA to the slide and de-proteinises 
the sample. 
- Air-dry the slides for 5-10 minutes and store in the fridge for up to 1 year. 
 
Immunostaining 
Place the slides in a black tray and keep covered as much as possible. 
- Wash (~1 minute) slides 2 x with 1 mL H2O (pour off liquid into plastic beaker). 
- Rinse 1 x with 1 mL freshly made 2.5 M HCl. 
- Denature with 2.5 M HCl for 1 hour 15 minutes (NO LONGER; optimised for all 
human cells). This makes the ssDNA accessible to the antibody. 
- Rinse 2 x with PBS. 
- Wash (~1 minute) 2 x with blocking solution (1 g BSA, 100 µl Tween 20, in 100 
mL PBS). 
- Incubate in blocking solution for 30 minutes - 1 hour. 
- Tip off the Blocking solution and add 115 µl primary antibodies i.e. 1:750 Rat 
anti-BrdU (anti-CIdU) and 1:750 Mouse anti-BrdU (anti-IdU). 
- Cover each slide with a long cover slip and incubate in the dark overnight 4 °C 
(can leave for 1 hour at room temperature but found overnight gives cleaner 
images). 
- Tip off the antibodies and cover slip into the beaker and rinse 3 x with PBS. 
- Fix with 0.5 mL 4% paraformaldehyde for 10 minutes. This fixes the antibody to 
the antigen. 
- Rinse 3 x with PBS. 
- Wash (~1 minute) 3 x with blocking solution. 
- Add 115 µl secondary antibodies i.e. 1:500 anti-rat Alexafluor 594 (red) and 
1:500 anti-mouse Alexafluor 488 (green). 
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- Cover each slide with a long cover slip and incubate in the dark for 1.5 hours. 
- Rinse 2 x with PBS. 
- Wash (~1 minute) 3 x with blocking solution. 
- Rinse 2 x with PBS. 
- Spread a drop of mounting medium over the surface and place a long cover slip 
over. 
- Allow to dry for 5-10 minutes before dabbing dry with a tissue and sealing edges 
with nail varnish. 
- Store in freezer. 
Image under Olympus BX53 microscope. 
 
 182 
Appendix C  CDC45 
C.1 qPCR standard curves for calculating primer efficiency 
RPS18 – Housekeeping gene 
 
Primer efficiency:  104.6779307 
 
Primer efficiency:  97.88790712 
Figure C1.1 RT-qPCR Standard curves for calculating RPS18 primer efficenies with control and 
patient DNA. A standard curve was set up for control (KDM14.9) or patient (LB192) cDNA 
using 100ng, 20ng, 4ng, 0.8ng or 0.16ng cDNA and RPS18 primers. The Ct value was 
plotted against the log value of the dilution and the primer efficey was calculated using 
the following equation: Primer efficieny = (10^(-1/slope value)-1)*100. 
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CDC45 Exons 1-3 
 
Primer efficiency:  113.1724605 
 
Primer efficiency: 103.2647088 
Figure C1.2 RT-qPCR Standard curves for calculating CDC45 Exon1-3 primer efficenies with control 
and patient DNA. A standard curve was set up for control (KDM14.9) or patient (LB192) 
cDNA using 100ng, 20ng, 4ng, 0.8ng or 0.16ng cDNA and CDC45 Exon 1-3 primers. The Ct 
value was plotted against the log value of the dilution and the primer efficey was 
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CDC45 Exons 5-6 
 
Primer efficiency:  96.72054787 
 
Primer efficiency:  92.36373275 
Figure C1.3 RT-qPCR Standard curves for calculating CDC45 Exon5-6 primer efficenies with control 
and patient DNA. A standard curve was set up for control (KDM14.9) or patient (LB192) 
cDNA using 100ng, 20ng, 4ng, 0.8ng or 0.16ng cDNA and CDC45 Exon 5-6 primers. The Ct 
value was plotted against the log value of the dilution and the primer efficey was 
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CDC45 Exons 15-16 
 
Primer efficiency:  110.3664857 
 
Primer efficiency:  106.8837256 
Figure C1.4 RT-qPCR Standard curves for calculating CDC45 Exon 15-16 primer efficenies with 
control and patient DNA. A standard curve was set up for control (KDM14.9) or patient 
(LB192) cDNA using 100ng, 20ng, 4ng, 0.8ng or 0.16ng cDNA and CDC45 Exon 15-16 
primers. The Ct value was plotted against the log value of the dilution and the primer 
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CDC45 Exons 17-18 
 
Primer efficiency:  105.5143591 
 
Primer efficiency:  112.4240658 
Figure C1.5 RT-qPCR Standard curves for calculating CDC45 Exon 17-18 primer efficenies with 
control and patient DNA. A standard curve was set up for control (KDM14.9) or patient 
(LB192) cDNA using 100ng, 20ng, 4ng, 0.8ng or 0.16ng cDNA and CDC45 Exon 17-18 
primers. The Ct value was plotted against the log value of the dilution and the primer 
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C.2 RT-qPCR biological replicates 
RT-qPCR biological replicate 1 
Table C.1  RT-qPCR biological replicate 1 expression fold change normalised to RPS18. 
RNA 1 replicate  
 KDM14.9 LB192 
Ex 1-3 1.07 0.28 
Ex 5-6 1.02 0.25 
Ex 15-16 1.02 0.17 
Ex 17-18 1.01 0.27 
 
 
Figure C2.1 RT-qPCR biological replicate one shows a knockdown of CDC45 expression in LB192 
Patient cells (orange) across the gene when compared to control DNA (KDM14.9 cells – 









RT-qPCR biological replicate 2 
Table C.1  RT-qPCR biological replicate 2 expression fold change normalised to RPS18. 
RNA 2 replicate  
 KDM14.9 LB192 
Ex 1-3 1.00 0.21 
Ex 5-6 1.00 0.23 
Ex 15-16 1.01 0.16 
Ex 17-18 1.00 0.17 
 
 
Figure C2.2 RT-qPCR biological replicate two shows a knockdown of CDC45 expression in LB192 
Patient cells (orange) across the gene when compared to control (KDM14.9 – Blue). 









RT-qPCR biological replicate 3 
Table C.1  RT-qPCR biological replicate 3 expression fold change normalised to RPS18. 
RNA 3 replicate 1  
 KDM14.9 LB192 
Ex 1-3 1.00 0.39 
Ex 5-6 1.00 0.49 
Ex 15-16 1.00 0.25 
Ex 17-18 1.01 0.44 
 
 
Figure C2.3 RT-qPCR biological replicate three shows a knockdown of CDC45 expression in LB192 
Patient cells (orange) across the gene when compared to control (KDM14.9 – Blue). 
Expression fold change was normalised to the hosekeeping gene RPS18. 
 
